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MODULATORS OF INNATE GUT IMMUNITY TO ENTERIC VIRAL 
INFECTIONS: MURINE NOROVIRUS (MNV) AS A MODEL     
OSAMA EISA 
ABSTRACT 
Challenged by a huge and diverse antigenic stimulus, the intestinal mucosa has 
developed a unique immune system that mainly functions to maintain tolerance to 
innocuous antigens while retaining the ability to respond swiftly to pathogenic threats. 
Central to this specialised immune system are the Intraepithelial Lymphocytes (IELs). 
These cells are uniquely located between Intestinal Epithelial Cells (IECs) ready to 
respond to exogenous antigens in the intestinal lumen. The intestinal immune system is 
constantly influenced, not only by the commensal microbiota, but also by the nutritional 
status of the host and the availability of certain essential micronutrients that are derived 
from a healthy-balanced diet. Additionally, age has a significant impact on the efficiency 
of gut immunity in responding to infectious pathogens, as reflected by the increased 
burden of gastrointestinal infections at the extremes of age. 
In this thesis, using the Murine Norovirus (MNV) oral infection model, I aimed to 
characterize intestinal mucosal antiviral-responses with specific focus on the role of 
IELs, the impact of aging and the influence of certain micronutrients whose effects are 
mediated through the Aryl Hydrocarbon Receptor (AhR). Employing different knock-out 
and adoptive transfer experiments, I concluded that, at least in our experimental 
conditions and in a viral strain-specific manner, the activated IELs are not essential and 
may play a minor role in the protective response against MNV infection. This work also 
demonstrated that various MNV virus strains activate IELs differentially and for the first 
time (to our knowledge) revealed distinct abilities of these different Norovirus variants to 
infect IECs. Recognising an impaired response in old (2-year) mice, we were also able to 
identify a specific defect in the IFN-l response of aged IECs. Furthermore, using the 
model of MNV infection to investigate the role of AhR signalling, the data I generated 
suggested a direct link between constitutive AhR signalling and innate interferon-
mediated responses. These findings have uncovered a potential preventive/therapeutic 
targets for enhancing anti-viral responses. 
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Chapter 1 INTRODUCTION 
 
1.1 The Intestinal Tract: Structure, Regional Specialisation and Ecosystems  
As an organ with the main function of digestion and absorption of nutrients, the 
alimentary tract presents a huge surface area, covering 200-300 m2 in adult humans1, to 
the outside environment. Unlike the tight seal of the skin, the intestinal epithelial layer 
forms a relatively leaky barrier to allow for the exchange of nutrients and fluids2. In 
addition to the constant exposure to dietary and environmental antigens, the healthy gut 
harbours a dense and diverse population of several trillion commensal microrganisms3, 
‘symbionts’, that, at steady state, peacefully cohabit with the host in a mutually 
beneficial relationship4. The intestinal mucosa also represents the main portal of entry for 
many pathogens, including viruses, bacteria, parasites and fungi, which can cause 
pathology and disease by local colonization and induction of destructive inflammation 
and/or by breaching the mucosal barrier and resulting in systemic infection5,6. 
Furthermore, the recent increased awareness about the far reaching influence of the gut’s 
physiology and its microbial contents in promoting the general wellbeing of an 
individual, and their central role in relieving, mediating and/or aggravating pathological 
processes throughout the body, has led to the emergence of such terminology as gut-
brain7,8 and gut-endocrine9,10 axes. This has been associated with a huge escalation on the 
number, and in-depth quality, of publications analysing and dissecting the intestinal 
mucosal system. A common caveat, however, in many of the gut-related studies is the 
assumption that the whole intestinal tract is a single uniform organ, while most 
macroscopic (endoscopic), histological and functional differences between its various 
segments suggest otherwise (Figure 1.1). Such an assumption will result in an over-
generalized, reductionist and incomplete analysis of an otherwise complex, regionally-
specialised and interactive biological system. 
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1.1.1 Anatomy and Structure 
 
Stretching as a continuous tube from the gastric outlet to the anus, the intestinal tract is 
categorised into two major segments; the small and large intestine, with the ileocecal 
valve forming the point of division1. The small intestine is further subdivided into the 
duodenum, the most proximal part; followed by the jejunum; and then the ileum. A 
single layer of columnar epithelium, made of Intestinal Epithelial Cells (IECs), lines the 
whole intestinal tract and forms the main physical barrier from the external environment. 
Together with the underlying Lamina Propria (LP) and a thin muscular layer, this 
epithelium constitutes the gut mucosa where most of the immunological processes take 
place. The LP consists of loose connective tissues embedding a dense layer of blood 
vessels, nerve connections and afferent/efferent lymphatic channels1,2. Although they are 
separated by a thin basement-membrane, the LP and IEC constitute quite distinct 
immunological compartments (discussed in more detail in Section 1.2.1). 
Macroscopically, the small and large intestine differ markedly in length, diameter and 
organisation. Having a narrower diameter, the small intestine in humans forms multiple 
coils with a length of approximately 6-7 m. Conversely, the colon is much wider, shorter 
and extends in straight lines into ascending, transverse and descending colon1,11.  
Scanned from the lumen by endoscopy, the different segments of the gut have quite 
distinct appearances (Figure 1.1). The proximal small intestine (duodenum and jejunum) 
is characterised by long, thin, finger-like projections extending into the lumen, called   
the villi, with the main function of increasing the functional surface area of the 
absorptive epithelium. This function is further augmented by the presence of extensive 
brush borders (consisting of microvilli) on the luminal surfaces of these epithelial cells. 
The crypts, which are moat-like invaginations of the epithelium around the villi, are also 
quite distinctive in this part of the gut. As we go down the length of the small intestine, 
the villi become progressively shorter and broader until we reach the cecum and colon 
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where they are almost absent and the surface is rather flat1,11.  
These structural and histological differences are reflected in distinct physiological 
functions of different gut sections. Well-equipped with numerous digestive enzymes and 
a huge surface area, the upper small intestine is the main site for digestion and absorption 
of nutrients. Consequently, pathologies that specifically target this site of the gut, such as 
Coeliac disease, consistently present with malabsorption and malnutrition2,12. Having a 
less impressive brush border and villi, the terminal ileum contributes much less to 
nutrition, apart from its essential role in absorption of bile salts and vitamin-B12 due to 
the presence of specific receptors1,13. The main functions of the large intestine, on the 
other hand, are the reabsorption of water and certain electrolytes and disposal of 
undigested materials. Protected by a thick overlying mucous layer, the large intestine also 
harbours most of the commensal microbiota1,11.  
Another common misconception is that the lymphatics of the entire gastrointestinal tract 
are drained into common Mesenteric Lymph Nodes (MLNs). Using a Chicago Blue dye 
injected into a mouse intestine, Carter and colleagues (1974) clearly demonstrated the 
segmental and quite separate MLN that drain different regions of the gut14,15. Additional 
subtle differences between various gut sections can be revealed by analysis of the cellular 
constituents and distribution of different gut-associated lymphoid tissues (GALT). The 
size and density of the Peyer’s Patches, one of the well-characterised members of the 
GALT, progressively increase from the jejunum to the distal ileum, where they are 
particularly concentrated16. The numbers of Intra-Epithelial Lymphocytes (IEL) (in the 
epithelial layer) and the CD11b+ dendritic cells (DC), TH17 and CD8+ T cells (in the LP) 
gradually decrease as we go down from the proximal small intestine to the colon, while 
those of macrophages, CD11b- DC, Foxp3-expressing regulatory T cells (Treg) and IgA-
producing plasma cells gradually increase17–19(Figure 1.1). This distinct cellular 
distribution can be regarded, at least in part, as a direct consequence of the variation in 
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the major antigenic stimuli at different sites of the gut. The proximal intestine is mainly 
influenced by dietary antigenic challenge, the intensity of which reduces as we go down 
the gut and is replaced by a strong commensal microbiota stimulus in the colon     
(Figure 1.1)11.  
 
1.1.2 Intestinal Epithelial Cells (IEC) 
 
The coexistence of the body’s largest population of innate and adaptive immune cells, 
together with trillions of diverse microbial communities in the gut ecosystem, 
necessitates the presence of a specialised barrier that maintains the physical segregation, 
while allowing bi-directional crosstalk, between the two. This barrier consists of a 
monolayer of polarised IECs that exhibit several physical and chemical adaptations to 
maintain barrier integrity20. As discussed earlier, the IEC-layer is organised into crypts 
and villi. It is continuously renewed by pluripotent Intestinal Epithelial Stem Cells       
(p-IESCs) that reside at the base of the crypts and are capable of both self-renewal and 
replication to be transformed into terminally-differentiated absorptive and secretory 
enterocytes21. Except for Paneth cells, which move downwards toward the base of the 
crypt, all other newly-formed enterocytes migrate along an escalator towards the villous 
tips, from where they are extruded into the lumen after a 4-5 day life span11,21. While 
about 80% of them are uniformly absorptive, highly-polarised columnar cells with brush 
borders at their apical sites containing many digestive enzymes, the functional diversity 
of IECs depends on the presence of additional specialised enterocyte-subsets. These 
include the mucin-producing goblet cells, the bactericidal-gatekeeper Paneth cells and 
the hormone-secreting entero-endocrine cells, in addition to the Microfold (M) cells 
that play a crucial role in sampling luminal antigens11,21. 
The density and proportion of different IEC-subtypes also show a remarkable regional 
variation. The frequency of goblet cells, for example, progressively increases along the 
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length of the gut. While they constitute less than 10% of all epithelial cells in the small 
intestine, they comprise up to 35% of those of the colon, where they maintain a copious 
layer of mucus that acts as an effective physical barrier to the abundant microbiota at this 
site22,23. In contrast, Paneth cells are only present in the small intestine, particularly 
concentrated in the terminal ileum. These Paneth cells are long-lived, relatively large 
epithelial cells that contain abundant secretory granules. They serve crucial functions in 
maintaining the stem cell niche by providing the IESCs with essential growth signals, in 
addition to their indispensable antimicrobial functions24. The physiological importance of 
Paneth cells has been highlighted by the central role of their dysregulation, e.g. defective 
autophagy and unfolded protein responses, in the pathogenesis of inflammatory bowel 
diseases (IBDs), mainly Crohn’s disease25,26. 
The integrity of IEC physical (tight junctions) and chemical (mucus, antimicrobial 
peptides) barriers is of paramount importance in maintaining and promoting health. This 
has been illustrated in a number of pathological conditions; such as the association 
between intestinal barrier dysfunction and progression of IBD27, and the evolution of 
chronic HIV and Hepatitis viral infections due to systemic chronic immune activation 
secondary to increased bacterial translocation28,29. Nevertheless, the IEC layer is not, and 
should not be viewed as, a mere static impermeable barrier. It has become clear now that 
it actually represents an integral component of a highly regulated, dynamic 
communication network that actively participates in shaping the constituents of the 
microbiota, maintaining gut homeostasis and eliciting mucosal immune responses30 
(discussed in more detail in Section 1.2.1).   
For many years, attempts had been made to grow and characterise IECs in vitro; to 
analyse their differentiation and dissect their intrinsic immune responses independent of 
other gut-associated immune cells. These attempts included generation of cell-lines, 
explants and isolated primary epithelial cell cultures. However, none of these methods 
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provided long-term maintenance of the crypt-villus morphology or reflected the 
physiological lineage-development of IECs31. This was, in part, due to the strict 
dependence of epithelial cell survival on contact with the extracellular matrix and the 
requirement of complex growth-factor cocktails for the maintenance, proliferation and 
differentiation of p-IESCs31. Advances in stem cell biology have facilitated the definition 
of these p-IESCs and have contributed to a better understanding of epithelial self-renewal 
and differentiation32–34. However, it was only in 2009, that Sato et al. finally published a 
protocol for in vitro cultivation of three-dimensional (3-D) intestinal epithelial 
organoids in Matrigel. Matrigel is a laminin- and collagen-rich matrix that polymerises 
at 37°C and forms 3-D structures mimicking the epithelial basal lamina35. Based on 
insights from the in vivo growth-factor dependency of p-IESC, Sato et al. were able to 
define the minimally-required growth-factor cocktail to grow and maintain the intestinal 
organoids in vitro35. This contains Epidermal Growth Factor (EGF) that is important for 
p-IESC proliferation, R-spondin-I (an important Wnt agonist) and noggin (a bone-
morphogenic protein, BMP, signalling antagonist).  Wnt signalling is a key repressor of 
differentiation. It is very active in the crypt domain and reduces gradually in the villi, 
allowing for the differentiation of enterocytes as they move along the crypt-villus axis34. 
BMP, on the other hand, is a negative regulator of crypt formation and stem cell 
proliferation36. Its signalling activity is highest in the villous domain.   
Under the culture conditions described above, isolated intestinal crypts round-up and 
grow into 3-D organoid structures, so-called mini-guts, consisting of a central cyst 
surrounded by crypt-like budding structures35,37. This in vitro intestinal organoid is a 
novel, robust culture system that maintains crypt-villus morphology, stem-cell 
proliferation and differentiation for a potentially infinite time span38. It provides a unique 
tool to specifically analyse IEC immunobiology and, combined with co-culture models, 
their interaction with other gut-associated immune cells. 
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1.1.3 The Microbiota 
 
The two distinct, but interdependent, mammalian cell-based communities of the gut 
mucosa, namely the immune and epithelial-mesenchymal cell compartments, are 
continuously exposed to, and influenced by, a third element of the gastrointestinal 
ecosystem created by trillions of co-resident microbiota39. Colonisation commences 
immediately upon birth by the largest population of symbiotic bacteria in/on the body, 
approximately 1x1014 bacteria, in addition to numerous and diverse viral, fungal and 
archaeal species40,41. Despite the huge diversity, four bacterial phyla have predominantly 
adapted to the anaerobic intestinal niche; namely the Bacteroidetes, Firmicutes, 
Actinobacteria and Proteobacteria42,43.  
The host-microbiota relationship is the result of millions of years of co-evolution and can 
be best characterised as either being a (no-cost) commensalism, in which one partner 
benefits and the other is unharmed; or a mutualistic relationship, in which both partners 
benefit44. The availability of reduced-price, gene-sequencing-based technologies has 
allowed for a more comprehensive characterisation of bacterial members of each type of 
the relationship and the identification of ‘pathogenic’ microbial-community profiles 
associated with several systemic and local diseases45. Moreover, it has facilitated the 
exploration of other, non-bacterial, constituents of the microbiota, especially the gut 
Virome46.  
As in any other biological system, there are always ‘cheating’ players that exploit the 
norm to obtain benefit without helping to create it. This can occur, for example, by 
acquiring a mutation that redirects resources toward increased fitness and faster 
replication of the microorganism itself instead of contributing to pathogen-interference or 
detoxification44. In a healthy gut, the mucosal immune system plays a determining role in 
developing and promoting anti-exploitation responses to prevent the dominance and 
systemic spread of the ‘cheating’ opportunistic and pathogenic organisms44. The 
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adaptations of the epithelial barrier for sampling of luminal contents can accommodate 
limited and controlled bacterial and antigen translocation to direct appropriate 
tolerogenic or anti-pathogen responses. By constantly sampling the intestinal contents 
and initiating local protective immune responses, the gut-associated immune system 
maintains a state of informed awareness about the composition of the gut microbiota. 
This state allows the microorganisms to compete for resources in the gut, generating a 
robust disease-resistant community, while at the same time ‘usually’ preventing 
uncontrolled exploitation of the limited resources by potentially harmful organisms44. In 
addition to the local immune system and IECs, the composition of the bacterial 
microbiota is directly influenced by external environmental factors; especially the diet47 
and the use of broad-spectrum antibiotics that alter the taxonomic, genomic and 
functional capacities of the human gut microbiota, with effects that are usually rapid and 
transient but sometimes persistent48.  
The number, composition and diversity of microorganisms varies greatly between 
different segments of the gut. From being absent to very low (100-1000 organisms/ml) in 
the harshly acidic environment of the stomach, the number of bacteria progressively 
increases down the alimentary tract to reach up to 1012 per ml in the colon11. Some 
reports suggest a denser bacterial population in the human caecum and terminal ileum 
than is seen in the colon49. Aerobic bacteria are, generally, more prevalent in the upper 
small intestine while anaerobic species dominate the large intestine11. Microbial diversity 
is most evident in the caecum and least diverse in the distal colon50. Both the density and 
diversity of gut microbiota have been shown to be relevant in many clinical conditions 
and pathologies. In mice, the higher incidence of tumors in the caecum has been 
attributed, at least in part, to its greater density of bacteria51. Dysbiosis, i.e. alteration in 
the composition, density and/or distribution of intestinal microbiota, has been linked to 
the development and progression of many different diseases ranging from psychiatric 
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illness to metabolic, inflammatory, allergic and autoimmune diseases52,53.  
Among the many substantial benefits of ‘healthy’ balanced microbiota profiles are the 
contribution to digestion, provision of essential metabolites such as vitamin-K and biotin, 
occupation of niches that would otherwise be available to pathogens and promoting 
immune system development54. This is clear in germ-free mice, whose growth is severely 
compromised in terms of development, immune function and lymphoid organ 
organisation55. Furthermore, it has become increasingly evident that colonization by 
individual members of the commensal microbiota can influence the regional 
specialization of the immune system along the length of the intestine. The presence of 
Segmented Filamentous Bacteria (SFB) in the terminal ileum of mice enhances the 
production of IgA antibodies and the polarization of TH17 cells, contributing to the 
variation in numbers of TH17 cells observed between mouse-strains from different 
suppliers56,57. Conversely, colonization of the colon by certain anaerobic Clostridia 
species drives the preferential generation of Treg cells, apparently by promoting a TGFb-
rich environment58. Additionally, short-chain fatty acids such as butyrate, acetate and 
propionate that are produced by colonic bacteria play a central role in influencing the 
immune functions in this part of the gut. The best characterized example of this is the 
enhancement of the number and functions of Foxp3-expressing Treg in the colon by the 
production of butyrate59.  
More recently, some of the beneficial functions of the understudied viral component of 
the microbiota (Virome) have been elucidated60, and its role in determining the 
susceptibility to, and progression of, certain pathologies such as IBDs has been 
identified61,62 (discussed in Section 1.2.2). 
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1.2 Intestinal Mucosal Immune System  
1.2.1 The Complexity and the Organization 
 
Faced with overwhelming antigenic challenges, and in order to fulfil the delicate task of 
mounting robust, protective, non-destructive responses to invading pathogens, whilst at 
the same time maintaining a state of tolerance and non-responsiveness to harmless food 
antigens and commensal organisms, the intestinal mucosal immune system has evolved 
as a distinct and sophisticated immunological organ that functions in a flexible, dynamic 
and multi-layered manner.  
At the centre of this complex immune system is the GALT, which consists of a network 
of highly organized lymphoid structures, including Peyer’s Patches (PPs), colonic 
patches, crypto-patches, isolated lymphoid follicles (ILFs) and mesenteric lymph nodes 
(MLNs). They are strategically located along the entire length of the gastrointestinal tract 
and represent the main Inductive Sites of the gut immune system63. Moreover, they are 
essentially equipped with all adaptations necessary for luminal antigen sampling, 
optimizing the chances of naïve lymphocytes encountering their specific antigens, 
induction of antigen-specific T and B cell responses, and for supporting the activated 
lymphocytes and their initial differentiation. The PPs, for example, located mainly on the 
anti-mesenteric side of the small intestine, form a lymphoid microenvironment made up 
of a large B cell follicle, an inter-follicular T cell region and numerous intervening 
antigen presenting cells; dendritic cells (DCs) and macrophages63. Luminal antigen 
sampling in the PPs is mediated mainly by the Microfold (M) cells, which represent a 
unique adaptation of the follicle-associated enterocytes that allows for the uptake and 
transport of antigens to DCs in the adjacent subepithelial dome region of the PPs64. A 
similar sampling mechanism may occur in ILFs of the colon and in the caecal patches, 
which were recently suggested to be the main site of induction of IgA-producing plasma 
cells65. Moreover, there is evidence for involvement of goblet cells66 and trans-epithelial 
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DCs67 in active sampling of the gut lumen at sites distant from organized lymphoid 
tissues. The distinct CD103+ DCs within the sub-epithelial dome are capable of 
migrating within the PPs, between the basolateral surface of the M-cells and the inter-
follicular T cell area to present antigens, and to travel to distant sites such as the MLNs 
and the LP to orchestrate an adaptive immune response68. Moreover, they play an 
important immunomodulatory role. Depending on the context and under the influence of 
the overlying epithelial cells, they can induce either tolerance or protective immune 
responses69,70. For instance, in the resting-state; i.e. in the absence of pathogens and the 
presence of a regulatory cytokine milieu at the enteric surfaces, these DCs release 
interleukin (IL)-10, TGF-β and vitamin A metabolites that favour the induction of Foxp3+ 
Treg71. Moreover, they can present antigens without up-regulating costimulatory 
molecules (e.g. CD80/CD86) leading to abortive or Treg responses (reviewed in 69). 
Activated lymphocytes egress from the PPs via the lymphatic system to the MLNs and 
then to the circulation. Ultimately they take residence in the LP of the intestinal tract, 
which represents the main Effector Site of the gut immune system72. The final migration 
to the LP is dependent on the interaction of site-specific adhesion molecules, such as 
α4β7, on activated lymphocytes with specific mucosal addressin cell-adhesion molecules 
on the surface of high-endothelial venules in the LP. Migration is further tuned and 
refined by the interaction of chemokines, such as CCL25 which is constitutively 
expressed by IECs, with chemokine receptors, e.g. CCR9, on the surface of activated 
lymphocytes73. The LP is, therefore, occupied by a heterogeneous population of effector-
memory and Treg lymphocytes, mononuclear phagocytic cells (macrophages and DCs) 
and IgA-producing plasma cells (reviewed in 74). The gut-associated T cells, although 
frequently displaying an alert-phenotype and hallmarks of recent activation, must remain 
immunologically hypo-responsive to innocuous antigens while retaining their capacity to 
respond swiftly to a pathogenic challenge74,75.  
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Unlike the migratory CD103+ DCs, CX3CR1hi intestinal-resident macrophages lack 
migratory properties in steady-state condition76. In addition to their important functions 
in phagocytosis and clearance of translocated microbes and apoptotic cells, they maintain 
a close proximity to and are directly influenced by IECs to maintain steady-state 
tolerance by producing IL-10 that promotes the survival and local expansion of 
previously primed Treg cells77.  
NK, NKT, granulocyte and myeloid cell populations are also present in the LP, as well as 
a recently identified immune cell population of innate lymphoid cells (ILCs). These ILCs 
are revealing themselves as crucial determinants of lymphoid tissue organogenesis and, 
again under the influence of IECs, as important modulators of gut homeostasis and 
immunity78. ILCs lack specific markers of conventional innate and adaptive immune 
cells and are characterised by their differential cytokine expression and developmental 
requirements. Sharing functional similarities with the three major CD4+ T cells subtypes; 
i.e. TH1, TH2 and TH17, they are classified into group1, 2 and 3 ILCs, respectively78–80. 
This extensive intestinal immune system is separated from the external environment by a 
monolayer of polarised IECs. By maintaining a continuous cell layer sealed by tight 
junctions and through secretory adaptations (mucin and antimicrobial peptides), IECs 
effectively sustain a physical and biochemical barrier integrity2,20. This is further 
augmented by the active transcytosis of secretory IgA complexes across IECs81,82, 
providing an adaptive immunity component to the epithelial barrier that regulates 
commensal bacterial populations and represents the first line of antigen-specific immune 
defence. Moreover, IECs actively participate in the maintenance of intestinal homeostasis 
and induction of the appropriate immune response in the gut30. Being frontline sensors 
for microbial encounters, IECs are equipped with a diverse range of pattern recognition 
receptors (PRRs), reviewed in83, that enable them to dynamically respond to microbes. 
Unlike the body’s sterile sites, where recognition of foreign microorganism by PRR 
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initiates a rapid cascade of strong pro-inflammatory responses, the proximity of IECs to 
an abundance of stimuli from symbiotic commensals necessitates specialised 
mechanisms to maintain altered or hypo-responsive PRR signalling, and to differentiate 
between friends (commensal microbes) and foes (pathogens). This ability to express a 
wide range of negative regulators, in addition to the subcellular segregation and polarised 
distribution of PRRs in the basolateral and apical surfaces, allows the IECs to act as 
‘sentinels’ for maintaining homeostasis and to differentiate between signals derived from 
commensal and pathogenic organisms based on their anatomic location83. Furthermore, 
by producing and controlling the levels of such cytokines as thymic stromal 
lymphopoietin (TSLP) and TGF-b, IECs directly instruct the function of other gut-
associated cells83–85. As discussed earlier, the IEC-conditioned DCs, macrophages and/or 
ILCs play a major role in maintaining tolerance and in shaping the innate and adaptive 
mucosal immune responses in the gut. Moreover, a unique population of intestinal T 
cells, IELs, is located within this epithelial layer above the basement membrane and is 
thought to play a role in promoting intestinal homeostasis and immunity86 (discussed in 
Section 1.2.3). Production of IL-7 and IL-15 by IECs is important for the maintenance of 
these IEL populations87, while IEC-mediated production of a proliferation-inducing 
ligand (APRIL) induces T cell-independent class switching of mucosal B cells87,88. 
Thus, under steady-state conditions, and despite the enormous load of microbial and 
dietary antigens present in the gut lumen, an appropriate immunological tolerance in the 
gut microenvironment is maintained by a tightly regulated, multi-layered network of 
different cells. The mechanisms by which this tolerance is broken by oral allergens or 
pathogenic challenges are, however, much less understood. One intuitive possibility is 
that the control of inflammation in the intestine may be adapted to rely on the recognition 
of ‘danger’ signals associated with pathogenesis, rather than on the presence of microbial 
signal alone89. 
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1.2.2 Intestinal Mucosal Immune System: Modulation by Viral Infections 
 
Being one of the main portals of entry for viral pathogens, intestinal mucosal surfaces are 
commonly involved in the induction, polarization and maintenance of immunity against 
viral infections6,90. Gastrointestinal viral infections constitute a major threat to the 
population, especially at the extremities of age, and cause significant morbidity and 
mortality worldwide91. However, the majority of the intestinal primary and secondary 
exposures to viruses are asymptomatic or induce only minor symptoms92,93, implying 
efficient mechanisms are employed by the gut mucosa to clear pathogenic viruses or at 
least to contain them with minimal inflammation and injury.   
The first line of defence against invasive viruses is the physical and chemical barrier 
produced by specialised enterocytes to limit viral spread94. At the apical surfaces of the 
polarized columnar epithelial cells lining the gut, a 500-nm thick glycocalyx layer covers 
the negatively charged microvilli and limits the uptake of antigens whilst promoting the 
absorption of nutrients95. This is overlaid by a mucin-rich layer containing glycoproteins 
that competitively bind to cellular surface receptors and act as a barrier to microbes such 
as rotavirus96. Secretory IgA, sIgA, produced by LP plasma cells and transported across 
the IEC to the lumen, plays an important role in neutralisation and immune-exclusion of 
infectious viruses97. In fact, the induction of rotavirus-specific intestinal IgA correlates 
with clearance of infection and protective immunity (reviewed in 97). Furthermore, the 
IECs, especially the Paneth cells, are significant sources of many soluble-humoral factors 
and antimicrobial-peptides (including defensins, cathelicidin and lactoferrin) that play a 
role in innate immunity against enteric viral infections. They are involved in opsonisation 
and enhancement of phagocyte-mediated killing, potentiation of cellular surveillance, 
pathogen recognition and direct disruption of viral envelope membranes98.  
During viral infections, virtually all nucleated cells can respond by producing, and being 
influenced by, type-I Interferons (IFNs) to limit viral replication and spread99.    
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However, it is the plasmacytoid DCs (pDCs) that are regarded as the main/major source 
of type-I IFNs, owing to their ability to respond to a broad range of viral stimuli and 
rapidly release large amounts of type-I IFNs100. Nonetheless, the sheer number of IECs 
that can sense, and be infected by a replicating virus dictates that they should also be 
considered as a significant source of type-I IFN in the context of enteric viral infections. 
Moreover, the influence of IECs on the activation of pDCs can serve to amplify this IFN 
signalling process90.  
To ensure immediate antiviral defence, IECs and mononuclear phagocytes at enteric 
surfaces employ multiple PRRs in different cellular compartments to sense the different 
viral Pathogen-Associated Molecular Patterns (PAMPs)101,102. Toll-Like Receptors 
(TLRs) 3, 7, 8 and 9 are localized within endosomal compartments and recognize viral 
dsRNA, ssRNA and CpG-containing DNA. The two members of the RIG-Like-Receptor 
(RLR) family, retinoic acid-inducible gene I (RIG-I) and melanoma differentiation-
associated protein-5 (MDA5) are localized in the cytoplasm to recognize 3`-triphosphate 
bearing RNA and long dsRNA viral structures, respectively103. The nucleotide-binding 
oligomerization domain (NOD)-Like-Receptor, NOD2, can also act as a cytosolic PRR 
for ssRNA viruses, triggering the activation of interferon-regulatory-factor 3 (IRF-3) and 
the production of IFNβ104. Notably, Danger-Associated-Molecular-Patterns (DAMPs), 
released subsequent to the death of virally-infected cells, can also trigger the activation 
of PRRs101. 
As discussed earlier, the PRR-signalling in the gut is tightly regulated to maintain 
tolerance to the abundant microbial flora (reviewed in 83,85). Infection with a virulent 
virus modulates this tolerance toward a more inflammatory-state. Indeed, viruses like 
rotavirus and coxsackie virus were shown to induce a significant increase in IEC-
expression of viral PRRs105. Engagement of multiple, diverse viral sensors induces 
varying signalling pathways that converge on phosphorylation of the TBK/IKKe 
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complex and activation of downstream IRF3, IRF7 and NFκB pathways to induce the 
production of type-I and III IFNs in addition to other inflammatory cytokines106,107 (and 
reviewed in99). 
IFNs are potent immunomodulators that are readily produced in response to a variety of 
viral and bacterial pathogens6. Based on differences of biological activities and receptor 
usage, three distinct types of IFNs are described; type I, II and III. Although all the types 
are involved in mediating protective responses against pathogenic viruses, only type I 
and III IFNs are directly produced in response to viral infection6. Type-I IFN consists of 
13 subtypes of IFNα and a single IFNβ (in humans), and all signal through a common 
receptor composed of IFNAR-1 and IFNAR-2 subunits108. Type-II IFN consists of a 
single member, IFNg, which mediates its response by signalling via a receptor consisting 
of INFGR1 and IFNGR2 subunits109. IFNl1, 2 and 3 constitute the three members of 
type-III IFN that signal through a heterodimer (IL-28Ra, also known as IFNLR1, and 
IL10Rb) receptor and share many of the intracellular signalling pathways and biological 
activities of type-I IFN110. Type-I IFNs and their receptor, as well as the IFNg receptor, 
are widely expressed by many cell-types, in contrast to the more restricted expression of 
IFNg, type-III IFNs and their receptor IFNLR1. IFNg  is mainly produced by T and NK 
cells109 and type-III IFNs by leucocytes, DCs and epithelial cells110,111. The type-III IFN 
receptor is primarily expressed by epithelial cells110. In fact, it has been shown that mice 
lacking a functional type-III IFN receptor have impaired control of oral rotavirus 
infection. The type-I IFN-system alone was not enough to protect against the infection 
and systemic administration of IFNl,  but not type-I IFN, to suckling mice was sufficient 
to suppress rotavirus replication in the gut112. This unique ability of the type-III IFNs to 
induce a protective antiviral response in intestinal epithelial cells that is independent of, 
and not overlapping with, type-I IFN-induced antiviral responses is quite intriguing.       
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It has been suggested that this phenomenon could be explained by the IECs-restricted 
expression of the IFNl-receptor and the differential expression of type-I IFN receptor in 
the apical vs the basolateral surfaces of the IECs112. 
Upon binding of type-I and III IFNs to their corresponding receptors, they trigger a JAK-
STAT signalling pathway that culminates in phosphorylation, dimerization and nuclear 
translocation of STAT1-STAT2 molecules. In the cytoplasm, this dimer recruits IRF-9 (to 
form interferon-stimulated gene factor 3 (ISGF3)), translocates to the nucleus and 
induces hundreds of IFN-stimulated genes (ISGs)108,110 including more type-I IFNs. 
Then, in an autocrine and paracrine positive-autoregulatory manner, these IFNs induce 
additional ISGs resulting in a non-specific ‘antiviral state’. The ISGs, such as RNA-
activated protein kinase (PKR), ISG15, RNAseL, 2’-5’-oligoadenylate synthetase (OAS), 
radical S-adenosyl methionine domain containing 2 (Rsad2), RNA specific adenosine 
deaminase (Adar) and myxovirus resistance (Mx) proteins, directly impact the early 
and/or late stages of the virus life cycle with involvement in preventing viral replication, 
degrading viral RNA, inhibiting viral functions and priming neighbouring cells to enter a 
refractory antiviral state113. In addition, type-I IFN can activate the mitogen activated 
protein (MAP) kinase and the phosphoinositide 3 (PI3) kinase signalling pathways that 
also contribute to the antiviral effect108, regulate inflammasome activation, production of 
other inflammatory cytokines and mediate apoptosis114. Apoptosis provides a mechanism 
of limiting viral replication without inducing inflammation and can, actually, facilitate 
the induction of the adaptive immune response115. In murine reovirus infection, for 
example, while enterocytes stained for both structural and non-structural viral proteins, 
the gut DCs contained only structural components co-localized with apoptotic inclusions 
and cytokeratin116, suggesting that DCs can obtain viral antigens from apoptotic 
enterocytes. Moreover, type-I IFN can also help in bridging the innate and adaptive 
antiviral immune responses by enhancing the recruitment and maturation of the CD103+ 
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DC, up-regulating MHC class-I molecule expression by IECs, promoting the 
differentiation and expansion of virus-specific T cell responses, and contributing to 
generation of antibody responses to mediate neutralisation of virus particles90,117.  
However, it is important to note that IFN signalling is not always pro-inflammatory and, 
depending on the context, it can indeed contribute to gut homeostasis by both immune-
activating and suppressing signals6. There is autoregulatory induction of the anti-
inflammatory suppressor of cytokine signalling proteins, SOCS-1 and 3118, the induction 
of pDC apoptosis in several systemic viral infections as a negative feedback to type-I 
IFN production119, and it has also been reported that type-I IFN can drive anti-
inflammatory IL-10 and IL-27 production by mononuclear phagocytes and negatively 
regulate IL-12 expression by DCs during certain viral infections120,121. Moreover, a recent 
report demonstrated that IFNl acts synergistically with IL-22 to maintain homeostasis, 
control rotavirus infection and prevent intestinal tissue damage122.  
Furthermore, type-I IFN is constitutively expressed in the intestine123. In addition to the 
expression of IL-10, small intestinal and colonic LP CD11c+ mononuclear cells of 
conventionally-housed mice were found to constitutively produce IFNβ with high mRNA 
levels of the downstream molecules, such as ISGs (reviewed in 6). The driving signal for 
this basal IFN production in the intestine has long been poorly understood. But recent 
advances in sequencing technologies and bioinformatics analysis unleashed huge efforts 
to discover and characterise the viral component of the microbiome and may have 
provided an answer to why there is constitutive type-I IFN expression. Largely composed 
of bacteriophages, the human gut Virome was found to show a substantial interpersonal 
variability regardless of genetic relatedness124, and a robust intrapersonal stability, in 
spite of diet modification125. Interestingly, in the steady-state and unlike the variable 
level of expression of the bacterial detection machinery, many mRNAs of viral detection 
PRRs in mice, especially TLRs, as well as all IFN-receptors and their downstream 
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mediators, such as JAK1, STAT1, IRF-3 and 9, are stably highly expressed by the IEC 
throughout the whole length of the small intestine (Dr Marc Veldhoen, personal 
communication). This has not been confirmed yet by detection at the protein level.  
A direct effect of basal type I IFN signalling on IEC function has been described by a 
recent report, in which mice with an IEC-specific, conditional deletion of the type-I IFN-
receptor displayed epithelial cell hyper-proliferation, Paneth cell expansion and increased 
tumour burden in response to a chemical carcinogen that was dependent on the specific 
microbiota present in these mice126. Furthermore, in an elegant experiment using a model 
of persistent Murine Norovirus (MNV-CR6), Kernbauer et al. (2014) were able to 
demonstrate that a single virus can functionally replace some of the beneficial effects of 
the microbiota, and reverse many of the structural and immunological defects that arise 
in the absence of the microbiota (by antibiotic treatment or using germ-free mice)60. The 
reversal of the abnormalities was partially dependent on type-I IFN signalling in addition 
to yet unidentified signalling pathways60. However, infection with the same persistent 
virus (MNV-CR6) can also cause pathology: it has been shown to contribute to 
development of the abnormal Paneth cell phenotype that characterises IBD in mice 
hypomorphic for the autophagy gene (Atg16L1)62. MNV also exacerbates intestinal 
inflammation in Il10-/- mice; a commonly used animal model of IBDs127. These data 
suggest a clear, albeit simplistic, example of an environmental factor triggering a disease 
phenotype in a genetically-susceptible host. They also demonstrate the ability of a single 
virus to mimic the double-edged effects of the bacterial microbiota in being both 
beneficial and a contributing factor to disease, and they open the door to redefine the 
concepts of persistent asymptomatic infection, commensalism and opportunism.  
Taken together, these new insights highlight the previously overlooked importance of the 
Virome and baseline type-I IFN signalling in maintaining intestinal mucosal immunity, 
homeostasis and function.  
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1.2.3 Intestinal Mucosal Immune System: The role of Intraepithelial Lymphocytes 
 
IELs, which reside within the epithelial layer of the intestine (Figure 1.2), compose a 
large T cell compartment that is highly conserved in all vertebrates128–130. Their unique 
location above the basement membrane in direct contact with IECs and in close 
proximity to antigens in the lumen is combined with their ability to respond swiftly 
without the need for clonal expansion or priming. This qualifies them to be a potent 
frontline immune defence against invading pathogens128,129. However, and despite being 
described for decades, relatively little is known about how exactly they function in this 
location in the intestinal mucosa especially regarding antiviral responses. 
Although almost exclusively T cells, the gut IEL compartment is extremely 
heterogeneous, consisting of several diverse subsets that differ in the expression of         
T cell receptors (TCRs), co-receptors and activation markers129 (Figure 1.2). The 
proportion of these various IEL subsets in the gut is both species and site specific. In 
humans about 70% of small intestinal IELs are CD8+ T cells, with alpha/beta (αβ) TCR+ 
IEL the predominant subtype131. Murine small intestine, in contrast, contains a much 
higher percentage of gamma/delta (gd) TCR+ IELs, representing about 70-75% of the 
total CD3+ T cells in the duodenum and jejunum132. This percentage decreases 
significantly in the ileum132.  
Within this compartment, the diverse population of IELs exhibits a number of common 
properties that distinguish it from systemic conventional T cells. Firstly, they all display 
an antigen-experienced phenotype with expression of activation markers, such as CD44 
and CD69 (reviewed in 131). Secondly, they do not recirculate as indicated by studies 
using parabiotic mice and intestinal grafting133, and they constitutively express CD103 
(also known as the αEβ7 integrin) that interacts with E-cadherin on the basolateral 
surfaces of IEC and is considered to be one of the main adhesion molecules involved in 
retention of IELs within the epithelial layer134. Thirdly, unlike systemic and LP 
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lymphocytes, CD4+ T cells are under-represented in the IEL compartment135. Conversely, 
CD4-CD8- ‘double negative’ (DN) cells, which are rare in the systemic circulation, can 
account for more than 10% of murine small intestinal IELs136. Moreover, the majority of 
IELs, especially in the small intestine, express the CD8αα homodimer137, which is 
essentially absent from the systemic circulation138. CD8αα is a marker of T cell 
activation139. Unlike CD4 and CD8αβ co-receptors, CD8αα expression results in 
sequestration of the intracellular signalling components outside the immunological 
synapse139, hence it is considered to be a TCR repressor that sets a new threshold for 
activation to prevent (or reduce) the potential for unnecessary or self-destructive immune 
responses139,140. Finally, unlike conventional T cells, the majority of IELs contain 
abundant cytotoxic cytoplasmic granules and characteristically express both activating 
and inhibitory NK cell receptors141,142, which allow them to be rapidly activated by TCR-
independent mechanisms. Thus, the IELs can be typified as stress-sensing, highly 
regulated immune cells that display an alert-phenotype without full activation. 
Despite the heterogeneity, two broad subsets of gut IELs can be characterized       
(Figure 1.2) based on similarities of the gene expression profiles128, the nature of 
cognate antigens they can recognize and the proposed mechanisms and pathways for 
their activation129. The first subset is referred to as ‘natural’ IELs (previously termed 
type-b143), and consists mainly of CD4-CD8- (DN) cells, cells expressing a TCR 
composed of the γδ chains and cells that express the CD8αα homodimer together with 
the αβ TCR. They do not express either CD4 or CD8αβ co-receptors. These ‘natural’ 
IELs are progeny of bone-marrow precursors, have a very restricted TCR diversity that 
tend to include self (auto)-reactive repertoire142,144, and populate the gut very early in life, 
in utero145. It is thought that they acquire their activated-phenotype by going through a 
thymic self-antigen based positive selection process that results in functional activation, 
followed by direct migration to the gut137. However, neither the identity nor the nature 
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(proteinaceous or non-proteinaceous) of these putative autoantigen(s) has been 
identified128. Moreover, maturation of these cells in the thymus is a subject of 
considerable debate with several pieces of evidence from athymic (nude), thymectomized 
and Rag-deficient mice that were reconstituted with bone-marrow from nude mice, 
suggesting they are a thymic-independent lineage146,147.  
In contrast, the second subset; referred to as ‘induced’ or  type-a143 IELs, are the progeny 
of conventional CD8αβ+ or CD4+ TCRαβ+ T cells that are activated post-thymically in 
response to non-self antigens129. Therefore, they comprise mostly tissue-resident memory 
(TRM) cells that are recruited back to the epithelial compartment after originally being 
activated in the GALT. In line with being memory cells, global analysis of the TCR-beta 
chain sequencing revealed that the TCR-repertoire of these ‘induced’ IELs is oligoclonal, 
unlike the polyclonal nature of conventional naïve T cells in the periphery144. However, 
compared to memory T cells in other tissues, the co-stimulatory requirements for these 
‘induced’ IELs are distinct148. For example, while the co-stimulatory CD40-CD40L 
interaction is redundant for splenic memory T cell activation, CD40L triggering was 
shown to be essential for the CD8αβ+ TCRαβ+ induced IEL response149.   
It has been speculated that the early presence of natural IEL in the gut, before birth, 
allows for a stress-sensing surveillance that recognises conserved antigens and/or 
responds to inflammatory cytokine cues129. A surveillance process that is expected to be 
tolerant to harmless antigens but protective against invasive stress-inducing pathogens. 
Indeed, human γδ TCR+ intestinal IELs were shown to interact with (recognise) the 
stress-induced MHC class I-related (MICA and MICB) molecules150. This recognition 
was independent of antigen processing150, and most likely involved the stimulatory 
NKG2D receptors128. On the other hand, in response to exogenous antigens exposure, the 
induced IELs gradually accumulate with age151. It has been suggested that this gradual 
accumulation allows for the development of a focused and ‘personalized’ mucosal 
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immune repertoire that is directed against the most likely to be re-encountered 
environmental antigens129. With the passage of time, the induced IELs gradually become 
the dominant population, while the natural IELs representing a minor population in spite 
of remaining steady in actual numbers129,152.  
Regardless of the subtype, the maintenance of all IELs is dependent mainly on the 
constitutive production of IL-7153 and IL-1587 by IECs. This is influenced by the 
intestinal microflora; for example TLR-mediated MyD88-dependent induction of IL-15 
by IECs had been shown to be essential for maintenance of CD8aa+ αβ TCR+ and gd 
TCR+ IELs154. Furthermore, the gut IEL-compartment is also directly affected by the 
diet. Replacing intact dietary protein, by feeding wild-type mice an equivalent amount of 
amino-acid based protein(antigen)-free diet from the time of weaning, results in poor 
development of intestinal immune cells similar to that seen in germ-free mice, with a 
significant reduction in CD3+ IEL populations155. Similarly, interruption of vitamin D 
signalling, by knocking-out its receptor, results in an intrinsic proliferative defect of the 
CD8αα+ IELs with a subsequent reduction in their numbers156.  
 
Collectively, these data, and others, highlight the importance of the aging process and the 
diet, in addition to the microbiota, as major modulating factors of the intestinal mucosal 
immune system.  
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1.2.4 Intestinal Mucosal Immune System: The Impact of Aging 
 
A growing body of evidence indicates that the immune system is drastically affected by 
the inevitable, natural, yet ill-defined aging process157–159. Aging, often compounded by 
malnutrition and dehydration, results in a significant deterioration of both innate and 
adaptive immune responses with a consequent increase in mortality due to increased 
incidence of infections and cancer160. Moreover, studies in healthy subjects revealed that 
advanced age is associated with a low-grade chronic hyper-inflammatory state, referred 
to as ‘inflammaging’161, that has been attributed to elevated circulating pro-inflammatory 
‘geriatric’ cytokines levels, including IL-6, TNF and IL-1β.  
Reportedly the age-associated alterations and defects arise in the gut mucosal immune 
system earlier than in the systemic immune compartments162. However, relatively little is 
known about the precise cellular and molecular mechanisms of gut mucosal 
immunosenescence163.  
Examples of the reported age-associated changes in gut immunity are: reduced ability to 
establish oral tolerance to antigens164, reduced levels of sIgA165 and alteration of the 
microbiota community166. These are associated with intrinsic regenerative defects in the 
aging gut-epithelial stem cells167, significant decline of Paneth cell numbers and 
secretory function168, alteration of the amount and chemical composition of the mucus 
produced by goblet cells169, and impairment of the functional maturation of M cells170.  
Moreover, in the context of intracellular parasite infection, aged gut-derived DC were 
found to be suboptimal at priming T cells and were characterized by a significant decline 
of IL12p70 and IL-15 production accompanied by decreased expression of CD80/CD86 
co-stimulatory molecules171. Exogenous application of IL-15 was sufficient to restore the 
co-stimulatory signal and the ability of the aged DCs to prime the T cell response171. 
Interestingly, under steady-state conditions and unlike the young gut-derived DCs, the 
aged DC fail to induce TGFβ secretion and the differentiation of Treg cells. Instead they 
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promoted T cells to produce IFNg172. The likelihood of a more pronounced pro-
inflammatory activity of the aged gut-derived DCs was not assessed. However, IECs can 
be a good source of the ‘geriatric’ cytokines and recent animal studies show that aging 
can increase IEC production of pro-inflammatory cytokines such as IL-1β and IL-6173. 
Therefore, it has been reasonably suggested that the low-grade chronic ‘inflammaging’ 
state typical of old age may originate from the intestinal environment174. In addition, or 
as a consequence of the above, the composition of the intestinal microbial communities 
is significantly altered in old age166 with evidence suggesting the growth of more disease-
promoting microbial populations175.   
Despite the growing attention and amount of literature concerned with the impact of 
aging on intestinal mucosal immunity, considerable gaps still exist in our knowledge 
especially in the cause-effect relationship of the various changes observed with aging in 
the gut and the response to external influences; i.e. commensals, diet and pathogens163. 
Basic aspects, such as the expression of PRRs by aged IECs and gut associated myeloid 
cells or the ability of aged IECs to mount an effective anti-pathogen responses were not 
assessed and are currently unknown.     
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1.2.5 Dietary Influences on Intestinal Mucosal Immunity: A Focus on the Role of 
Aryl Hydrocarbon Receptor (AhR)    
 
Evidence for the influences of nutritional status and dietary choices in the development, 
maintenance and shaping of the gut mucosal immune system are continually 
emerging176,177. Protein-energy malnutrition increases the susceptibility of the host to 
severe and prolonged enteric viral infections178. By using a mouse malnutrition-model of 
Norovirus (MNV) infection, thus minimising host genetic and other environmental 
variables, Hickman et al. (2014) were able to demonstrate a direct (causal) link between 
malnutrition and the increased severity of MNV infection, as defined by weight loss, 
reduction of protective immunity and enhanced viral evolution179. Furthermore, several 
epidemiological studies have associated the so-called ‘Western diet’, deficient in 
vegetables and micronutrients, with an increased prevalence of several inflammatory 
disorders, including inflammatory bowel disease180,181. Nutrients and pathogens share a 
number of cellular sensing pathways that can be the mediators for the nutrient-induced 
chronic inflammatory disorders182. Moreover, the impact of the dietary components on 
the intestinal mucosa can be observed at several levels including the modulation of IEC 
function and permeability183, the modification of microbial load and composition184, in 
addition to the effects on the development, recruitment and function of the various 
lymphocyte populations and immune cells in the gut177. Many of the ligand-activated 
transcription factors involved in the development and function of immune cells are 
directly influenced by or, are themselves nuclear receptors for naturally occurring 
molecules such as lipids and vitamins185, thus providing a connection between the 
cellular transcription machinery of immune cells and dietary components. For example, 
the nuclear receptors for vitamin A and D metabolites are highly expressed by immune 
cells occupying the barrier mucosae, i.e. the major sites for acquiring these essential 
vitamins. By mediating the response to their corresponding ligands, those receptors have 
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been shown to have very important effects in the differentiation, function and homing 
properties of T and B lymphocytes and to significantly contribute to gut 
homeostasis177,186.  
Recently, more attention has been drawn to the Aryl Hydrocarbon Receptor (AhR), an 
evolutionary highly-conserved basic Helix-Loop-Helix (bHLH) cytosolic transcription 
factor187 that is widely expressed in the body, but again significantly high expression has 
been detected in the immune cells of the barrier sites188. 
The AhR belongs to the family of Per-Arnt-Sim (PAS) domain-containing sensing 
proteins and has been extensively studied by pharmacologists and toxicologists as a 
mediator of responsiveness to xenobiotics and to environmental pollutants such as dioxin 
(and its most potent subtype 2,3,7,8-tetrachlorodibenzo-p-dioxin; TCDD)189. Intensive 
research over three decades has linked AhR signalling to many biological processes such 
as cell cycle regulation, circadian rhythm and reproduction190–192. However, the main 
physiological function of this evolutionary highly conserved receptor193 remained elusive 
and poorly understood. In the absence of a ligand, AhR is found in the cytoplasm bound 
to chaperon proteins; namely Heat-Shock-Protein-90 (HSP90), co-chaperone (p23) and 
the AhR-interacting protein (AIP)188 (Figure 1.3). Upon ligand binding, AhR translocates 
to the nucleus, where it dissociates from the chaperons and hetero-dimerizes with its 
protein partner AhR-Nuclear Transporter (ARNT). The AhR-ARNT complex binds to 
genomic DNA regions containing the dioxin-response element (DRE) binding motifs, 
and induces the transcription of several genes including cytochrome-P450 enzymes; such 
as CYP1, TCDD-inducible poly(ADP-ribose) polymerase (TIPARP), aldehyde 
dehydrogenase, and the AhR repressor protein (AhRR)188,194,195 (Figure 1.3).  
The physiological functions of AhR might require transient and tightly controlled 
signalling, as sustained AhR signalling, mediated by dioxin for example, results in 
pathological consequences196. Moreover, a number of regulatory mechanisms are already 
                                                   			
- 28 - 
in place in the AhR system to ensure this controlled and transient signalling. Examples of 
these regulatory mechanisms include; the disruption of the AhR/ARNT complex by 
AhRR, proteasomal degradation of activated AhR and autoregulatory ligand metabolism 
by the cytochrome-P450 enzymes188 (Figure 1.3). It is important to note that many of the 
reported AhR functions are mediated through interaction with many other cellular 
signalling pathways197. DRE motifs were found in the promoter region of many genes 
relevant to immune responses, such as the genes encoding TLRs, IL-6 and TNFa188. An 
interesting interaction between the AhR, STAT1 and NFκB molecules has been detected 
by Kimura et al. (2009)198. They observed significantly augmented inflammation in 
response to LPS in AhR-deficient peritoneal macrophages. Analysis of wild-type 
macrophages revealed a physical association between activated AhR and STAT1 
molecules. This AhR-STAT1 complex blocked the inflammatory cascade initiated by 
NFκB in response to LPS, a regulatory mechanism that is absent in the Ahr-/- 
macrophages198 (Figure 1.3). The physical interaction between activated AhR and 
STAT1 molecules had also been shown to down regulate the activity and phosphorylation 
of STAT1, thus reinforcing the TH17 transcriptional program by blocking the alternative 
pathway that leads toward TH1 effector differentiation199.    
In line with being an environmental sensor, AhR is strongly expressed by different cell 
types at the barrier sites; i.e. the gut, skin and lung. The hematopoietic immune cells with 
a high level of AhR expression include TH17 and, to a lesser extent Treg cells200,201. AhR 
expression in these two cell types has an important role in controlling their reciprocal 
plasticity and, thus, the development of TH17-mediated immunopathology200–202. Other 
immune cells expressing high levels of AhR are the gut CD8αα+ IEL203 and some subsets 
of innate lymphoid cells (ILCs)204.  
AhR is directly involved in the production of IL-22 by RAR-related orphan receptor 
gamma t (RORgt)+ ILCs and TH17 cells200,204, thus favouring intestinal homeostasis. 
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Indeed, AhR signalling via IL-22, was shown to inhibit inflammation in mouse-models 
of colitis and AhR expression was found to be downregulated in intestinal tissues of 
human patients with IBD205. Furthermore, characterization of AhR-deficient (AhR-/-) 
mice revealed a pronounced phenotype where there is a reduction in the number of cells 
normally expressing high levels of AhR; i.e. IELs and ILCs203,206. The Ahr-/- mice also 
suffered from a reduced ability to control the microbiota, with a detectable increase in its 
load and a change in its composition; a heightened-state of immune activation in the gut, 
with increased levels of IFNg and/or IL-17; and an increased prevalence of 
immunopathology203,207. Severe phenotypes with development of skin abnormalities, 
colitis, rectal prolapse and even premature death have also been reported in the 
literature208,209. It is important to note, however, that the development of immunological 
defects and phenotypic manifestations in Ahr-/- mice largely depends on the 
environmental factors and microbial status of the animal facilities in which the mice are 
bred188. In a clean environment and under strict specific-pathogen free conditions, Ahr-/- 
mice on a C57BL6 background do not exhibit an overt immunopathological 
phenotype188,210. This finding substantiates the notion that AhR signalling might not be 
essential for the development of a fully functional immune system, but rather functions 
in fine-tuning of immune responses according to environmental cues210,211. It is also 
worth mentioning that although lacking systemic assessment of differential expression in 
different organs, microarray data revealed evidence of AhR expression by myeloid cells, 
including macrophages and DCs, and non-hematopoietic cells such as epithelial cells212. 
The importance of AhR expression in these cells and its contribution to the maintenance 
of homeostasis and development of protective immune responses are largely unknown. 
What is known so far is that tissue-specific deletion of AhR in lymphocytes is sufficient 
to impair the maintenance of IELs and the formation of lymphoid clusters in the 
intestine, suggesting that the defective maintenance of IELs and ILCs in Ahr-/- mice is 
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cell intrinsic203,213. Contrarily, AhR deficiency restricted to skin keratinocytes is sufficient 
to replicate the hyper-inflammatory phenotype observed in skin lesions of Ahr-/- mice214.    
Reportedly AhR is quite promiscuous, i.e. has the ability to bind to, and be activated by, 
structurally diverse exogenous and endogenous molecules ranging from environmental 
pollutants, drugs, and dietary components to endogenous essential amino acid by-
products such as the tryptophan derivative 6-formylindolo[3,2-b]carbazole (FICZ)215.    
In fact, it has been demonstrated recently that AhR can sense distinct bacterial (M. 
tuberculosis and P. aeruginosa) pigments and subsequently induces antibacterial 
responses, suggesting that the AhR can function as an intracellular PRR216. This ligand 
promiscuity, however, has been challenged by the finding that many of these putative 
ligands interfere with CYP1 enzyme activity, thereby indirectly activating the AhR by 
increasing the availability of endogenous ligands217. This is further complicated by the 
fact that, despite many efforts to crystallise the AhR, its 3-dimensional structure has not 
been resolved yet. As a result, receptor-ligand interactions have so far only be estimated 
via computer modelling215. Hence, the affinity and specificity of many putative AhR 
ligands remain controversial. The most promising candidates for endogenous ligands are 
groups of tryptophan photo-oxidized products discovered late in 1987218, the best and 
most studied example of which is FICZ. FICZ was found to be a high-affinity AhR 
ligand that occurs in human and murine skin upon UV-light exposure and activates AhR 
in vivo. Unlike dioxin, it is readily metabolized by the AhR-regulated CYP enzymes and 
therefore results in transient activation of AhR (reviewed in 219).  
Furthermore, the consequences of AhR activation are quite contextual and depend on 
many factors including the affinity of AhR for the ligand, the half-life of the ligand and 
its method of administration188. This is best exemplified by contradictory reports 
regarding the role of different AhR ligands in progression of the mouse model of 
Multiple Sclerosis (MS). Injection of dioxin (a long-acting AhR-agonist) ameliorates the 
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autoimmunity and inflammation in this model201, while local, but not systemic220, 
administration of FICZ (a short-acting agonist) aggravates the pathology200. These 
differences can be partially explained by the fact that sustained activation by dioxin will 
eventually result in down regulation of AhR protein and a loss of function phenotype 
rather than AhR over-activation221.      
A good indicator of AhR induction is the level of expression of the AhR target gene 
Cyp1, which in the intestine has been directly attributed to dietary AhR ligands222. The 
dietary sources of AhR ligand include cruciferous vegetables, which are rich in 
glucosinolate glucobrassicin. Enzymatic degradation of this component yields indole-3-
carbinol (I3C) which under the influence of stomach acid will be converted to the high 
affinity AhR ligands; 3,3-di-indolylmethane (DIM) and indolo[3,2-b]carbazole (ICZ)223. 
Interestingly, when compared to control mice that were fed a standard diet, wild-type 
mice fed a synthetic diet deficient in vegetable materials but supplemented with all 
essential nutrients had substantially altered intestinal immunity and architecture, similar 
to that observed in Ahr-/- mice, with decline of both IEL numbers and function203. 
Supplementation of the same synthetic deficient diet with only I3C, the AhR ligand 
precursor, was sufficient to restore the IEL numbers and function to levels comparable to 
those of mice on a standard diet203.  
Thus, manipulation of the AhR system, either genetically or by diet modification, directly 
influences the number and function of IELs with subsequent effects on gut homeostasis. 
Given the potential contribution of activated IELs in the induction of an antiviral state, 
and the, previously mentioned, possible interactions between AhR- and STAT1-signalling 
pathways, it is intriguing to investigate the effects of AhR manipulation in the context of 
enteric viral infection.  
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1.3 Noroviruses  
1.3.1 History, Structure and Classification 
 
Belonging to the Caliciviridae family, noroviruses are icosahedral, non-enveloped, 
single-stranded, positive-sense RNA viruses, with a genome size of around 7.4 kb224. 
Identified for the first time following a human gastroenteritis outbreak in Norwalk, Ohio 
in 1968225,226; they were originally named Norwalk viruses. They were subsequently 
discovered in a wide range of species including rodents, cows, sheep and non-human 
primates227–230. The first identification of a norovirus infection of mice in 2003231, called 
murine norovirus (MNV), is considered a major landmark in the field as it provided a 
novel, viable and accessible in vivo model to study norovirus biology. 
Norovirus genome contains at least three open reading frames (ORFs). ORF1 is 
translated as a polyprotein that is subsequently cleaved into 6 non-structural proteins 
including a viral protease, a 5’ terminal genome-linked (VPg) protein and an RNA-
dependent RNA polymerase. ORF2 and ORF3 encode the major (VP1) and minor (VP2) 
capsid proteins respectively232,233. A fourth reading frame (ORF4) that overlaps ORF2 
has been recently identified in the genogroup of noroviruses infecting mice but not in 
other norovirus genogroups234. The protein encoded by ORF4 was termed virulence 
factor 1 (VF1) and was shown to play a role in delaying both the induction of type-I IFN 
and apoptosis234. 
Based on the predicted amino acid sequences of the major capsid protein, VP1, which 
shows the greatest variation due to strong selection pressure by the immune response, 
noroviruses are classified into five genogroups. To an extent, this classification system 
correlates with the host-specificity of different viruses. Genogroup I (GI), GII and GIV 
viruses infect humans, with the GII.4 strain being the most prevalent, while GV viruses 
infect rodents235,236. Human histo-blood group antigens (HBGAs), likely recognised by 
the protruding domain of the major capsid protein, have been regarded as the main host 
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receptors for noroviruses, and their differential expression has been considered to be the 
major determinant of host range and humans susceptibility237–239. In fact, the levels of 
neutralising antibodies blocking this interaction between the virus and HBGAs were 
shown to correlate with the development of protective immunity against norovirus 
infection in human240. Attempts to harness this for the development of protective human 
vaccines are currently under extensive research focus241. 
 
1.3.2 Human Noroviruses: The burden and the challenges 
 
Human Noroviruses (HuNoVs) are leading causes of acute, self-limiting gastrointestinal 
infection. Although asymptomatic (sub-clinical) infections occur frequently242, a typical 
illness resolves within 1-4 days, with abdominal cramps, nausea, vomiting and diarrhoea 
being the common symptoms243,244. Viral shedding in the faeces, however, may last for 
weeks to months in symptomatic/asymptomatic healthy individuals245, and years in 
immunocompromised patients246,247. A recent report suggested that new emerging 
variants of HuNoVs result in infections of healthy hosts with a longer average duration 
of viral shedding compared with that of previously circulating strains248. 
Since the introduction of rotavirus vaccines and control of rotavirus infections, HuNoVs 
have become the predominant gastrointestinal pathogen within the paediatric population 
in developed countries249,250. They are now considered to be responsible for more than 
90% of non-bacterial gastroenteritis cases and the commonest cause of both epidemic 
and sporadic cases of acute food-born enteric infections worldwide251–253. This, in part, is 
due to the low infectious dose required for infection, the extended viral shedding and the 
high environmental stability and contagiousness of HuNoVs with rapid person-to-person 
transmission either directly through the faeco-oral route and/or indirectly from contact 
with contaminated fomites, food or water254. In addition to the increased morbidity and 
mortality in the most vulnerable population of the very young, the elderly and the 
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immunocompromised, HuNoV disease causes a substantial economic burden as a 
consequence of health care costs and loss of productivity; estimated at about US$60 
billion in societal costs every year255. 
Due to this huge burden, strong efforts have been employed to bridge the gaps in the 
understanding of the natural history, pathogenesis, and immunobiology of HuNoVs. For 
several decades, these efforts had been curbed by the lack of a valid cell culture system 
and the absence of small animal models for HuNoV256. Recent efforts addressing these 
obstacles have yielded some progress. Firstly, using ‘humanised’ T and B lymphocyte 
and cytokine receptor common gamma chain (Rag-gc) double-deficient BALB/c mice, 
Taube et al. (2013) were able to develop the first mouse model of HuNoV257. Secondly, 
by generating human intestinal enteroids (organoids) from stem cells isolated from 
intestinal crypts, Ettayebi and colleagues (2016) developed a reproducible in vitro culture 
system that allowed the cultivation of multiple HuNoV strains258. The extremity of the 
first model and the high cost of the second, together with the fact that studying factors 
regulating HuNoV pathogenesis in the natural host, humans, will always be difficult due 
to ethical considerations, have driven the long-standing usage of surrogate models of 
related noroviruses in their natural hosts as the most popular and sensible strategy259. 
Among these, MNV provides the most widely used, readily tractable model system to 
explore viral and host factors regulating norovirus infection260,261. 
 
1.3.3 Murine Noroviruses (MNVs): A model of enteric viral infections 
 
A natural mouse pathogen endemic to wild mice and animal facilities throughout the 
world262–264, MNV has been widely used as a model to study the immunobiology of 
enteric viral infections. However, Owing to distinct features of infection in their 
respective natural hosts (reviewed in 261) MNV has always faced criticism as to whether 
it is a relevant surrogate model for HuNoV infection261. Indeed, the MNV model does not 
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recapitulate all aspects of HuNoV infection. As clinical disease has not been reported 
after infection of immunocompetent mice265, MNV is considered an infection-only 
model. The genetic variation between MNV strains is also much less prominent than that 
observed between HuNoV strains266. Moreover, MNV and HuNoV have distinct 
differences in their known attachment factors and receptors261. Nonetheless, recent data 
suggest more shared properties between the two viruses in terms of the common 
carbohydrate nature of their distinct receptors, their potential abilities to establish 
persistent viral shedding and importantly some aspects of their cellular tropism261. 
The currently prevailing paradigm is that MNV (with the help of the microbiota267) first 
breaches the intestinal epithelial barrier by hijacking the Microfold (M) cell transcytosis 
pathway268. It then infects mononuclear phagocytes of the LP before being trafficked to 
local lymph nodes, MLN and to distal sites, such as the spleen and liver, by migratory 
DCs269–271. MNV infection of IECs has never been demonstrated in vitro, though has 
been observed in vivo after infection of Stat1-/- and Rag1-Stat1-/- double deficient 
mice265,272. It is important to note, however, that most of the studies supporting the above 
infection pathway were conducted using the MNV-1 (prototypic strain) as the only 
pathogen. There was no reference to the possibility that different MNV strains (discussed 
in more details in subsequent sections) might differ in their initial site of infection and in 
their broad tissue tropism. Indeed, different MNV strains have quite distinct biological 
properties despite limited sequence (genetic) variation266. Studies that directly compared 
the tissue tropism of different MNV strains showed that MNV-3 and MNV-O7, both 
considered to be attenuated strains of MNV, resulted in higher intestinal and lower 
splenic viral titres compared to those caused by the acute strain MNV-1 (273 and 
unpublished work by Dr James Chettle). The picture is even less clear in HuNoV 
infection, with evidence of initial infection and replication in both IECs258 and 
mononuclear phagocytes of the LP274. A recent interesting report suggests that both MNV 
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and HuNoV infect B cells and share a dependence on commensal bacteria for efficient 
replication267. 
A major determinant of cellular tropism, and overall species specificity is the diversity 
and differential expression of the attachment receptors. The importance of HBGAs in 
HuNoV infection was discussed above. The first MNV-1 receptors identified were 
terminal sialic moieties on gangliosides (Taube et al, 2009)275. Recently, two members of 
the mouse-specific type-I transmembrane CD300 protein family, namely CD300LF and 
CD300LD, have been shown to act as proteinaceous receptors for MNV276,277. 
Experimental (induced) expression of these molecules in multiple, non-susceptible cell 
lines, including human-derived HeLa cells, supported MNV infection and propagation, 
while knocking-out the expression of these molecules rendered mice resistant to viral 
shedding following oral infection with MNV276,277. These recent data will pave the way 
for more investigation of the molecular details of norovirus internalisation. 
Generally, the ability to cultivate MNV in multiple in vitro cell lines, to genetically 
manipulate both the virus and the host and the availability of both acute (MNV-1) and 
persistent (e.g. MNV-CR6, MNV-3, and MNV-O7) strains, add a substantial strength to 
the MNV model as a tool to study, analyse and dissect not only HuNoV infection but 
different aspects of enteric viral infections in general. 
 
1.3.4 Murine Noroviruses (MNVs): Viral determinants of Virulence and Persistence 
 
Being highly prevalent in research animal facilities278,279, new isolates and strains of 
MNV with diverse biological behaviours continue to emerge and be reported. At least 60 
new strains of MNV had been defined and uploaded to Genbank during the last decade. 
Our lab has recently characterised a new strain of MNV, known as MNV-O7, which was 
originally isolated from a mixed colony of Stat1-/- and Ifngr1-/- mice. Unlike MNV-1, 
MNV-O7 was found to cause chronic infection in wild-type mice and attenuated 
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pathology in Stat1-/- mice280. In fact, to date, the vast majority of newly identified MNV 
strains show a phenotype of long-term persistence in wild-type mice and attenuated 
infection in immunocompromised hosts273,279,281, in direct contrast to the original MNV-1 
(CW1 and CW3) isolate’s phenotype of rapid clearance in immunocompetent, and severe 
and/or persistent disease in immunodeficient hosts231,265. This is also in contrast to the 
perceived acute pathogenesis of HuNoVs. Research has taken place to identify the 
determinants of these different phenotypes of virulence and persistence with a focus on 
different aspects of viral factors, tropism and the elicited immune responses. 
Several viral proteins have been implicated in virulence of different viral strains. Given 
its function in antagonising the innate immune response and delaying apoptosis, ORF4-
encoded VF1 is considered to be an important contributor to MNV virulence in vivo234. 
Early studies on MNV revealed an association between the virulent phenotype and the 
expression of lysine instead of glutamic acid at position 296 of the major capsid protein, 
VP1271. Subsequently, it was shown that this K296E substitution in VP1 is sufficient to 
attenuate MNV-1 infection in Stat1-/- mice282. However, there is no evidence, to date, that 
naturally occurring attenuated strains can be made more virulent by the reverse E296K 
mutation.  
The persistent phenotype, on the other hand, has been shown to be associated with 
superior colonic tropism in the early stages of infection, with the subsequent 
consideration of the cecum and colon as the major tissue reservoir of persistent MNV 
strains283,284. A single amino-acid substitution (D94E) in the NS1/2 non-structural protein 
was suggested to be sufficient to determine persistence, with exchange of that region 
between MNV-1.CW3 (naturally acute) and MNV-CR6 (naturally persistent) conferring a 
persistent phenotype on CW3 and an acute one on CR6284. How this mutation relates to 
specific cellular tropism (i.e. IECs vs mononuclear phagocytes), and to the subsequent 
immune responses elicited has not been defined, however.  
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1.3.5 Murine Noroviruses (MNVs): The Immunology 
 
While rather blunt and inevitably complicated by compensatory feedback mechanisms, 
genetic knockout mouse models have proved to be extremely valuable and tractable for 
interrogating the MNV-induced immune response261. Innate immunity with the 
production of, and response to, IFNs has been consistently shown to be crucial for the 
control of MNV infection. It has been reported that the innate viral sensor MDA5 (from 
the Ifih1 gene) and, to a lesser extent, TLR-3 are involved in the control of MNV-1 (the 
acute strain) infection both in vitro and in vivo285. However, neither Ifih1-/- nor Tlr3-/- 
mice succumbed to the oral infection with MNV-1 and the virus load in both, although 
higher, was cleared within the same time frame as wild-type mice, i.e. 5-7 days post-
inoculation285. This indicates redundancy and involvement of other, not yet identified 
PRRs in detection of MNV. Downstream of these viral sensors, IRF-3, IRF-5 and IRF-7 
have been recognized as the critical mediators of the IFN response to MNV 
infection286,287. Both type-I and II IFNs can inhibit the translation of MNV non-structural 
proteins288, and whilst it does not cause serious clinical disease in immunocompetent 
hosts, oral MNV-1 infection causes fatal disease in IFNαbg receptor triple-knockout and 
Stat1-/- mice231. STAT1-dependent responses rapidly control MNV-1 (the acute strain) 
infection in the intestine, prevent the development of clinical disease and limit viral 
dissemination to peripheral tissues265. Interestingly, for the persistent strains of MNV, 
IFNAR1 expression does not control viral shedding nor determine viral titres in the gut 
but rather regulates the ability of the virus to spread to extra-intestinal sites such as the 
spleen289,290. Two recent complementary studies showed that the faecal shedding of these 
persistent strains is instead limited by type-III IFN signalling through IFNLR1289,290. 
Thus, intraperitoneal administration of IFNl was sufficient to cure persistent MNV-CR6 
infection289. More intriguingly, it has been found that the presence of commensal bacteria 
suppresses an endogenous type III IFN response that would otherwise prevent and/or 
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clear this persistent MNV-CR6 infection290, so a treatment of wild-type mice with broad-
spectrum oral antibiotics for 2 weeks prior to inoculation with the persistent MNV-CR6 
strain, prevented the establishment of persistent enteric infection by type III IFN-
dependent mechanisms290. More recently, it has been revealed that the expression of 
IFNLR1 on intestinal enterocytes (IECs), but not on other cells, is critical to this antiviral 
effect of IFNl291. While the argument for broad-spectrum antibiotic therapy may be 
thought of as an impractical due to the anticipated drastic side-effects (although it has 
already been justified in some severe infections in immunodeficiency cases292,293), IFNl 
administration is an especially attractive therapeutic approach for HuNoV infection, 
given its safety profile in treatment of chronic hepatitis C virus294,295.  
Collectively, these data indicate that the IFN-JAK-STAT signalling pathway is 
particularly relevant in the protective immunity against MNV infection. Redundancy 
exists at the level of PRRs and also at the level of the downstream ISGs231, with possible 
differential roles and importance of different IFN subtypes. However, a functional STAT1 
molecule is absolutely necessary for protection from MNV infection. 
While it might not be critical for survival, the adaptive immune response appears to play 
an important role in clearance of MNV infection. Unlike Stat1-/- mice, oral infection of 
Rag1-/- or Rag2-/- mice with MNV-1 did not induce lethality, however, for up to 90 dpi 
the mice maintained a high level of virus in faeces, blood and all organs analysed231. The 
long-term infection with the acute strain, MNV-1, in this instance was associated with 
minor disease and the absence of the overt pathological changes commonly seen after 
infection of wild-type mice.  
Adoptive transfer of splenocytes from MNV-immune, but not from non-immune, wild-
type mice was sufficient to clear persistent MNV-1 infection from the intestine of Rag1-/- 
mice by day 6 post-transfer296,297. By comparing the effects of transferring immune 
splenocytes from wild-type mice, µMT mice (genetically deficient in B cells) or from 
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HELMET mice (lack B cells capable of producing antigen-specific antibodies) into 
Rag1-/- mice, it was demonstrated that B cells and the MNV-1-specific antibodies they 
produce are essential for the clearance of the virus297. Similarly, depletion of either CD4 
or CD8 T cells from the transferred splenocytes resulted in a significant increase of the 
viral titres compared to those of the control depletion296. Interestingly, while adoptively 
transferred immune splenocytes from Ifng-/- mice were as effective as those transferred 
from wild-type mice in clearing the persistent MNV-1 infection from Rag1-/- mice, 
immune splenocytes from Perforin (Prf1)-deficient mice were less effective296, 
suggesting a superior role of direct cell-to-cell cytotoxicity by T cells compared to their 
cytokine production in clearing the virus. Moreover, CD4+ and CD8+ T cells seem to play 
different combinatorial roles in controlling MNV infection. CD4+ T cell deficient mice 
present with higher tissue titres but normal viral clearance, whilst mice lacking CD8+ T 
cells exhibit delayed viral clearance296,298. Indeed, the persistent phenotype of MNV has 
been associated with a suboptimal virus-specific CD8+ T cell response299.  
Taken together, the data discussed above suggest that infection with various MNV strains 
elicits differential innate and adaptive immune responses. While adaptive immunity is 
critical to control and clear acute strains such as MNV-1; persistent strains, by induction 
of milder innate immune responses, fail to generate effective antigen-specific T cell 
responses (299,300 and Dr James Chettle’s, unpublished work). However, it has been 
shown recently that robust adaptive immunity alone is both not essential for cure of 
persistent MNV-CR6 infection, as in its absence IFNl treatment was enough289; and is 
not sufficient to confer clearance of acute MNV-1, as the virus persists systemically in 
mice conditionally deficient for type-I IFN signalling in DCs, despite an intact and fully-
functional adaptive immunity301. Thus, in my opinion, an effective, innate anti-MNV 
immune response is the key and should be the focus for immuno-protective (–
therapeutic) strategy design.  
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1.4 The overall aim and objectives of this project 
The main hypothesis of this thesis was that; owing to their state of activation, abundance 
and unique location above the basement membrane, IELs play an important role in gut 
mucosal immunity that protects against enteric viral infections. I also hypothesized that 
this protective anti-viral immunity is directly affected by the aging process and by the 
manipulation of the gut-associated AhR system, as both the maintenance and functions 
of IELs and the efficiency of enteric mucosal immunity in general are directly influenced 
by aging and by the availability of certain micronutrients that act as ligands to AhR. 
Using MNV as a mouse-model of enteric viral infections, my overall aim was to address 
these hypotheses through a combination of in vivo and in vitro studies.  
The main objectives of the project were as follows: 
1. Determine the Role of IELs on Early Gut Immunity Against MNV (Chapter 3). 
2. Investigate the Influence of Aging on Early Gut Immunity Against MNV (Chapter 4).   
3. Analyse the Effects of AhR manipulation on Early Gut Immunity Against MNV 
(Chapter 5). 
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Chapter 2 GENERAL MATERIALS AND METHODS 
 
2.1 Cell Lines 
BV-2 cells (a mouse microglial cell line303), a kind gift Prof. Ian Goodfellow (Pathology 
Department, University of Cambridge), were derived from primary microglial cell 
cultures from C57BL/6 mice immortalised by infection with a v-raf/v-myc oncogene-
carrying retrovirus. This cell line was found to share the antigen profile, phagocytic and 
antimicrobial properties of activated macrophages304. The cell line was maintained by 
growing in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10 % 
foetal calf serum (FCS), 100 U penicillin/ml and 0.1 mg streptomycin/ml (10%DMEM). 
The cells were seeded (at 2-5 x 104 cells per cm2) in tissue culture flasks and incubated at 
37 º C, 5 % CO2. Every 3-4 days the cells were split (approximately 1:10) using cell 
scrapers (Greiner Bio-One).  
RAW 264.7 (a mouse monocyte macrophage cell line), was originally established from 
an ascites of a tumour induced in a male mouse by intraperitoneal injection of Abelson 
Leukaemia Virus (A-MuLV) (HPA Culture Collections 91062702). This cell line was 
maintained in an identical manner as that described for BV-2 cells.  
 
2.2 Viruses 
MNV-O7, a kind gift from Dr. Amita Shortland (University of Cambridge), was cultured 
from a faecal sample of a Stat1-/- mouse, passaged twice through RAW 264.7 cells then 
twice through BV-2 cells to generate the MNV-O7P4 virus stock used for the infection 
assays. 
MNV-1.CW3P5 (1 x 107 genome copies/ml), a kind gift from Prof. Herbert Virgin 
(Department of Pathology and Immunology, Washington State University, USA), was 
passaged twice through RAW 264.7 cells and then twice more through BV-2 cells to 
generate the MNV-1.CW3P9 stock used for oral infection of mice.  
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MNV-3 (6.61 x 107 TCID50/ml), a kind gift from Prof. Ian Goodfellow (Department of 
Pathology, University of Cambridge), was used immediately as a working stock for the 
infection assays. 
 
2.3 Generation of high-titre virus (working) stocks and ultra-violet inactivated virus 
stock 
Working virus stocks were grown on BV-2 cells in 10% DMEM by infecting 50% 
confluent (175 cm2) tissue-culture flasks with a diluted virus, in 10 ml of media per flask, 
at a multiplicity of 0.01-0.1 TCID50/cell. Infected flasks were incubated for 1 hour at 37 
°C with gentle agitation applied every 15 minutes. After this incubation, the media in 
each flask was topped up to 25 ml and the cells returned to the 37 °C incubator until clear 
cytopathic effects (CPE) were detected or for 5 to 6 days if CPE were not obvious. The 
cells were then subjected to 3 cycles of freezing (-80 °C) and thawing and the culture 
fluid was decanted from the flasks to sterile tubes and centrifuged (2000 x g, 10 min).  
The resulting clear supernatant, which contained virus, was passed through a 0.22µm 
filter, aliquoted and stored at -80 °C. Virus titre was determined by measuring TCID50 in 
BV-2 cells and by quantitative RT-PCR. 
For some in vitro experiments an UV- inactivated virus stock was used to differentiate 
the effects of viral attachment and productive viral replication and infection. This 
inactivated virus stock was generated, tested and stored at -80 °C by Dr. James Chattle 
(University of Oxford) during his PhD study. Briefly; diluted working stocks of MNV-
O7P4 and MNV-1.CW3P9 were mixed at 1:1 ratio. This mixture was subjected to UV-
light irradiation (254 nm) for 10 minutes in sterile Pyrex beakers. This was sufficient to 
achieve a reduction in viral infectivity of at least five orders of magnitude as measured 
by TCID50 on BV-2 cells. 
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2.4 In Vivo Experiments 
2.4.1 Mice 
 
The origin and breeding of specific mice lines will be detailed in subsequent chapters. 
Unless otherwise stated, the age of the mice used at the beginning of the experiments 
described ranged between 6 to 14 weeks (mostly 8-12 weeks). In experiments with a 
mixture of male and female mice, sexes were distributed evenly between different study 
groups to account for the possibility of sex-specific differences. All mice were housed in 
individually ventilated cages and fed sterilised water and diet. The experimental 
procedures were performed at the Departments of Anatomy and Pathology, University of 
Cambridge. Transport, housing, care and procedures were all carried out in compliance 
with the University ethical review process and Animals (Scientific Procedures) Act 1986. 
 
2.4.2 Intraperitoneal Injection of Anti-CD3 and Isotype Control (ITC) Antibodies 
 
Anti-CD3 (Biolegend, 2C11, LEAF) and isotype control Armenian Hamster IgG 
(Biolegend, LEAF) antibodies were prepared to a concentration of 0.125 µg/µl by 
diluting the stock solution (1 µg/µl) in PBS. Mice were gently restrained (without 
anaesthesia) and injected intra-peritoneally with 200 µl of the diluted antibody solution 
administered from a 1 ml syringe attached to a ½ inch, 27-gauge hypodermic needle. 
 
2.4.3 Oral Gavage Infection with MNV 
 
MNV-O7 (O7P4) and/or MNV-1.CW3 (CW3P9) virus stocks were diluted, in PBS, to the 
required infectious titre. Mice were gently restrained and orally inoculated with 200 µl of 
the diluted virus inoculum administered from a 1 ml syringe attached to a blunt metal 2 
inches 20-gauge curved needle (Vet Tech Solution, UK) with a smoothed 2 mm wide 
metal sheath. Anaesthesia was not used, except for the antibiotic treatment and aging 
experiments in which the mice were lightly anaesthetised with isofluorane, held by the 
skin between the eyes and allowed to swallow the needle, which passed to the stomach. 
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2.4.4 Sample Collection 
 
Faeces: Faecal samples were collected from individual mice by placing them into 
separate clean containers for a few minutes and collecting the faecal pellets from that 
container. 
Tissues: mice were euthanized by CO2 asphyxiation with death confirmed by dislocation 
of the neck. For viral titration, small segments of the relevant tissues, usually small 
intestine, mesenteric lymph nodes and spleen were collected into labelled 2 ml 
Eppendorf tubes. 
 
2.5 Quantification of Infectious Virus Titre by TCID50 Assay 
A limiting dilution 50 % Tissue Culture Infectious Dose (TCID50) assay was used to 
quantify viruses that do not form plaques. BV-2 cells (at 3 x 104 in 100 µl of 10% 
DMEM) were seeded into 96 flat-bottomed well plates. 10-fold serial dilutions of the 
virus samples were made in 10%DMEM and 150 µl of the diluted virus were plated into 
each well with 6 replicates per dilution. The plates were then incubated at 37 º C, 5% 
CO2 for	4-5	days.	Wells	showing	cytopathic	effects	at	each	dilution	were	scored	by	microscopy	 and	 the	 TCID50	 was	 calculated	 using	 the	 Reed	 and	 Muench	 formula	(Reed,	1938).	
 
2.6 RNA Extraction Extraction	of	RNA	from	different	samples	(faeces,	tissues	and	cells	 in	culture)	was	performed	 using	 the	 Mammalian	 GenElute	 Total	 RNA	 Miniprep	 kit	 (Sigma-Aldrich,	RTN350),	 according	 to	 the	 manufacturer’s	 guidelines.	 Protocols	 for	different	samples	were	identical	once	the	sample	was	added	to	the	RNA	lysis	buffer	(containing 1% of 2-mercaptoethanol). Briefly, up to a maximum of 400 µl of lysis 
buffer containing the sample RNA was added to a filtration column and centrifuged 
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(1min, 16,000 xg) to remove the cellular debris and shear genomic DNA. One volume 
equivalent (i.e. a maximum of 400 µl) of 70% ethanol was added to each sample, and up 
to a maximum of 700 µl of the resulting mixture was centrifuged (15 sec, 16,000 xg) 
through a GenElute Binding column. Using the washing solution provided in the kit, 
several column washes were performed and the RNA was then eluted from the column 
into 50 µl of the kit elution buffer. Processing of different samples to the step of RNA 
lysis buffer were performed as detailed below. 
 
2.6.1 RNA Extraction from Faeces 
 
Weighed faecal samples were suspended into PBS to prepare 10% faecal homogenates. 
The faecal pellets were homogenised into the PBS by using 5 mm stainless beads in a 
Mixer Mill MM300 (Qiagen). The homogenates were then centrifuged (2 min, 16,000 
xg). 50 µl of the resulting supernatant (clear of any pelleted faecal debris) was added to 
300 µl of the RNA lysis buffer.  
 
2.6.2 RNA Extraction from Tissues 
 Tissue	samples	(weighing	no	more	than	40	mg)	were	homogenised	directly	into	500	
µl RNA lysis buffer (containing 1% 2-mercaptoethanol) using a Mixer Mill MM300 
(Qiagen) and 5 mm stainless beads. The samples were then centrifuged (2 min, 16,000 
xg) and 400 µl of the resulting supernatant was used for RNA extraction. 
 
2.6.3 RNA Extraction from Cells in in vitro Cultures 
 
RNA was extracted from cell cultures after removal of the supernatant. 96-well cell 
culture plates were centrifuged (5 min, 2,000 xg) and all but 50 µl of the supernatant was 
removed. 200 µl (i.e. four volume equivalents) of RNA lysis buffer was added to each 
well and the RNA extraction was performed as described above. 
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2.7 Quantification of Viral RNA Titre by RT-PCR 
The number of vRNA molecules in the extracted RNA samples was estimated by a one-
step quantitative RT-PCR analysis using the KAPA One-Step Probe qRT-PCR Universal 
Kit (Anachem, KK4752) with a 5’-JOE, 3’-BHQ-1 dual-labelled probe (Table 2.1). 
Briefly, a master-mix containing 1x KAPA One-Step Probe qRT-PCR master-mix,1x 
KAPA RT Mix, 0.25 µM of each primer (Q2F and Q2R, Table 1), 0.3 µM probe and the 
sample RNA was prepared and the PCR performed in a Rotorgene6000 (Qiagen) with the 
following parameters: reverse transcription	 (5	min,	42	 °	C);	RT inactivation and DNA 
polymerase activation (5 min, 95	°C), followed by 40 cycles of denaturation (5 s, 95 ° 
C), annealing and extension (30 s, 60 ° C). All the sample, standard and no template 
control (NTC) reactions were performed in duplicate, and the fluorescence data were 
collected at the end of each extension	 phase.	 Primer	 and	 probe	 sequences	 and	locations	are	shown	in	Table	2.1.	
Table 2.1 Quantitative RT-PCR prime and probe sequences and locations 
Name Sequence (5’ to 3’) Location in MNV-1 
genome 
Dual-labelled 
probe  
CCGCAGGAAYGCTCAGCAGTCTT 5028 to 5050 
Q2F GCTTTGGAACAATGGATGCTGAG 5002 to 5024 
Q2R CGCTGCGCCATCACTCATC 5061 to 5079  
 
 
 
The number of vRNA copies in each reaction was calculated using a standard curve 
generated by Dr. Amita Shortland (University of Cambridge) and further validated by Dr 
James Chettle (University of Cambridge). Briefly, the standard curve was designed using 
a linearized pT7-MNV-O7-Rz DNA plasmid. The initial concentration of the plasmid 
DNA was determined using a NanoDrop1000 Spectrophotometer (Thermo Scientific 
UK), and was then diluted in 10 µg carrier RNA (yeast tRNA, Roche UK 10109223001) 
per ml in water to obtain 5 x 1011 DNA molecules/µl as the highest concentration. A 
DNA standard curve (R2= 0.99761, Efficiency 1.01) was obtained by performing a serial 
10-fold dilution of plasmid DNA into tRNA/water. The assay was then validated using 
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10-fold serial dilutions of extracted viral RNA which showed similar efficiency to the 
DNA standard curve.  Data were analysed using the Rotorgene6000 series software 1.7 
(Corbett Life Science Research now Qiagen). The sensitivity of the assay was 5 vRNA 
molecules/reaction with a linear dynamic range of 100 to 109 vRNA molecules/reaction. 
Viral RNA titres from faecal samples were multiplied by the relevant dilution factor to 
calculate the number of viral genome copies per mg of faeces. Viral RNA titres in tissue 
samples were expressed relative to the weight (in mg) of the tissue segment analysed, 
while those of cell culture extract were expressed relative to the concentration of total 
RNA in the sample. 
 
2.8 Reverse Transcription and Gene Expression Assays 
2.8.1 Reverse Transcription 
 
The extracted RNA samples from tissues were reverse transcribed into cDNA, using the 
QuantiTect Reverse Transcription kit (Qiagen, 205313), according to the manufacturer’s 
protocol except for scaling down the total reaction volume from 200 µl to 12 µl. 
2.8.2 Gene Expression Analysis 
 
A Rotorgene SYBR green PCR kit and Quantitect primer assays (Qiagen, Table 2.2.) 
were used to analyse the gene expression levels in cDNA samples. Using a QIAgility 
automated pipetting robot (Qiagen), the reactions were set as per the manufacturer’s 
protocol with the exception of scaling down the reaction volume to 15 µl. The PCR was 
performed in a Rotorgene6000 and the parameters were: DNA polymerase activation (5 
min, 95 ° C); 40 cycles of denaturation (5 s, 95 ° C), annealing and extension (10 s, 60 ° 
C); followed by a melt curve, ramping from 60 ° C to 95 ° C, to check the specificity of 
the PCR product. For each cDNA sample, PCRs for 2 housekeeping genes (Rpl38 and 
Eef2) were performed. Fluorescence data were collected at the end of each extension	phase. 
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Data analysis was done using the Rotorgene6000 series software (version 1.7) and 
threshold cycle (Ct) values were assigned from a set threshold value. The “Housekeeping 
Ct” of a sample is defined as the mean Ct value of the 2 housekeeping genes of that 
sample. The level of expression of target gene was expressed as 2^(-ΔCt) multiplied by a 
factor of 1000.  ΔCt was calculated by subtracting Ct value of the gene of interest from 
“Housekeeping Ct”. This is the opposite of the usual subtraction of the housekeeping 
gene Ct from the gene of interest Ct but allows the graphical presentation to show 
samples with increased levels of expression higher than those with lower levels of 
expression. 
Table 2.2 Quantitect Primer assays (Qiagen) used for gene expression analysis 
Gene symbol
  
Catalogue numbe
r 
Gene symbol  Catalogue number 
Rpl38 
 
QT00145726 
 
Mx1 QT01064231 
Eef2 
 
QT00167293 
 
Isg15 QT00322749	
 Ifnl3 QT01774353 Adar  QT00165592  
Ifnb1 QT00249662 Rsad2 QT00109431 
 Ifng QT01038821 Prkr QT00162715 
 Tnfa QT00104006 Il10Rb 
 
QT00101367 
 Tgfb1  QT00145250  Il28Ra 
 
	QT00494137		Irf3  QT00108759  MX1 (Human) 	QT00090895		
Irf7 QT00245266 
 
ISG15 (Human) 	QT00072814		
 
2.9 Statistical Analysis 
All statistical analyses were performed using Prism Software. As data did not meet the 
assumption of being normally distributed, they were analysed by the non-parametric 
Mann-Whitney test. Graphs were produced using Graphpad-Prism 4 (GraphPad Prism 
Software, CA) and Microsoft Excel (Microsoft, WA). 
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Chapter 3 THE ROLE OF INTRAEPITHELIAL LYMPHOCYTES 
(IELS) IN EARLY GUT IMMUNITY AGAINST MURINE 
NOROVIRUS (MNV) 
  
3.1 Background 
Intestinal IELs constitute a highly-conserved T cell compartment, which is uniquely 
located above the basement membrane and in close proximity to both IECs and 
exogenous antigens in the intestinal lumen. They are usually defined as stress-sensing, 
highly regulated immune cells that, in steady-state conditions, are held in a ‘poised’ 
semi-activated state with the display of an alert-phenotype without full activation. 
Further details about IELs’ classification, intestinal distribution and differentiating 
features that characterise them from systemic lymphocytes, in addition to the factors that 
influence their maintenance and activation are included in Section 1.2.3.  
Several studies have focused on the ability of activated IELs to promote reparative 
epithelial growth86,305,306, to induce potent cytotoxicity128 and to produce large amounts 
of biologically-active soluble mediators, including cytokines and chemokines, that recruit 
other immune cells141,307,308. An interesting report revealed an early protective role of the 
gd TCR+ IELs in the context of Salmonella enterica ser. Typhimurium infection309. These 
IELs effectively limit bacterial dissemination by producing the antimicrobial factor 
RegIIIg, via a mechanism that depends on bacterial stimulation of IEC-intrinsic MyD88 
signalling309, suggesting a microbiota-dependent crosstalk between IECs and IELs. Older 
literature reported an immunoregulatory role of murine IELs in response to the Eimeria 
parasite infection310–312. A yet to be published report by the Veldhoen group (the 
Babraham Institute) elegantly demonstrated that at steady-state conditions IELs are kept 
in a ‘poised’ state of activation as a direct consequence of alterations in their 
mitochondrial cardiolipin composition that restrict their metabolic rate, proliferation and 
effector functions (Konjar et al., in revision). Upon inflammation, secondary to Eimeria 
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infection for example, the mitochondrial activity, and hence IEL proliferation and 
effector functions are released from this repression (Konjar et al., in revision). 
In contrast, little is really known about the potential contribution of activated IELs to the 
anti-viral responses of the gut mucosa. In order to address this, and in collaboration with 
our lab, Swamy et al. (2015) employed an in vitro IEL-IEC co-culture system, with 
subsequent in vivo validation of the molecular and biological impact, to analyse the 
effects on IECs upon activation of IELs by agonistic anti-CD3 antibodies302. Indeed, one 
of the most conspicuous impacts of activated-IELs on the IECs was the significant up-
regulation of ISGs and other genes of the antiviral response302. This induced anti-viral 
response could be directly attributed to the production of type-I, II and III IFNs by IELs. 
Agonistic anti-CD3 antibodies result in TCR-mediated activation of IELs302. The authors 
in this report were able to detect inducible phosphorylation of TBK1/IKKe on the 
activation loop Ser172 following the TCR-triggering of rested IELs. Inhibition of the 
phosphorylated TBK1/IKKe by a chemical inhibitor significantly reduced the induction 
of IFNa and IFNl mRNA upon stimulation of IELs by CD3/TCR complex triggering302. 
As phosphorylated TBK1/IKKe had been shown to be important for the phosphorylation 
and nuclear translocation of IRF-3 and IRF-7313, these findings suggest a possible 
pathway by which the production of type-I and III IFNs can be induced by anti-CD3 
stimulation of IELs. Consistent with the ‘anti-viral signature’ imposed on IECs, 
activated-IEL supernatant rendered IECs more resistant to encephalomyocarditis virus 
(EMCV) infection in vitro. Moreover, activation of T cells in vivo, by intra-peritoneal 
(i.p.) injection of anti-CD3 antibodies, induced a rapid up-regulation of ISGs in villous 
epithelial cells and enhanced resistance of mice to a murine norovirus (MNV-O7) 
infection302. Taken together, these data suggest a novel and powerful role of activated 
IELs in the early innate immune response to enteric viral infections. However, further 
characterization of this role and of the anti-CD3-MNV experimental model was needed. 
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For example, assessment of the already documented systemic broad effects of anti-CD3 
injections, the influences of microbiota and aging, the differential importance and 
involvement of different IEL-subsets and the exact in vivo contribution of the activated 
IELs in the observed protective immune response to MNV, are key questions that had not 
been addressed in previous studies.  
Furthermore, the availability of different strains of MNV that can result in either an acute 
self-limiting infection such as MNV-1.CW3 (hereafter MNV-CW3)265,271, or a persistent 
infection, e.g. MNV-O7314 and MNV-3283 (discussed in more details in Section 1.3), 
facilitates the analysis of the differential roles of, and influences on, IELs upon infection 
with acute versus persistent viral strains. 
In this chapter I aimed to address questions relevant to the role of IELs in this context. 
The chapter is divided into three major sections with the following main objectives: 
1) Characterise the anti-CD3-MNV experimental model by: 
a) Assessing the gut-associated and systemic effects of i.p. injections of anti-CD3. 
b) Attempt to improve the model by oral administration of anti-CD3. 
c) Confirm the importance of the IFN-STAT signalling pathway in the observed 
anti-CD3-mediated protection against MNV. 
d) Assessing the effects of microbiota manipulation, by antibiotic treatment, on the 
observed anti-CD3-mediated protection against MNV. 
 
2) Apply the anti-CD3-MNV model to determine the in vivo role of IELs by: 
a) Using knockout mouse-lines. 
b) Employing an adoptive transfer-model of lymphocytes into Rag2-/- mice. 
c) Comparing the role of IEL upon infection with MNV-O7 (persistent strain) vs 
MNV-CW3 (acute strain). 
 
3) Follow the leads from the results of the above to infer the differential immuno-
biological features and cellular tropism of different strains of MNV.   
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3.2 Materials and Methods 
For cell lines, viruses, in vivo infection and anti-CD3 administration, sample collection, 
RNA extraction, viral quantification, reverse transcription, gene expression assays and 
statistical analysis, please refer to Chapter 2. For generation of small intestinal 
organoids and bone marrow-derived mononuclear cells (BMMCs) cultures please refer to 
Section 4.2.3.3 and Section 5.2.2, respectively.    
 
3.2.1 Mice 
 
C57BL/6 wild-type, Il15ra-/-, Tcra-/-, Rag2-/-, Tcrd-H2B-eGFP and Il22-/- mice were bred 
at Babraham Institute (The Babraham Institute, Cambridge). 129 wild-type 
(129S6/SvEvTac) mice were originally purchased from Taconic (Taconic 
Farms Inc., USA) and a breeding colony is maintained at the Department of Pathology, 
Cambridge University. Stat1 knockout (129S6/SvEvSTAT1tmRds, hereafter Stat1-/-) 
mice, obtained from Taconic (Taconic Farms Inc., USA), were bred to homozygosity by 
Dr. Amita Shortland (University of Cambridge) and maintained as a breeding colony at 
the Gurdon Institute, University of Cambridge.  
For mouse transport, maintenance and setting of the experimental mouse groups, please 
refer to Section 2.4.1.  
 
3.2.2 Oral Treatment with Antibiotic Cocktail 
 
C57BL/6 wild-type mice were treated with a 'cocktail' of antibiotics containing 
streptomycin (5 g/l, Sigma Aldrich), colistin (1 g/l, Melford Laboratories Ltd), ampicillin 
(1 g/l, Sigma Aldrich) and 5 % (wt/vol) glucose in filter sterilized drinking water for 14 
days. Non-treated control mice received only the 5 % (wt/vol) glucose in filter sterilized 
drinking water. Drinking bottles were changed at least once weekly. Faecal samples from 
each mouse were collected before and at the end of the treatment.   
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3.2.3 Isolation and Adoptive Transfer of Splenic T and B lymphocytes and Intestinal 
gd TCR IELs into Rag2-/- mice 
 
Splenic T and B lymphocyte isolation: spleens collected from untreated wild-type or 
experimental mice were pushed, in PBS, through 70 µm cell filters. The single-cell 
suspension generated was re-suspended in red blood cell lysis buffer (Table 3.1) for 5 
min at room temperature. The cells were then washed in PBS and stained for flow 
cytometry analysis (Section 3.2.4) otherwise the CD3+, CD8+ (CD44hi) T- or CD19+ B-
splenocytes were purified by flow cytometric sorting (BD Influx) for adoptive transfer 
into Rag2-/- mice, in vitro MNV-O7 infection (Figure 3.11) or gene expression analysis 
(Figure 4.3). 
 
IEL isolation: This part was performed in collaboration with Ulrika	 Frising under the 
supervision of Dr Marc Veldhoen. Briefly, the small intestines were collected from GFP+ 
gd T cell knock-in (Gfp-reporter/Donor) mice, the recipient (injected) Rag2-/- or wild-
type mice after the experimental protocol, flushed with 20 ml cold phosphate buffered 
saline (PBS) and freed of fat, mesentery and Peyer’s patches (PP). The tissue was cut 
longitudinally and then into small (0.5-1 cm) pieces and incubated at 37 º C, with 
vigorous shaking (200 rpm) for 10 min, and then moderate shaking (100 rpm) for 20 min 
in 15 ml of IEL buffer (Table 3.2). Cells released into the supernatant were filtered 
through a 70 µm filter and collected by centrifugation at 500 xg for 8 min. The cells 
(extracted from up to two small intestinal samples) were then re-suspended in 20 ml 37.5 
% isotonic Percoll (Sigma, P1644) and centrifuged (700 xg; 10 min) at room temperature 
to separate the IELs from the upper layer of epithelial cells. The supernatant was 
discarded and the pellet (containing IELs) was washed once with PBS, re-suspended in 
IEL buffer (Table 3.2), filtered through a 70 µm sieve and stored at 4 º C. Cells were 
then either stained for flow cytometric analysis (Section 3.2.4) or enriched for GFP+ gd 
TCR IELs by flow cytometric sorting (BD Influx) for adoptive transfer into Rag2-/- mice. 
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For certain experiments (Figure 3.9) this protocol of isolation was modified to include 
the lymphocytes of PPs by not removing them at the dissection of the gut, increasing the 
duration and vigorousness of the shaking step (220 rpm for 30 min) and mashing the gut 
tissue through filter after the shaking. Lymphocytes of the LP were isolated by 
incubation of the undigested tissue after the shaking step into a digestion mixture 
containing 1 mg Collagenase D/ml (Roche, 11088882001) and 0.1 mg DNase/ml (Sigma, 
DN25) for 40 min at 37 ° C. 
 
In order to inject the Rag2-/- mice with the GFP+ FACS-sorted gd TCR IELs, CD3+ or 
CD19+ FACS-sorted splenocytes, the mice were briefly acclimatised in a warming 
cabinet at 37-40 º C for 10-15 min and then restrained. Each mouse was injected with 
about 2 x 105 gd TCR IELs or about 1 x 106 splenic T, B cells or both into the tail vein 
using insulin syringes. Mice were kept for 3-4 weeks to allow for lymphocytes 
proliferation and reconstitution of the intestinal compartments. After the experimental 
protocol (of anti-CD3/isotype control antibody injection and/or MNV infection) and the 
sacrifice of the mice, and as a quality control procedure, splenic and small intestinal 
specimens from the recipient Rag2-/- mice were collected in cold PBS and put through 
the same protocols above to isolate the GFP+ gd TCR IELs and splenocytes, to confirm 
the efficiency of the adoptive transfer reconstitution of the splenic and intestinal 
compartments. 
 
Table 3.1 Constituents of Red Blood Cell Lysis Buffer 
Amount Reagent Supplier (Catalogue Number) 
0.15 M NH4Cl BDH-AnalaR (100173D) 
10 mM               Na2HCO3 Sigma (S8875) 
  0.5 M EDTA Boehringer Mannheim (808270) 
                                              pH 7.4 
Gibco (15140-12) 
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Table 3.2 Constituents of IEL Buffer 
Amount Reagent Supplier (Catalogue Number) 
500ml   MgCl- and CaCl-free PBS  Sigma (D8537) 
50ml Fetal Bovine Serum (Heat inactivated) Sigma (F9665) 
    5ml Sodium Pyruvate, 100 mM Sigma (S8636) 
10ml HEPES, 1 M Sigma (H0887) 
10ml EDTA, 0.5 M Fluka (O3690) 
5ml Pen/Strep (100x) Gibco (15140-12) 
100µl Polymyxin B, 50 mg/ml Sigma (81334) 
 
3.2.4 Flow Cytometric Analysis 
 
Single cell suspensions of splenocytes, IELs and LP lymphocytes were generated as 
described in Section 3.2.2. BMMC were extracted from long bones (femur and tibia) of 
mice and differentiated as detailed in Section 5.2.2. Cells were washed in PBS, and re-
suspended in Iscove's modified Dulbecco's medium (IMDM) supplemented with 10 % 
foetal calf serum (FCS), 100 U penicillin/ml and 0.1 mg streptomycin/ml (10% IMDM). 
 
3.2.4.1 Staining of Surface Molecules  
Cells were re-suspended in FACS buffer (2.5 % FCS, 0.05 % sodium azide in PBS) 
containing 20 µg 2.4G2/ml to block Fc receptors (BD Biosciences). Antibody cocktails 
prepared in FACS buffer were added to the cells and incubated at 4 ° C, 30 min. Cells 
were washed twice with FACS buffer and fixed with 1 % paraformaldehyde in PBS.  
 
3.2.4.2 Staining of Intracellular Cytokines and Molecules  
Cells were re-suspended in 10% IMDM supplemented with 0.5 µg ionomycin, 0.5 µg 
phorbol-12,13-dibutyrate and 1 µg Brefeldin A per ml (Sigma-Aldrich: I3909, P1269, 
B7651) and incubated at 37	 ° C, 5 % CO2. After 4 hrs incubation, the cells were re-
suspended in FACS buffer and stained for surface molecules as described previously 
prior to fixation in 1 % paraformaldehyde in PBS at 4 ° C overnight. Cells were washed, 
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re-suspended in permeabilisation buffer (FACS buffer containing	0.5 % saponin, Sigma-
Aldrich, 47036), and incubated for 10 min at room temperature. Antibody cocktails, 
prepared in permeabilisation buffer, were added to cells and incubated at room 
temperature for 20 min to stain the intracellular cytokines and viral double stranded RNA 
(dsRNA). The cells were then washed twice with permeabilisation buffer,	 once with 
FACS buffer and maintained in FACS buffer until time of analysis. 
For viral dsRNA (Figure 3.11), primary mouse monoclonal (J2) antibody (Scicons, 
10010500) was used with subsequent detection by anti-mouse PE-conjugated secondary 
antibodies (Dako, R0439).  
For mitochondria staining by Mito-Tracker Green (Invitrogen, M7514) (Figure 3.13), 
the IELs were stained for surface markers as previously described but were not incubated 
in paraformaldehyde prior to permeabilisation as fixation inhibits the staining.  
 
3.2.4.3 Antibodies  
Table 3.3 lists the antibodies used for the extracellular and intracellular staining and their 
sources. Cells were stained with cocktails containing up to four antibodies with 
FITC/Alexa Fluor 488, PE, PerCP-Cy5.5 or APC/Alexa Fluor 647 conjugates. 
 
Table 3.3 List of antibodies used for flow cytometry 
Marker Fluorophore Clone Isotype Catalogue no. 
CD19 PE 1D3 
 
Rat IgG2aκ 
 
553786  
CD3 
 
FITC 
 
145-2C11 
 
Armenian Hamster IgG1κ 
 
 553061 
 CD4 Alexa Fluor 647  RM4-5 
 
Rat IgG2aκ  557681 
 
CD4 FITC RM4-5 Rat IgG2aκ 553046 
CD8a PerCp-Cy5.5 53-6.7 Rat IgG2aκ 100733 * 
CD8a PE     53-6.7 
 
Rat IgG2aκ  553032 
 
CD11c FITC HL3 
 
Armenian Hamster IgG1l2 
 
 
553801 * 
CD108 PerCp-Cy5.5 2e7 
 
Hamster IgG isotype control 
 
121415  
 IA/IE 
 
Alexa Fluor 647   114.15.2 
 
Rat IgG2aκ 107617 
    Table 3.3 continued overleaf  
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Continue Table 3.3 List of antibodies used for flow cytometry 
Marker Fluorophore Clone Isotype Catalogue no. 
 CD80 
 
PE  16-10A1 
 
Armenian Hamster IgG2κ 
 
 553769 
  CD86 
 
PE GL1  
 
Armenian Hamster IgG2κ 
 
553692 
IFN-γ AlexaFluor647 XMG 1.2 
 
Rat IgG1κ 557735 
IL-10 PE JES5-16E3 Rat IgG1κ 505005* 
* Indicates antibodies obtained from Biolegend, otherwise from BD Biosciences 
 
3.2.4.4 Detection of Cell Markers by Flow Cytometry 
Cells were acquired using an Accuri C6 flow cytometer (BD Biosciences, CA) and 
expression of cell markers was analysed using the Accuri C6 software. Relevant isotype 
control antibodies were used to exclude non-specific binding and cells stained with them 
did not display additional staining compared with the unstained controls. Spectral 
overlap between fluorescence channels was compensated electronically using double 
negative and single positive stained cells to set compensation values. 
 
3.2.5 Immunofluorescent staining of organoids 
 
This part was performed by our collaborators in The Babraham Institute, with the help of 
Ms. Ulrika Frising. Briefly, small intestinal organoids were generated as detailed in 
Section 4.2.3.3, seeded into ibidi µ-slides and incubated for 2-4 days at 37 ° C, 7 % CO2. 
The intestinal organoids were then fixed in 4 % formaldehyde for 20 min, permeabilised 
with 1 % TritonX-100, blocked in 2 % BSA/1 % TritonX-100/PBS and stained for 
proliferation markers at 4 ° C overnight using anti-Edu, anti-Ki67 and anti-EpCam 
primary antibodies. The following day, the samples were stained with AF555, AF488, 
APC-coupled secondary antibodies, respectively. The samples were washed once with 
PBS and then mounted with Vecta-shield Hard Mounting medium containing DAPI 
(Vector, H-1500). Images were acquired on a Zeiss 780 confocal microscope and 
exported using Imaris software.  
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3.3 Results 
3.3.1 Characterization of the Anti-CD3-MNV Experimental Model 
 
3.3.1.1 Effects of Intraperitoneal (i.p.) Injection of Anti-CD3 
To assess the effects of stimulation with agonistic anti-CD3 antibodies, I injected 
C57BL/6 wild-type mice i.p. with 25 µg of the stimulatory antibodies. The unstimulated-
control mice received isotype-control (ITC) antibodies. After 3 hrs, the mice were 
sacrificed and gut sections, mesenteric lymph nodes (MLN) and spleen were collected. 
IELs were extracted from gut sections as outlined in Section 3.2.3, and analysed together 
with the MLN samples for mRNA expression of the cytokines; TNFa, IFNg, IFNl3 and 
IFNb1 (Figure 3.1A & B). Small gut sections from the duodenum and ileum were 
further examined for the expression of the ISGs; Mx1 and Isg15 and the cytokine TNFa 
(Figure 3.1D). There was a clear upregulation of almost all the genes analysed after i.p. 
administration of anti-CD3; Tnfa, Ifng, Ifnl3 and Ifnb1 in the IEL and MLN 
compartments, and Mx1 and Isg15 in the gut tissues. In the IEL compartment the 
expression of TNFa and IFNg in the anti-CD3-stimulated mice was almost 10-fold that 
of the isotype controls. This was associated with a strong induction of the anti-viral 
cytokines (IFNl3 and IFNb1); the expression of which was almost undetectable in the 
isotype controls (Figure 3.1A). The spleen samples were analysed by flow cytometry 
(Figure 3.1C) with the gating detailed in Supplementary Figure 3.1 used as the strategy 
for the analysis. In order to account for the expected late induction of the cytokine 
proteins, an additional post-stimulation time-point was included with mice being 
sacrificed 8 hrs after i.p. injection of anti-CD3. Comparison of the proportions of IFNg-
expressing CD8 T cells revealed a marked increase after 8 hrs of anti-CD3 stimulation, 
with the percentages doubled those of the controls (Figure 3.1C). 
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The results of this experiment are in agreement with the findings of Swamy et al.302, that 
i.p. injection of anti-CD3 antibody results in marked systemic and local (gut) activation 
of CD3+ T cells with the production of many cytokines (both inflammatory and anti-
viral) that culminate in induction of a strong anti-viral state in the gut302. 
To assess the biological impact of such activation, I infected C57BL/6 wild-type mice 
with a standardized (5 x 106 TCID50) dose of MNV-O7, 8 hrs after (Figure 3.1E) or 
before (Figure 3.1F) i.p. injection with 25 µg of anti-CD3 or ITC antibodies. Forty hours 
after the infection, the mice were sacrificed and gut sections (duodenum, jejunum, ileum) 
and MLN were collected and analysed for viral titres. Except for minor changes in virus-
kinetics, anti-CD3 stimulation both after and before MNV-O7 infection resulted in robust 
inhibition of viral replication and significant reduction of the viral titres in all tissues 
examined (Figure 3.1E & F). It was noted that the efficacy of this anti-CD3-induced 
inhibition of viral replication decreased distally down the GI tract and in the MLNs. The 
lowest viral titres of the anti-CD3-injected mice were measured in the duodenum and the 
highest were observed in the ileum and MLN (Figure 3.1E & F). This gradation of the 
anti-viral effect induced by anti-CD3 broadly correlated with the density of IELs that is 
found along the length of the small intestine132, supporting the hypothesis that activated 
IELs functionally enhance innate resistance to enteric viral infections302. The observed 
reduction of MNV-O7 viral titres in the MLNs of wild-type mice after anti-CD3 
stimulation could either be due to an anti-CD3-triggered inhibition of the migration of 
the MNV-infected mononuclear cells from the gut to the MLN, direct killing of the 
virus/virus infected cells in the MLNs or a combination of both.  
Taken together, the data presented in this section suggested a potential role of importance 
for IEL and confirmed that anti-CD3-mediated stimulation, with the associated ‘cytokine 
storm’, resulted in an effective gut-mucosal anti-viral state that is sufficient to both 
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prevent the establishment of, and clear, MNV-O7 infection especially in the proximal 
parts of the gut. 
 
3.3.1.2 Oral Administration of Anti-CD3 Antibody Does Not Activate IELs 
In an attempt to minimize the systemic effects of i.p. anti-CD3 injections, I administered 
three different doses (5 µg, 25 µg and 50 µg) of the agonistic anti-CD3 antibody orally 
into wild-type mice and assessed the resultant local and systemic immune activation as 
described in the previous section (Section 3.3.1.1). Indeed, oral administration of anti-
CD3 did not induce systemic responses as the cytokine levels in the MLN and the 
percentages of IFNg-expressing CD8 T-splenocytes remained low and comparable to 
those of the isotype controls (Figure 3.1B & C). However, there was no activation of 
IELs, even with the highest dose of oral anti-CD3 and the cytokine levels in this 
compartment remained also low and comparable to the controls (Figure 3.1A). Evidence 
exists in the literature that orally-administered anti-CD3 antibodies overcome the gastric 
digestion and, especially at low doses, become biologically active through stimulation of 
regulatory T cells and induction of oral tolerance315,316. Unlike with the i.p. injected anti-
CD3, we did observe an increasing level of TNFa expression with the higher doses of 
oral anti-CD3 administration especially in the ileal samples (Figure 3.1D). This was 
associated with a minor increase in ISG expression, which was of less amplitude than 
that seen by i.p. injected anti-CD3. 
Thus, we concluded from this experiment that, unlike systemic (i.p.) injection, oral 
administration of agonistic anti-CD3 antibodies did not trigger the activation of IELs, 
though at higher doses it may result in a non-specific inflammatory response that induces 
a minor anti-viral-state in the gut. 
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3.3.1.3 The Role of STAT-1 in the Anti-CD3-MNV Experimental Model 
Given the well documented importance of the STAT-1 pathway in the early control and 
prevention of lethal MNV infection231,265, we investigated the effects of anti-CD3 
stimulation in STAT-1 deficient (Stat1-/-) mice. As demonstrated in Figure 3.2A, Stat1-/- 
mice maintained very high viral titres in all gut sections examined, regardless of anti-
CD3 or isotype antibody treatment. This was associated with absence of induction of ISG 
(Mx1) expression in gut sections (duodenum and ileum) after anti-CD3 stimulation 
(Figure 3.2B), despite good upregulation of IFNg cytokine expression (Figure 3.2C). 
Interestingly, unlike the wild-type controls, there was no detectable levels of IFNl 
cytokine expression in the gut sections of Stat1-/- mice even after anti-CD3 stimulation. 
This might be due to the absence of the positive feedback loop mediated through the 
JAK-STAT pathway110, however this result should be taken with caution as the 
IFNl levels were extremely low in the crude intestinal samples of wild-type mice 
(Figure 3.2C). The picture was different in the MLN. Although very high levels of 
MNV-O7 viral titres were seen in Stat1-/- mice compared to wild-type controls, there was 
a statistically significant reduction of the MLN viral titres after anti-CD3 stimulation of 
Stat1-/- mice (Figure 3.2A). This finding suggested the presence of STAT1-independent 
mechanisms of viral control in the MLNs, which could be, at least in part, mediated by 
the marked induction of pro-inflammatory cytokines (TNFa and IFNg) by anti-CD3 
stimulation in the MLN of Stat1-deficient mice compared to the wild-type counterparts 
(Figure 3.2D).  
Thus, in spite of the wide array of different cytokines triggered by anti-CD3 stimulation, 
absence of the STAT-1 pathway in the gut prevented the anti-CD3-induced MNV 
protection. A finding that supported the importance of this pathway in early gut mucosal 
immunity against MNV. It is important to note that in this experiment we used 129 mice 
as wild type controls because the Stat1-/- mice available were from 129-mouse 
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background (Section 3.2.1). The MNV-O7 infection kinetics in the small intestine of 129 
wild-type mice differ from that in C57BL/6 mice, with approximately one to two orders 
of magnitude lower viral titres in the duodenum (Compare Figure 3.1E and           
Figure 3.2A). Nonetheless, stimulation with anti-CD3 antibody had a comparable 
protective effect against MNV-O7 infection in both wild-type mouse strains.   
 
3.3.1.4 Effects of Antibiotic Treatment in the AntiCD3-MNV Experimental Model 
We next aimed to determine the role of microbiota in our experimental model of anti-
CD3 stimulation and MNV-O7 infection. For that, we treated C57BL/6 wild-type mice 
with an antibiotic cocktail in drinking water for 14 days and then compared their 
response to that of non-treated, age matched control mice. The efficacy of this antibiotic 
cocktail treatment in the eradication of the non-specific microbiota has previously been 
confirmed by 16S analysis of the faecal samples in previous reports (Konjar et al., in 
revision). Notably, all antibiotic-treated mice developed diarrhoea and caecal swelling, 
which was detected at the time of sacrifice and indicated the effectiveness of the broad-
spectrum antibiotics used. 
Administration of anti-CD3 antibody was protective in both antibiotic-treated and 
untreated age-matched mice (Figure 3.3). The only difference that could be observed 
was a slightly (less than a log) higher MNV-O7 viral titres in the antibiotic-treated ITC-
injected mice compared to their untreated counterparts. This difference was statistically 
significant in all gut tissue examined. However it is not in agreement with recent reports 
in the literature, where antibiotic treatment resulted in reduction in MNV viral titres and 
clearance of persistent MNV infections267,290. Possible explanations for this discrepancy 
may be the differences in the antibiotic mixtures, tissue examined (gut segments vs 
faeces) and/or in MNV strains used. Perhaps, more importantly is the different time 
points at which viral titres were analysed. Indeed, Baldridge and colleagues (2015) 
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observed differential MNV-CR6 levels at 4 and 24 hrs post-infection, with significantly 
higher titres of faecal viral shedding in antibiotic treated mice at 24 hrs compared to 
untreated mice, suggesting a delayed intestinal transit time of the viral inoculum with 
antibiotic treatment, which was then confirmed by Evan blue dye oral 
administration290. Moreover, we observed a significant reduction of the ileal viral titres of 
antibiotic treated wild-type mice 7 days post-inoculation of MNV-CW3 (Figure 3.13, 
discussed in more details in subsequent sections). 
Thus, the data presented in this section indicated that the efficacy of anti-CD3-triggered 
protection from MNV-O7 infection is not influenced by the presence or antibiotic 
modulation of the microbiota. 
 
3.3.2 The Contribution of Gamma/Delta (gd) TCR+ IEL to the Anti-CD3-Mediated 
Inhibition of MNV Viral Replication 
 
Given the broad and systemic effects of anti-CD3 stimulation, we aimed to investigate 
the exact in vivo role of ‘innate’ gd TCR+ IEL in the protection observed following anti-
CD3 administration. To that end, we employed knockout mouse-lines and adoptive 
transfer models described in the following sections.  
 
3.3.2.1 The Knockout Mouse lines   
Firstly, I compared the anti-viral responses of wild-type, Il15ra-/- and TCRalpha (Tcra)-/- 
mice using the exact same experimental protocol of anti-CD3 administration followed by 
MNV-O7 viral infection (Figure 3.4).  
Knocking out the alpha subunit of the IL-15 receptor results in severe deficiency of the 
CD8aa+ IELs (both the ab TCR+ and gd TCR+) as well as variable reduction of other 
cell types (including the NK, NKT and memory CD8ab+ T cells)317,318. As observed in 
                                                   			
- 68 - 
Figure 3.4A, there were no differences in the anti-CD3 response between wild-type and 
Il15ra-/- mice. Both established a similar level of MNV-O7 infection when injected with 
non-specific ITC antibody, whilst upon anti-CD3 stimulation, anti-viral protection was 
induced that decreased in the distal small intestine similarly in both mouse lines. This 
observation strongly suggested, at least in the context of our experimental conditions, 
that CD8aa+ IELs are not essential for the protection against MNV-O7 infection 
stimulated by anti-CD3 antibodies. However, it does not rule out the possibility that 
activated IEL might have a role which is masked by the broad array of cytokines induced 
by anti-CD3 stimulation in Il15ra-/- mice. 
 
In order to investigate this possibility, we used Tcra-/- mice in which only gd TCR+ T cells 
are available to respond to anti-CD3 injection319. A complicating factor of this mouse 
model is the development of a microbiota-dependent, spontaneous and chronic form of 
inflammatory bowel disease with age due to an exacerbated number and function of the 
gd TCR+ T cells, which accumulate in older mice320–322. For this reason, we used 
(relatively) young Tcra-/- mice (8-10 weeks) and included non-infected controls, which 
did not show overt features of inflammation in gut sections when examined by 
histopathology (Supplementary Figure 3.2). As observed in Figure 3.4B, the Tcra-/- 
mice (with or without anti-CD3 antibody treatment) had significantly lower MNV-O7 
viral titres (two log reduction in the duodenum) compared to wild-type mice. This might 
be due to a high basal inflammatory state, even without overt features of inflammation in 
histology slides, in these Tcra-/- mice (with a high steady-state level of pro-inflammatory 
cytokines and/or abnormally hyperactive gd, gb and db T cells) preventing the 
establishment of the infection. Anti-CD3 stimulation of the TCR+ T cells in these mice 
only slightly enhanced this protection, mainly in the proximal part of the gut. 
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3.3.2.2 Adoptive Transfer of gd IELs Into Rag2-/- Mice 
Due to the limitations of the Tcra-/- mouse model and to further analyse the role of gd 
TCR+ IELs, we performed an adoptive transfer experiment of IELs into Rag2-/- mice. It 
has already been documented that IELs, isolated from small intestinal epithelia of wild-
type mice and injected into lymphopenic mice (such as Rag2-/-), will circulate and home 
back to the small intestine, expand in an IL-15-dependent manner and express the a4b7 
integrin, CCR9 and CD103 (aEb7 integrin); important for retention within the epithelial 
compartment (323 and Konjar et al., in revision). Interestingly, the injected (gd TCR+) 
IELs re-establish intra-epithelial populations that reflect the normal distribution in wild-
type mice; with the highest number of gd TCR+ IELs in the duodenum and the lowest in 
the ileum (Dr Marc Veldhoen, personal communication). Having TCRd-eGFP knock-in 
mice, we were able to FACS-sort the intestinal gd TCR+ IELs (without triggering the 
TCR receptor and stimulating the cells) using the protocol outlined in Section 3.2.3. 
Purified IELs were then injected intravenously (i.v.) into Rag2-/- mice (approximately 2 x 
105 cells per mouse) which were maintained for 3-4 weeks to allow for the proliferation 
and the reconstitution of the gut IEL compartment. Then matched groups of wild-type, 
IEL-conditioned Rag2-/- mice and Rag2-/- mice not receiving IELs were compared using 
the same experimental protocol of anti-CD3/ITC stimulation and MNV infection.  
We injected only purified GFP+ gd TCR+ IELs and after the (3-4 week) incubation period 
I performed a quality control flow cytometric analysis of the spleens and small intestinal 
segments of the injected Rag2-/- mice to assess the efficacy of the reconstitution    
(Figure 3.5). Indeed, 4 weeks after the adoptive transfer, GFP+ IELs were not detected in 
the spleens of the IEL-conditioned Rag2-/- mice (Figure 3.5A). In the IEL compartment, 
GFP+ IELs could be detected in the injected Rag2-/- mice and most of them had 
reconstituted cells to approximately 35-40% of the normal levels of gd TCR+ IEL 
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(Figure 3.5B & C). As expected the majority of the injected GFP+ IEL were either CD8+ 
or double negative with complete absence of a GFP+CD4+ subtype. It is important to note 
that our collaborators at the Babraham Institute used to be able to get better yields (of 60-
75%) of GFP+ IEL in the gut of injected Rag2-/- mice after 4 weeks of transferring the 
same number of cells per mouse. The discrepancy is most likely due to a technical 
problem in my experiment with the longer transit time of sample collection in the Dept. 
of Pathology then sample processing in the Dept. of Veterinary Medicine.  
Comparing the responses to MNV-O7 infection (figure 3.6), the most striking finding 
was the significantly low MNV-O7 viral titers in all Rag2-/- mice analysed, both in the 
tissues and faecal samples. A similar resistance to MNV infection in Rag1-/- mice has 
been reported in the literature using other persistent strains of MNV; MNV-3298 and 
MNV-CR6290. These findings support the emerging theory of lymphocytes, particularly  
B cells being important for the establishment of and cellular targets for certain MNV 
strains infection267. Another possibility is that Rag-1 or -2 knockout mice, like the Tcra-/- 
mice, may also have a high basal innate inflammatory state, especially from innate 
lymphoid cells, that may function in generating an inhibitory environment influencing 
the establishment of the infection. Frustratingly, the low viral titres in Rag-2 deficient 
mice make it difficult to assess the role of injected IELs, which in general resulted in a 
minor trend of viral titre reduction in the gut sections, MLNs (figure 3.6A) and faecal 
samples (figure 3.6B) analysed. The difference between (Rag2-/- + IEL) and Rag2-/- was 
statistically significant only in the jejunum samples. Stimulation of these injected IELs 
with anti-CD3 antibodies, resulted into more reduction of the MNV-O7 viral titres in all 
tissue examined (figure 3.6A). However, the anti-CD3-mediated inhibitory effect in 
these IEL-injected Rag2-/- mice (ranging between 0.5 to 1 log difference, by comparing 
the mean viral titres of the anti-CD3- vs ITC-injected mice) was much less than that 
observed in the wild-type controls (ranging between 1.5 to 3 log difference). 
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In a small follow-up experiment, we compared the responses of wild-type, IEL-
conditioned Rag2-/- mice and Rag2-/- mice not receiving IELs using the acute strain of 
MNV; MNV-CW3. Interestingly, although lower than those of MNV-O7, the viral titres 
of MNV-CW3 were quite similar and comparable in both wild-type and Rag2-/- mice 
(figure 3.7). The differences between MNV-CW3/MNV-O7 infection profiles of wild-
type/Rag2-deficient mice is discussed in more details in the subsequent Section 3.3.3. 
The number of IELs injected into Rag2-/- mice in this (MNV-CW3) experiment were the 
same as those used for the (MNV-O7) experiment (figure 3.6A). The same batch of mice 
was used. However, by comparing figure 3.6 and figure 3.7 there was a clear difference 
between the anti-CD3-mediated inhibitory effect on MNV-O7 vs MNV-CW3 viral titres. 
Unlike MNV-O7, stimulation of the injected IELs by anti-CD3 antibodies resulted in 
inhibition (2 log reduction) of MNV-CW3 titres in Rag2-/- mice similar to, and in the 
distal parts of the gut (jejunum and ileum) even better than, that observed in wild-type 
controls (figure 3.7). This observation suggested that the effects of the anti-CD3-
activated IEL might be more prominent in the context of MNV-CW3 infection. I was 
unable to do statistical tests in this experiment due to the small sample size. 
Taken together, our knockout and adoptive transfer experiments suggest that, in the 
context of our experimental conditions, the activated (gd TCR) IELs are not essential and 
may play a minor role in the anti-CD3-mediated early innate protection against the 
persistent strain (MNV-O7) infection. Their role may be more prominent in the context 
of the acute strain (MNV-CW3) infection. It is important to note, however, that these 
experiments do not exclude a role for the more conventional ‘induced’ subtypes of IELs, 
i.e. αβ TCR+ CD8αβ+ and CD4+ IELs. These would include resident-memory T cell 
subsets that have been shown to be able to induce a rapid, strong and non-specific innate 
antiviral state upon reactivation by their specific antigen by producing IFNg, TNFα and 
IL-2Rβ-dependent cytokines324. 
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3.3.3 Insights into MNV Immunobiology Drawn from the Wild-type/Rag2-Deficient 
Experimental Model 
 
During the course of investigating the in vivo role of IELs we observed interesting and 
characteristic differences between the MNV-O7 (persistent strain) and MNV-CW3 (acute 
strain) short-term infection of wild-type and Rag2-/- mice. I decided to follow that lead 
with the aim of further elucidating the differential cellular tropism and immuno-
biological features of different MNV strains.  
 
3.3.3.1 MNV-O7 (but Not CW3) Showed Differential Infection Profiles of Wild-
Type vs Rag2-/- Mice 
The first observation was the preferentially enhanced viral replication of MNV-O7 in 
intestinal tissues of C57BL/6 wild-type mice when compared to that of Rag2-/- mice. A 
feature that was not observed in infections with the acute strain; MNV-CW3. Thus, when 
we orally infected aged-matched wild-type and Rag2-/- mice with equal doses of the two 
virus-strains and sacrificed the mice 40 hrs P.I. (Figure 3.8); the MNV-O7 viral titres of 
the wild-type mice were significantly (almost two log) higher than those of the Rag2-/- 
mice in all tissues examined (Figure 3.8A). Confirming its superior intestinal tropism 
(Dr James Chettle’s, unpublished data), the viral titres of the MNV-O7-infected wild-
type mice were higher than those of the MNV-CW3-infected counterparts. However, no 
major differences in viral titre were observed when comparing MNV-CW3 infection of 
wild-type vs Rag2-/- mice (Figure 3.8B) except for a minor (non-statistically significant) 
trend of viral titre reduction in the distal gut (ileum) of Rag2-/- mice.   
The efficient establishment of MNV-O7, but not CW3, infection preferentially in the 
wild-type mice as compared to Rag2-/- mice strongly suggested a differential specific 
cellular tropism of the two different MNV strains; a possibility that will be addressed in 
subsequent sections. One can also hypothesize from the data presented in this section that 
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the presence of RAG-dependent T and B lymphocytes (in wild-type as opposed to   
Rag2-/- mice) is detrimental (or counterproductive) to the host in the context of MNV-O7 
infection.  
 
3.3.3.2 Adoptive Transfer of Splenic B and ab T lymphocytes Into Rag2-/- Mice 
In order to examine the above hypothesis, we employed the adoptive transfer strategy, 
however, this time we injected B and/or T lymphocytes FACS-sorted from the spleen of 
C57BL/6 wild-type control mice into the lymphopenic (Rag2-/-) hosts. Further details 
about the procedure are outlined in Section 3.2.3.  
After the (3-4 week) incubation period, flow cytometric analysis revealed a clear 
establishment (reconstitution) of the T and/or B splenic compartments of the injected 
Rag2-/- mice (Figure 3.9A) with percentages of lymphocytes comparable to those of 
wild-type controls (Figure 3.9D). However, only transferred CD3+ T cells (not CD19+ B 
cells) were detectable in the LP and IEL compartments of the splenocyte-conditioned 
Rag2-/- mice (Figure 3.9B, C & D). It is important to note that a modified protocol for 
lymphocyte isolation was used in this experiment (Section 3.2.3) to include the PP 
lymphocytes, which explain the high percentages of CD19+ B cells in the IEL 
compartment of wild-type controls (Figure 3.9C). The inability of the injected CD19+ B 
lymphocytes to reach and populate the lymphopenic gut tissues of Rag2-/- mice was 
interesting and supports the findings of previous reports where Rag-deficient hosts 
reconstituted with either unfractionated or CD25- splenocytes (both of which contain 
nearly 60% B cells) displayed very low frequencies of circulating B cells two weeks after 
the transfer325, and most of the i.p. or i.v. injected B lymphocytes were found to localise 
mainly into the spleen and peripheral (popliteal and inguinal) lymph nodes of Rag2-/- or 
B lymphocyte-deficient mice326,327.   
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Analysis of the 40 hrs P.I. MNV-O7 viral titre revealed a significant (stepwise) increase 
in the intestinal viral titres of the (T and/or B) splenocyte-injected Rag2-/- mice when 
compared to those of non-injected Rag2-/- controls (Figure 3.10) with about one log rise 
upon transfer of either B or T lymphocytes and about one and a half log increase upon 
transfer of both types of lymphocytes. The increase in MNV-O7 viral titres in the 
splenocyte-conditioned Rag2-/- mice was consistent throughout the length of the small 
intestine, however, the level of infection never reached that of wild-type controls, which 
remained at least one log higher than that of all Rag2-/- mice (Figure 3.10).   
Thus, although there was variation in their ability to reconstitute the lymphopenic 
intestinal compartments upon injection into Rag2-/- mice, adoptively transferred T and/or 
B splenocytes promoted the establishment of MNV-O7 infection. A possible explanation, 
at least in part, for this observation is that these transferred systemic lymphocytes 
provided additional targets for MNV-O7 infection, i.e. the virus infected the T cell, 
though there are no previously-reported evidence for that, and/or infected the B cells, 
which has indeed been reported before for some strains of MNV267,328,329. However, I 
could not detect the transferred B-splenocytes in the gut tissues of the recipient Rag2-/- 
mice (Figure 3.9). Alternatively, the presence of these systemic lymphocytes may create 
or reflect a more favourable host environment for MNV-O7 infection of other cell targets 
(i.e. mononuclear phagocytes and/or IECs).  
 
3.3.3.3 MNV-O7 Does Not Infect B- and T-Splenocytes in vitro 
To assess the possibility of MNV-O7 infecting B- and T-splenocytes, I FACS-sorted the 
lymphocytes from the spleen of C57BL/6 wild-type mice as in the previous section, co-
cultured them in vitro with MNV-O7 at MOI of 0.05 and compared the viral growth to 
that of bone marrow-derived mononuclear cells (BMMCs) extracted from the long bones 
of the same wild-type mice (Figure 3.11A). Unlike the exponential viral replication 
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observed in the infected BMMCs during the 48 hrs infection period, there was no growth 
of the MNV-O7 virus in the FACS-sorted T and B lymphocytes. This was further 
confirmed by the absence of the viral dsRNA signal inside the splenocytes compared to 
the clear signal observed, using flow cytometry, in the BMMCs 12 hrs post-MNV-O7 
infection (Figure 3.11B). It is important to note that I did not include the 
supplementation of Human histo-blood group antigens (HBGA), which was shown to 
enhance the in vitro infection of B cells by MNV267, in my in vitro co-culture model.  
  
Collectively, the data presented in this section indicated a counterproductive role of T 
and B lymphocytes in the context of MNV-O7 infection that resulted in increased viral 
titres in gut segments. The finding that MNV-O7 does not replicate in T- and B-
splenocytes, at least in the context of our in vitro culture conditions, suggested the 
presence of other cytokine- and/or contact-dependent mechanisms by which these 
lymphocytes promote the establishment of MNV-O7 infection and its replication in other 
cellular targets. A major gut-homeostatic factor that is produced mainly by 
lymphocytes330,331 is IL-22, and this was a possible candidate for such a role. However, 
comparing the MNV-O7 infection of Il22-/- mice to that of wild-type controls 
(Supplementary Figure 3.3) did not reveal any significant differences of the intestinal 
viral titres during the acute (40 hrs) infection setting and if anything, a trend of higher 
viral titres in the proximal gut of Il22-/- mice was observed after 14 days of MNV-O7 
infection when compared to the wild-type counterparts (Supplementary Figure 3.3). 
This finding clearly did not exclude the possibility of other yet to be identified factors, or 
even IL-22 cytokine effects that had been compensated in the Il22-/- mice, promoted by 
the adoptively transferred lymphocytes that facilitate the MNV-O7 infection.  
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3.3.3.4. MNV-CW3 (but Not O7) Infection of Wild-type Mice Resulted in Significant 
Changes in The IEL Compartment 
Returning to the differences between MNV-CW3 (acute strain) and MNV-O7 (persistent 
strain), we recognised interesting differential effects on the cellularity of the IEL 
compartment upon infection of wild-type mice with equivalent doses of either of the two 
viral strains (Figure 3.12). Forty hours after the oral inoculation of virus, there was no 
difference between the MNV-O7-infected and non-infected wild-type mice in terms of 
cellular compositions of the IEL compartment with respect to B and T lymphocytes 
proportions. Both had small populations of CD19+ B cells, and almost 3 times higher 
percentages of CD8+ T cells compared to that of CD4+ T cells (Figure 3.12A & B). Upon 
MNV-CW3 infection, on the other hand, a sharp rise in the proportions of CD19+ B cells 
and a significant increase of the CD4+ T cell percentages were observed (Figure 3.12A 
& B). There was no significant change in the CD8+ T cell population. As CD19+ and 
CD4+ cells are not normally present in such high proportion in the IEL compartment at 
steady-state conditions129,135, their accumulation post-MNV-CW3 infection suggested 
recruitment from the LP and/or systemic circulation. 
The observations presented above were further supported by utilising a recently proposed 
staining protocol for the IELs’ activation status with Mito-tracker Green (Konjar et al., in 
revision). Mito-tracker Green is a carbocyanine-based probe reported to localize to 
mitochondria independent of membrane potential332–334. In the yet to be published report, 
Konjar et al. (2017) showed that at steady-state conditions Mito-tracker Green-based 
mitochondrial detection was markedly reduced in resting IEL compared with splenic 
naïve and memory CD8 T cells. Upon oral infection of the mice with the unicellular 
intestinal parasite Eimeria vermiformis or injecting anti-CD3 antibodies i.p., the 
mitochondrial detection of the IELs increased in a time-dependent manner and correlated 
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with increased proliferation and induction of effector functions, such as IFNg and TNFa 
production, by the IELs (Konjar et al., in revision).  
To apply this staining protocol in the context of MNV infection, we orally infected 
C57BL/6 wild-type mice with equivalent doses of either MNV-O7 or MNV-CW3. The 
mice were sacrificed at 2, 4 and 7 days P.I. and ileal samples were used to quantify the 
viral titres (Figure 3.13A). As expected the MNV-O7 viral titres were about 2 log higher 
than those of MNV-CW3 at all time-points examined. The rest of the collected small 
intestinal samples were used to extract the IELs to be stained with the Mito-tracker 
Green probe (refer to Section 3.2.3 and 3.2.4 for more details). Analysis of the median 
fluorescent intensities (MFI) of the CD8+ IELs revealed no significant changes after 
MNV-O7 infection (Figure 3.13B). MFI values, and hence the mitochondrial staining, 
remained significantly lower than those of naïve (CD8+CD44lo) and memory 
(CD8+CD44hi) splenocytes and comparable to those of uninfected (steady-state) controls. 
Infection with MNV-CW3 resulted in a significant peak of CD8+ IELs’ MFI within the 
first 48 hrs P.I. (Figure 3.13B). MFI values gradually tapered off subsequently, but 
remained significantly higher than those of the uninfected baseline. 
These MNV-CW3 infection-associated changes in the CD8+ IEL were microbiota-
dependent. Treatment of the mice with a mixture of broad-spectrum antibiotics for 2 
weeks prior to MNV-CW3 infection resulted firstly in significant drop of the day-7 P.I. 
ileal viral titres (Figure 3.13A) and secondly in complete disappearance of the CD8+ IEL 
mitochondrial staining changes at different time points post-MNV-CW3 infection 
(Figure 3.13B), including day-2 and day-4 P.I. where the MNV-CW3 viral titres were 
comparable to those of the antibiotic-untreated controls. This suggested that the absence 
of the mitochondrial staining associated with antibiotic treatment was not due to a 
reduced viral titre.   
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Taken together, the differences between MNV-O7 and MNV-CW3 in establishment of 
intestinal infection in wild-type vs Rag2-/- mice and their differential effects on the IEL 
compartments of wild-type mice pointed toward differences in the initial cellular targets 
of the two viral strains. The ability to infect enterocytes (IECs) is a strong possibility for 
such differential consequences. Thus, a hypothesis could be that MNV-CW3 does not 
infect the IECs, and in order to get access to the LP and systemic compartments (where 
mononuclear phagocytes, i.e. its major cellular targets, are abundant) it causes an 
epithelial barrier dysfunction associated with intestinal microbiota translocation. This 
results in microbiota-dependent IEL activation, recruitment of B and CD4+ lymphocytes 
from the LP and/or circulation to the IEL compartment and the development of robust 
inflammatory (protective) immune reactions. The final outcome is an acute self-limiting 
infection. In contrast, I hypothesised that MNV-O7 does infect IECs but non-lytically. 
This may in part explain the increased intestinal MNV-O7 titres upon adoptive transfer of 
splenocytes into Rag2-/- mice, which have been reported to improve IECs homeostasis, 
replication and differentiation335–338. Moreover, it certainly provides an attractive 
explanation for the persistent, insidious nature of the MNV-O7 infection as infection of 
the IECs may preclude the development of barrier dysfunction, microbial translocation 
and/or the subsequent overt inflammatory responses.    
 
3.3.3.5 Small Intestinal Organoids Support MNV-O7 and MNV-3 (Persistent 
Strains) Replication but Not MNV-CW3 (Acute Strain) Infection 
To test the above hypothesis, we examined the ability of different MNV strains to infect 
IECs. Several attempts had been made in the past to address this ability using in vivo 
experimental models and traditional in vitro epithelial cell cultures, however with 
inconsistent and contradictory results265,270–272. In collaboration with Ulrika Frising of the 
Veldhoen Lab, we decided to tackle this question by using small intestinal organoid 
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system, which has the advantages of preserving the 3-D structure of the IECs and 
reflecting their physiological lineage-development (more details in Section 1.1.2). 
Indeed, by infecting intestinal organoids generated from small intestinal samples of wild-
type mice with different strains of MNV (MNV-O7, -3 and –CW3) at an MOI of 5, we 
could demonstrate clear differential replication patterns in IEC-based cultures       
(Figure 3.14A). As an additional control in this experiment, we included UV-irradiated 
virus stock (comprising a mixture of MNV-O7 and –CW3) to differentiate between viral 
binding (internalisation) and viral replication. MNV-CW3 (acute strain) was unable to 
replicate as viral genome copy analysis showed a flat growth curve similar to that of the 
UV-irradiated control infection. The two persistent MNV strains (MNV-O7 and -3), on 
the other hand, displayed a fluctuating but progressive increase in the viral titres    
(Figure 3.14A). The high viral titres of MNV-O7 and -3 at 1 hr P.I. indicated their 
increased ability to attach to the IECs compared to MNV-CW3. However, the viral 
growth of MNV-O7 within the 45 hrs infection period (from about 1 x 106 to 2 x 106 
vRNA/µg total RNA) was much less impressive than that observed for MNV-O7-
infected BMMCs (Figure 3.11A). This suggested a decreased ability of IEC to support 
MNV-O7 infection as compared to that of BMMCs, which may have resulted from 
increased sensitivity to viral infection and/or induction of strong antiviral responses. 
Indeed, staining of 24 hrs MNV-O7-infected intestinal organoids revealed a marked 
shutdown of most replication-marker signals that are normally observed in non-infected 
growing organoids (Figure 3.14B). 
 
Thus, unlike the acute (MNV-CW3) strain, persistent strains of MNV infect IECs, a 
finding that may explain their insidious course and their ability to cause persistent viral 
infection.   
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3.4 Discussion 
Intestinal IELs compose a large, heterogeneous T cell compartment that is highly 
conserved in all vertebrates128,129. Their unique location above the basement membrane 
allows for extensive crosstalk with the IECs and qualifies them to be important 
modulators of immune responses to invading pathogens. Indeed, their ability to promote 
reparative epithelial growth86,305,306, and to induce protective (and/or immunoregulatory) 
responses in the context of bacterial and parasitic infections309–312, have been well 
reported in the literature. However, their contribution (role) to gut mucosal anti-viral 
responses to enteric viral infections remained largely unknown.  
In this chapter, I was able to show that in vivo activation of CD3+ T cells in wild-type 
mice, by intraperitoneal injection of agonistic anti-CD3 antibody, resulted in induction of 
a strong antiviral state in the gut mucosa that prevented the establishment of MNV-O7 
infection. This protective effect was STAT1-dependent. However, the protective effect of 
anti-CD3 cannot be attributed to the activation of the gut-associated T cells only. The 
anti-CD3 antibody has a marked systemic, ‘cytokine storm’-like effect as indicated by 
the activation of lymphocytes in the spleen and MLNs. Moreover, although the gradation 
of this protective effect, being strongest in the duodenum and weakest in the ileum, 
correlates well with the distribution of the CD3+ IELs in the small intestine, the 
observation of the same gradation in the Il15ra-deficient mice strongly excludes an 
essential role of (at least CD8aa+) IELs in this gradation effect. A possible alternative 
explanation for the high viral titres detected in the ileum is an acceleration of gut 
motility, and thus the viral inoculum, induced by anti-CD3 stimulation.  
We could not detect any difference in the response of antibiotic-treated mice to anti-CD3 
stimulation and the subsequent MNV-O7 titre suppression compared to that of antibiotic 
untreated controls. This indicated that our experimental system was not sensitive enough 
(rather blunt) to detect the fine disturbances and changes in the architecture and immune 
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function of the gut induced by the antibiotic modulation of commensal bacteria. 
Alternatively, different treatments or reconstituted gnotobiotic mice need to be studied. 
The lack of a known specific IEL stimulatory ligand and the inability to specifically 
target and activate the IELs by oral administration of anti-CD3 antibodies necessitated 
the use of more complex knockout and adoptive transfer experimental models to track 
down the contribution of IELs in the protective biological readout induced by i.p. 
injection of anti-CD3 antibodies. The possibility of a heightened basal inflammatory state 
and development of several compensatory feedback mechanisms in immunodeficient 
(Il15ra-/-, Tcra-/- and Rag2-/-) mice, added further complexities in studying immunity 
against MNV-O7 infection and defining the role of IELs in the anti-viral immunity. 
Taken that into account, the Il15ra-/-, Tcra-/- and Rag2-/- adoptive transfer experiments all 
suggested that activated (γδ TCR+) IELs are not essential and may only play a minor role 
in the protection against MNV-O7 infection induced by anti-CD3 stimulation, at least in 
the context of this experimental model. The similarity of the anti-CD3 stimulation 
response of MNV-CW3-infected IEL-injected Rag2-/- to that of wild-type controls 
suggested a more prominent role of these (γδ TCR+) IELs in the protection against this 
acute strain of MNV, and pointed towards differential immuno-biological characteristics 
and cellular targets of different MNV strains. 
Indeed, by further dissection of these differences we were able to demonstrate the 
differential viral replication profiles of MNV-O7 (but not CW3) upon infection of wild-
type vs Rag2-/- mice. Further analysis revealed a counterproductive role of systemic T 
and B lymphocytes in the context of MNV-O7 infection that resulted in increased viral 
titres in gut segments of Rag2-/- mice. Under our in vitro infection conditions, MNV-O7 
did not infect the splenic-derived T and B lymphocytes. This observation suggested that 
the enhanced establishment of MNV-O7 infection upon adoptive transfer of T- and/or B-
splenocytes into Rag2-/- mice was most likely due to production of soluble and/or contact 
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dependent factor(s) that create a more favourable host environment for MNV-O7 
replication in other cellular targets (i.e. IECs and/or mononuclear phagocytes). 
Further analysis of the differential immuno-biological characteristics of different MNV 
strains revealed the ability of MNV-CW3, but not MNV-O7, to cause the recruitment of 
LP and/or systemic lymphocytes to the IEL compartment and to activate IELs in a 
microbiota-dependent manner. This observation raises several questions. The first is 
whether it is IEL activation itself that mediates recruitment of the LP/systemic CD4+ T 
and B cells? Secondly; is there an interaction (inter-dependence) between the two cell 
types? Thirdly; what is the importance of such a response in production of protective 
anti-MNV antibodies297. We were also able to show the ability of MNV-O7 (and     
MNV-3), but not MNV-CW3, to infect IEC-based organoid cultures.  
In a recent report, Zhu et al. (2016) observed similar differential effects of MNV-CW3 
versus MNV-3 infection in activation of, and induction of granzyme B production by, 
CD8+ (both ab and gd TCR) T cells in the PP and IEL compartments300. The model 
proposed in this report was that MNV-CW3 infects B cells (in PPs) and induces their 
expression of MHC class I molecules. These infected B cells act as antigen presenting 
cells to activate cytotoxic CD8+ T cells and their granzyme B production, and play an 
important role in control of the acute (MNV-CW3) infection300. MNV-3, on the other 
hand, although it similarly infects PP B cells, does not stimulate the upregulation of 
antigen presentation molecules and subsequently displays an impaired control of the 
acute stage of infection. The MNV-3-mediated inhibition of B cell antigen presentation 
was shown to be partially dependent on the expression of strain-specific viral structural 
(VP2) protein300. A caveat of this model, in my opinion, is the discrepancy of viral titre 
comparisons between the B cell deficient (µMT) and C57BL/6 wild-type mice. In an 
earlier report by the same group, (1-day P.I.) viral titres of MNV-CW3 in the terminal 
ileum and MLNs were significantly higher in the wild-type mice compared to µMT 
                                                   			
- 83 - 
mice267, supporting the hypothesis that MNV-CW3 targets the PP’s B cells. However, in 
the more recent report, infection with the same virus (MNV-CW3) resulted in markedly 
higher (40-fold and 11-fold) viral titres in the distal ileum and MLN of µMT mice 
compared to their wild-type counterparts when measured 3 days P.I.300, supporting the 
proposed importance of B cells in control of acute MNV-CW3 viral infection. The 
discrepancy is apparently due to a significant and rapid drop of the wild-type mouse viral 
titres between 1 and 3 days post-MNV-CW3 infection. I did not observe a similar drop 
(fluctuation) of viral titres when infecting C57BL/6 wild-type mice with MNV-CW3 
(Figure 3.13A). Furthermore, I could not demonstrate the infection of splenic B cells by 
MNV-O7 (Figure 3.11) nor MNV-CW3 (data not shown) at least in the conditions of our 
in vitro infection model. A possible explanation for these contradictory observations 
might be the different methods of measuring MNV viral titres (I used qPCR vRNA titres 
in my experiments, Zhu et al. used TCID50 infectious virus titres) and the different B 
cells examined for in vitro MNV infection (splenic B cells vs PP B cells). 
To our knowledge, the data presented in this chapter are the first to report distinctive 
abilities of different MNV strains to infect IECs. The finding that MNV-CW3 (the acute 
strain) did not infect IECs, together with the associated microbiota-dependent activation 
of IELs, suggested the development of epithelial barrier dysfunction and microbiota 
translocation. Further analysis to confirm and determine the extent of this barrier 
dysfunction, and to identify the specific component(s) of the microbiota that involved in 
IEL activation, will be of interest. Similarly, the ability of the persistent strains (MNV-O7 
and -3) to infect and replicate in IECs while, at least for MNV-O7, not activating the 
IELs, open the door to further analyse the IEC-IEL crosstalk and to investigate the 
possibility of inhibitory (IL10- and/or TGFb-mediated, for example) signal interactions 
in addition to the well documented stimulatory MyD88-dependent IL-15/IL-7 interaction 
model153,154,309.   
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Chapter 4 THE INFLUENCE OF AGING ON EARLY GUT 
IMMUNITY AGAINST MURINE NOROVIRUS (MNV)  
  
4.1 Background 
Population aging was manifest as a universal phenomenon by the beginning of the 
current millennium339,340. Being a triumph of development, medical advancement, 
economic wellbeing, improved education, nutrition and sanitation, this worldwide trend 
of aging is definitely a cause for celebration340. However, the social, economic and health 
implications of this phenomenon are profound, global and need to be addressed by 
multiple disciplines. Although the percentage of old people is currently higher in 
industrialised countries, the pace of population aging is much more rapid in developing 
countries with exhausted economic resources and, thus, less time to adjust to the 
transition from a young to an old age structure341. The prevalence of chronic diseases and 
severity of most acute illnesses increase sharply in the aging population adding further 
strain and cost to already overburdened health-care systems. A major challenge lies in 
sustaining healthy aging and maintaining good quality of life over the full lifespan by 
decreasing the risk, and improving the outcome, of age-associated illness342. 
The bulk of age-related literature highlights the drastic effects of the aging process in 
both innate158 and adaptive159 immune defences. Often compounded by dehydration, 
malnutrition, chronic antibiotic use and other comorbidities, the age-associated immune 
deterioration is thought to arise in the gut mucosa earlier than in the systemic immune 
compartments162. Several age-associated gut mucosal changes have been reported, and 
the ‘aged’ intestinal environment has been suggested to be the main driver of the low-
grade ‘inflamm-aging’ typical of old age174 (Refer to Section 1.2.4 for more details). The 
increased basal production of pro-inflammatory cytokines, such as TNFa, IL-6, IL-1 and 
IFNg161,343, does not translate into more effective immune responses. Paradoxically, it 
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correlates with decreased ability to respond to foreign antigens, to maintain tolerance to 
self-antigens, increased susceptibility to infection/cancer and reduced responses to 
vaccination344–347. The incidence and burden of HuNoV infections, for example, are 
much higher in the elderly with an associated mortality rate estimated to be nearly 200 % 
higher among individuals 65 years and older compared to those < 5 years of age348,349. 
Yet, little is really known about the exact cellular and molecular mechanisms of gut 
mucosal immune-aging, and how those age-associated changes relate (in a cause/effect 
fashion) to the increased susceptibility to, and severity of, enteric infectious diseases. 
The importance of IFN production and signalling in immunity against enteric viral 
infections, especially Noroviruses, was discussed and highlighted in previous sections 
(Section 1.2.2 and 1.3.5). Consistent with the heightened pro-inflammatory yet 
unproductive immune state of the elderly, Pillai et al. (2016) recently reported that 
influenza virus-infected peripheral blood monocytes from old (> 65-year-old) human 
donors have impaired anti-viral interferon (IFN-b) production, but retain intact and 
normal inflammasome responses, compared to those from younger donors350.  
Although type-I and -III IFNs share similar signal transduction pathways and regulate the 
same modulators of IFN responses with a strong possibility of extensive in vivo crosstalk 
and interdependence111,351,352, the preferential expression of IFNl-receptor (IL-
28Ra/IL10Rb) at the epithelial barriers results in differential, distinct and tissue-specific 
roles of these IFNs in mediating antiviral responses112,353. Both type-I and –III IFNs are 
produced in response to influenza A virus infection, however it is the IFNl that 
predominates in the lung secondary to intranasal inoculation of the virus354, and 
intranasal administration of IFNl induced strong anti-influenza responses without the 
inflammatory side-effects of IFNa treatment355. Similarly, in the gut, the IFN-anti-viral 
responses are spatially well-orchestrated to tackle different enteric viral infections. Using 
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young-adult (6-8 weeks of age) mice, Mahlakoiv et al. (2015) clearly demonstrated that 
IFNα/β has a minimal effect on intestinal epithelial cells whereas IFNλ has a minimal 
effect on cells of the lamina propria356. They attributed this differential response to the 
respective high and low expression levels of IFNl-receptor and IFNa/b-receptor on the 
surfaces of IECs356, however as discussed earlier it can also be explained, at least in part, 
by the IEC’s apical-surface trafficking of IFNa/b-receptor112 (Section 1.2.2). 
Consequently, rotaviruses with their specific tropism for mature enterocytes of the small 
intestine357 are controlled exclusively by IFN-λ with no defined role for type-I 
IFNs112,357. Replicating in both epithelial and non-epithelial cells of the gut358, reoviruses 
are controlled cooperatively by IFNα/β and IFNλ, with IFNλ limiting replication in 
epithelial cells and IFNα/β restricting infection in non-epithelial cells356. In norovirus 
infection, type-I IFNs prevent extra-intestinal spread, while IFNλ inhibits the persistent 
shedding of the virus in faeces (discussed in Section 1.3.5). Interestingly, this effect of 
IFNλ has been demonstrated only for the persistent strains of MNV (MNV-CR6 and 
MNV3290,291) that, as shown earlier, have the ability to replicate in IECs (Chapter 3). 
A recent report showed even more intriguing differential roles of type-I and –III IFNs. 
By comparing the responses of neonatal and young-adult (6-8 weeks of age) mice, Lin 
and colleagues (2016) could demonstrate that IECs were sensitive to both IFN types in 
neonatal mice. However, their responsiveness to type-I, but not type-III IFNs, diminished 
in adult mice359. This revealed an unexpected age-dependent change in specific 
contribution of type-I versus type-III IFNs to anti-viral defences in the gut. What happens 
upon transition from adult to old age is unknown, nor how this will reflect on the 
outcome of enteric viral infections.  
In this chapter I aimed to address these questions. Using MNV-O7 as a model of enteric 
viral infections, and in collaboration with the Veldhoen group (The Babraham Institute, 
Cambridge) we set the following specific objectives: 
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1) Demonstration of increased burden of enteric viral infections with aging in an in vivo 
experimental MNV-mouse model. 
2) Determining the immunological defect underlying the phenotype in elderly mice and 
defining it as (a) specific signalling defect(s). 
3) Examining the reversibility of the defect and the possibility of therapeutic options. 
4) Setting up an experimental model to compare and translate our findings from above to 
human samples.     
 
4.2 Materials and Methods 
For cell lines, viruses, in vivo infection and anti-CD3 stimulation, sample collection, 
RNA extraction, viral quantification, gene expression assays and statistical analysis, 
please refer to Chapter 2. For splenic CD8 T cells and IEL extraction please refer to 
Section 3.2.3. 
4.2.1 Mice 
 
Male C57BL/6 wild-type mice; young-adult (8-12 weeks old) and old (15 months or 24 
months), were bred and housed to age at the Babraham Institute under Specific Pathogen 
Free (SPF) conditions. They were supplied to us, at the specific ages above, by our 
collaborator Dr Marc Veldhoen (The Babraham Institute, Cambridge). For mouse 
transport, maintenance and setting of the experimental mouse groups, please refer to 
Section 2.4.1.  
4.2.2 In vivo Treatment with IFNl 
 
Recombinant Murine IFNl-2 (PeproTech, 250-33) was prepared to a concentration of 
0.125 µg/µl by reconstituting the stock (250 µg) in PBS (containing 0.1% BSA). Mice 
were gently restrained (without anaesthesia) and injected intra-peritoneally with 200 µl 
of the diluted cytokine solution administered from a 1 ml syringe attached to a ½ inch, 
27-gauge hypodermic needle. 
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4.2.3 Ex Vivo Intestinal Epithelial Cell (IEC) Culture and Generation of Intestinal 
Organoids 
 
This part of the animal experiments was done by our collaborator in the Babraham 
Institute, Cambridge, with the great help of Dr Marc Veldhoen, Marisa Stebegg and 
Ulrika Frising. The human organoids were generated, from endoscopic samples taken 
from healthy young-adult volunteers, and treated for 6 hrs with recombinant human 
IFNl-2 (PeproTech, 300-02K) by our collaborator in Addenbrooke’s Hospital, 
Cambridge, with the help of Dr Matthias Zilbauer and Ms Komal Nayak.  
 
4.2.3.1 Isolation of Highly-Enriched ‘crypt’ IECs 
Epithelial cells from the small intestine (of mice after sacrifice or from endoscopic 
human samples) were isolated using a procedure adapted from Sato and Clever’s 
method37. Briefly, murine small intestines were collected from wild-type C57BL/6 mice, 
divided into two equal halves (proximal; duodenum and distal; ileum), opened 
longitudinally and cut into small (0.5 – 1 cm long) pieces. The small intestinal pieces 
were then washed (5-7 times) with MgCl2- and CaCl2-free PBS until the supernatant 
became clear, and incubated in 2 mM EDTA-PBS solution for 20 min on a shaker (50 
rpm) at 4º C to loosen the Ca2+-dependent epithelial cell-to-cell contacts. The small 
intestinal pieces were subsequently washed into PBS and subjected to several (6-7) 
rounds of manual mechanical disruption by shaking the tissues; i.e. manually moving the 
tube up and down at a rate of about 3 times per second, in 20 ml PBS for 10-15 seconds. 
Following each round of manual shaking; the small intestinal fragments were left to 
settle down by gravity and the resultant clear cell suspension, which is enriched for 
intestinal crypts, was collected into a separate tube and labelled as fraction 1. This 
procedure was repeated until a total of 6-7 fractions were generated. The contents of each 
fraction were inspected by microscopy, and the ‘dirtiest’ fractions; i.e. containing many 
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loose villi and cell debris (usually the first ones), were discarded. The remaining 
fractions were passed through a 70 µm cell strainer and pooled into BSA-coated 50 ml 
Falcon tubes. 
Isolation of colonic IECs (For Supplementary Figure 4.3) followed the same protocol 
as above, except for longer incubation in the thermal shaker (for 1 hrs instead of 20 min) 
with a higher concentration of EDTA (30 mM instead of 2 mM EDTA-PBS) and longer 
manual disruption rounds (for 5 min instead of 15 seconds) to increase the yield of the 
more strongly-attached colonic IECs. 
 
4.2.3.2 Further Processing of Isolated IECs for Gene Expression and Short-Term 
Culture 
IECs, isolated by the procedure above, were pelleted at 4º C with 500 xg for 5 min and 
washed once into cold PBS (400 xg; 4 min). When the gene expression of freshly 
isolated IECs was investigated (Figure 4.3), the cells were transferred to Eppendorf 
tubes into 1.5 ml of PBS, centrifuged (600 xg; 5 min) and the pellets were stored at -80º 
C for future RNA isolation (Section 2.6.3), reverse transcription and gene expression 
analysis (Section 2.8). Alternatively, when short-term ex vivo IEC culture was wanted 
(Supplementary Figure 4.2. 4.3), IEC survival was improved by seeding into Matrigel 
droplets (Corning, 356231) and cultivation in growth factor-rich medium optimised for 
organoid growth by Sato and Clever37. Firstly, the IECs were washed once into cold basal 
culture medium (Table 4.1) at a reduced centrifugation force of 300 xg for 3 min to 
reduce the number of single cells in the pellet. The resultant supernatant was discarded 
and the pellet was re-suspended in Matrigel diluted to 40 % in cold basal culture 
medium. The cells were subsequently seeded at 50 µl droplets/well of a pre-warmed 24-
well culture plate, which was then incubated for 15-30 min at 37º C to allow Matrigel 
polymerisation. Once the Matrigel droplets had gelled, 400 µl of growth factor-rich 
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medium (Table 4.2) was added to each well and the plate was incubated at 37º C with     
7 % CO2. IECs were cultured ex vivo for a maximum of 24 hrs and treated with either; 
30 ng recombinant murine IFNl-2/ml (PeproTech, 250-33) or 2.5 ng recombinant murine 
IFNg/ml (PeproTech, 315-05), both of which were pre-diluted in basal medium and 
added to the wells in a total volume of 10 µl. After the indicated time points, the IECs 
were transferred to Eppendorf tubes into 1.5 ml of PBS, centrifuged (600 xg; 5 min) and 
the pellets stored at -80º C for future RNA isolation (Section 2.6.3), reverse transcription 
and gene expression analysis (Section 2.8).    
  
4.2.3.3 Generation of Intestinal (Duodenal) Organoid cultures 
IECs (crypts) obtained from one duodenum by the procedure outlined in Section 4.2.3.1 
were washed once into cold PBS (400 xg; 4 min), re-suspended in 400 µl 100 % Matrigel 
(Corning, 356231) and seeded as 50 µl droplets into 6-8 wells of a pre-warmed 24-well 
culture plate. The plate was placed at 37º C to allow Matrigel solidification and then 500 
µl of growth factor-rich medium (Table 4.2) was added to each well. The crypts 
developed into full intestinal organoids within 2-3 days of incubation at 37º C with 7 % 
CO2. The culture medium was changed every 3-4 days and the organoids were 
maintained by passaging (at a split ratio of 1:2) every 7 days. The duodenal organoids 
were treated by the addition of 10 µl of basal medium (Table 4.1) containing one of the 
following: 
- For murine organoids, Supplementary Figure 4.1: 25 ng recombinant murine 
IFNl/ml or 25 ng recombinant murine IFNa (2b subtype)/ml. 
- For human organoids, Figure 4.5: 25 ng recombinant human IFNl/ml (PeproTech, 
300-02).  
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- For the organoid-MNV time points experiment (Figure 3.14): the stocks of the 
various viruses used (MNV-O7, MNV-1.CW3, MNV-3 and UV-irradiated stocks) 
were diluted to the correct concentration to infect organoids at an MOI of 5 in basal 
medium and added to the well containing the duodenal organoids in total volume of 
10 µl.  
After the indicated time points, the organoid’s IECs were transferred to Eppendorf tubes 
into 1.5 ml of PBS, centrifuged (600 xg; 5 min) and the pellets were stored at -80º C for 
future RNA isolation (Section 2.6.3), reverse transcription and gene expression analysis 
(Section 2.8) or quantification of viral RNA titre by RT-qPCR (Section 2.7). 
 
Table 4.1 Constituents of Basal Culture Medium  
Amount 
(ml) 
Reagent Supplier (Catalogue Number) 
500 Advanced DMEM/F12 Gibco (12634-010) 
5   HEPES buffer solution Gibco (15630-056) 
5 GlutaMax-I	(100x) Gibco (35050-038) 
5 Pen/Strep (100x) Gibco (15140-12) 
     
 
Table 4.2 Constituents of Growth factor-rich medium 
Amount Reagent Supplier (Catalogue Number) 
1 ml basal culture medium Table 4.1. 
10 µl     10x N2 supplement Invitrogen (17502-048) 
   20 µl     5x B27 supplement Invitrogen (12587-010) 
    2 µl 500 mM N-acetylcysteine Sigma (A9165-25G) 
    1 µl 500µg rmEGF/ml  Life Technologies (PMG8043) 
   1 µl     100µg rmNoggin/ml  eBioscience (34-8004-82) 
  10 µl 100µg rhR-spondin-I/ml  PeproTech (120-38) 
                       rm; recombinant murine.     rh; recombinant human.   
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4.3 Results 
4.3.1 Demonstration of Increased Burden of MNV Infection in Old Mice 
 
To assess the effect of aging on the susceptibility to, and early protection against, enteric 
viral infections, we compared faecal and intestinal tissue viral burdens of young (8-week 
old) and old (24-month old) C57BL6 wild-type mice within 7 days of infection with a 
standardised dose of the persistent strain of MNV (MNV-O7). An infectious viral dose of 
5 x 106 TCID50 was administered orally and the kinetics of virus shedding in faeces from 
infected mice were followed for a week with daily faecal sampling for viral titration 
(Figure 4.1A). On day 7 P.I. the mice were sacrificed and viral titres were measured in 
gut sections and MLNs (Figure 4.1B). As expected, MNV-O7 infection of young wild-
type mice resulted in persistent viral shedding in faeces that tended to drop within the 
first 3 days of infection (about two-log reduction) and then was maintained at a fairly 
steady level of about 104 viral genome copies per mg of faeces. Seven days P.I. the tissue 
viral titres were higher (almost a log difference) in the MLN compared to intestinal 
segments.  
Whilst they had comparable viral loads on day 1 P.I., the 24-month old wild-type mice 
maintained a significantly higher MNV-O7 viral titre in excreted faeces and in all tissues 
examined, with approximately a 3-fold rise in the distal small intestine and MLNs, 
compared to those of younger counterparts. There was a minor reduction in faecal virus 
shedding during the first few days of infection, however it was less impressive than that 
of young mice and the faecal viral titres were maintained at around 105 viral genome 
copies per mg of faeces.  
Thus, although the wild-type mouse-MNV-O7 experimental model is sub-clinical 
(asymptomatic) and so does not allow for assessment of the clinical impact, it clearly 
demonstrated the increased viral burden and impaired control of a persistent enteric virus 
in the elderly. 
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4.3.2 Immunological Basis of the Old Mouse Phenotype 
 
To investigate the immunological defect underlying the increased burden of MNV-O7 
infection observed in old mice we used the in vivo anti-CD3/MNV-O7 model, which 
allowed us to probe the anti-viral defence capacity of the gut mucosa under different 
conditions (Chapter 3). The characteristics, effects, limitations and procedure of this 
experimental model has been detailed previously (Section 3.3.1). Briefly mice were 
orally infected with MNV-O7 8 hrs after i.p. injection of either agonistic anti-CD3 or 
non-specific isotype control (ITC) antibodies. Mice were sacrificed 40 hrs after virus 
challenge to determine the degree of protection observed at different sites of the small 
intestine and draining MLNs. In young (8-12 weeks old) wild-type mice stimulation with 
anti-CD3 resulted in a broad, systemic cytokine response with release of all three types 
of IFN, up-regulation of immune-protective ISGs and induction of an effective antiviral-
state in the gut (Chapter 3). In Figure 4.2 we compared the control of virus replication 
in young (8-week old) and old (24-month old) C57BL6 mice using this model. As shown 
in the figure, young mice were able to significantly control and prevent the establishment 
of overt MNV-O7 infection following stimulation with agonistic anti-CD3 antibodies. 
After ITC antibody injection, both old and young mice had comparable levels of virus in 
intestinal tissues, however the old (wild-type) mice had a strikingly reduced capacity to 
suppress the viral load upon anti-CD3 stimulation and maintained significantly higher 
viral titres in all tissues examined compared to anti-CD3-injected young controls. There 
was a trend for reduction of the virus titre with anti-CD3 stimulation of old mice in the 
middle small intestine (jejunum) and MLNs, however it was statistically insignificant 
when compared to that of ITC-injected controls and much (about two orders of 
magnitude) less than that observed in the young mice.  
These findings were of particular interest and encouraged the investigation of whether 
the observed old mouse phenotype was due to reduced production of protective antiviral 
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cytokines by intestinal lymphocytes, mononuclear phagocytes and/or IECs. Another 
possibility is that the defect could be due to the impaired ability of IECs and/or 
mononuclear phagocytes to respond to these protective cytokines and mount effective 
anti-viral immune responses. 
 
4.3.3 Is there a Cytokine Production vs Response Defect Or Both? 
 
To track the anti-viral protective responses mediated by anti-CD3 stimulation, we 
compared the anti-viral gene expression of 8-week old (young) and 24-month (old) wild-
type mice 3 hrs post-stimulation by i.p. administration of anti-CD3 antibody. Due to the  
reduction in naïve/memory T cell ratio in the elderly with the proportional accumulation 
of fully differentiated memory T cells with aging360,361, we decided to isolate the splenic 
CD8+ memory (CD44hi) T cells from the young and old mice to compare memory T cell 
cytokine mRNA expression directly. We also isolated and compared the responses of 
IELs and IECs from the small intestine of all mice (Figure 4.3). Consistent with the 
‘infamm-aging’ theory, RT-qPCR analyses revealed elevated expression levels of the pro-
inflammatory cytokines (TNFa and IFNg), both in the splenic CD8 memory T cells and 
IEL fractions of the 2-years old wild-type mice, almost double that of the young 
counterparts (Figure 4.3A & B). In fact, the old C57BL6 mice reacted poorly to anti-
CD3 injections, with the clinically-observed development of pili-erection, tremors and 
decreased mobility, suggesting the development of a severe ‘cytokine-storm’ compared 
to the young controls. The young-old differences in other IFNs were less impressive with 
comparable expression levels of IFNb and IFNl mRNA by both CD8 memory T cells 
and IELs. As discussed earlier, the systemic cytokine expression stimulated by anti-CD3 
antibodies culminated in an effective anti-viral state in the gut with induction of several 
ISGs. This was evident in the duodenal and ileal IECs extracted from young mice that 
showed clear up-regulation of all ISGs examined; Mx1, Adar, Rsad2 and Prkr       
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(Figure 4.3C). The mRNA levels of these ISGs were, however, markedly reduced in the 
duodenum and ileum of the 2 years old, aged, anti-CD3-treated mice. The difference was 
clearer for certain ISGs, namely Mx1 and Rsad2, with almost 10 orders of magnitude 
reduction in the expression in the old mice compared to that of young controls. 
Taken together, the data presented in figure 4.3 strongly suggested that the aging process 
negatively affected the IFN responsiveness of IECs and their ability to mount an 
effective anti-viral state. Although the expression level of type-II IFN seemed to be 
elevated, rather than reduced, with relatively stable expression levels of type-I and –III 
IFNs by old lymphocytes, it is important to note that these data do not conclusively 
exclude the possibility of a production defect. The aging process might have post-
translational effects that modify cytokine production at the protein level. Moreover, given 
their sheer numbers, location, and ability to sense and respond to replicating viral 
particles, IECs and mononuclear phagocytes (DCs and macrophages) are important 
sources of type-I and –III IFNs that have not been addressed and examined in this 
experiment. 
 
4.3.4 A Specific, Age-Dependent Small Intestinal Defect in IECs’ Response to IFNl 
 
This section was done in collaboration with Ms. Marisa Stebegg at the Babraham 
Institute, Cambridge. Following the hypothesis drawn from the previous sections that 
aging affects IFN responsiveness of IECs, we aimed to analyse and dissect the 
mechanism by in vitro and ex vivo experimental models. To that end, we firstly 
confirmed the previously reported observation of superior responses of IECs to type-III 
IFNl rather than to type-I IFNs112,356. In Supplementary Figure 4.1 small intestinal 
organoids were established from the gut of young (8-12 weeks old) C57BL6 wild-type 
mice, and were treated with equivalent doses (25 ng/ml) of either recombinant murine 
IFNa (2b subtype) or IFNl-2 for the indicated time points. Indeed, the expression levels 
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of the ISGs Mx1 and Isg15 increased exponentially with time after IFNl treatment, with 
Isg15 expression reaching a 1000-fold increase after 24 hrs. This was associated with 
induction of IFNl expression by IECs at late time-points. In marked contrast, Ifnl mRNA 
levels and ISG expression remained constantly low upon IFNa treatment compared with 
IFNλ. Thus, the in vivo anti-CD3 mediated induction of protective ISGs, and hence the 
anti-viral state, in small intestinal IECs is most likely mediated through production of, 
and in response to, type-III IFNs. 
  
Following this conclusion, we directly compared the IFN-responsiveness of small 
intestinal IECs isolated from young (8-week old) and old (24-month old) wild-type mice 
(Figure 4.4). For short-term ex vivo cultures, IECs were maintained under the same 
cultivation conditions as intestinal organoids, preserving cell-cell contact, to achieve 
optimal IEC survival (Section 4.2.3.2). After ex vivo treatment with recombinant murine 
IFNg for 6 hrs, IECs from small intestines of old mice showed a comparable response to 
those sourced from young mice when assessed for IFNγ-induced Ido1 mRNA expression 
(Figure 4.4). The expression of another IFNg-responsive gene, Cxcl9, was different with 
old IECs displaying a significantly stronger expression compared to the young 
counterparts, a finding in line with the ‘inflamm-aging’ theory, as CXCL9 recruits the 
pro-inflammatory CXCR3+-cells that produce the prototypical inflammaging cytokine 
IFNγ362,363. Furthermore, this IFNg response confirmed that the aged IECs were not in an 
overall state of hypo-responsiveness. We did, however, observe a significant reduction in 
expression levels of the IFNl-induced genes Mx1 and Isg15, in aged small intestinal 
epithelium compared to those of the young controls (Figure 4.4). Isg15 mRNA levels of 
old mice were decreased by almost three-fold, while a two-fold reduction was detected 
for Mx1 levels.  
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This was associated with a less prominent, but statistically significant, drop in the 
expression levels of the Il28ra subunit of the IFNl-receptor in the IECs sourced from old 
mice, while those of the Il10rb subunit remained unchanged (Supplementary Figure 
4.2A). Unfortunately, we could not link these data with the protein levels of the IL-28Ra 
subunit because anti-mouse IFNlR antibodies are currently unavailable and the anti-
human IL-28Ra antibody, that was tested, failed to produce specific staining in mouse 
samples. 
We further confirmed that the IFNl-defective response was specific for IECs isolated 
from the small intestine of old mice, as those extracted from the colon had, if anything, a 
similar or even slightly higher expression levels of ISGs in response to IFNl treatment 
compared to those of the young counterparts (Supplementary Figure 4.2A). 
Importantly, this specific, small-intestinal, IFNl-response phenotype appeared to be age-
dependent. The defect became more apparent with advancement of age. Fifteen-month 
old mice had a very similar, but less pronounced phenotype compared to that of 24-
month old mice (Supplementary Figure 4.2B). Compared to the young controls, 
expression levels of Isg15 were significantly reduced in IFNl-treated duodenal IECs 
sourced from 15-month old wild type mice, while the decrease in Mx1 expression was 
not statistically significant. This was also associated with a reduction (at the transcription 
level) of the Il28ra subunit of IFNl-receptor, and as expected, a stable unchanged IFNl-
responsiveness of colonic IECs (Supplementary Figure 4.2B). 
 
4.3.5 The IFNl-Defect of The Elderly Is Treatable 
 
To investigate whether the specific IFNl-hyporesponsive phenotype of the aged small 
intestinal IECs was due to an irreversible, inherent defect or if it could be overcome by 
exogenous IFNl administration, we persistently infected young and old mice with MNV-
O7, as described in Section 4.3.1. On day-1 and -3 P.I. the mice were treated i.p. with   
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25 µg IFNl (per mouse per injection) or with PBS as a control (Figure 4.5). Young mice 
responded swiftly to IFNl injections with significant reductions in viral titres in faeces 
and gut tissues, confirming previously reported data289. Interestingly, the 24-month old 
mice responded to IFNl treatment in a similar and indistinguishable manner compared 
with the young mice. MNV-O7 was rapidly cleared from older mouse faeces, within 1 
day of the second IFNl dose (Figure 4.5A), and significantly reduced in the gut sections 
and MLNs to very low levels (Figure 4.5B) following IFNl treatment. It is important to 
note that I did not titrate the dose of IFNl to determine the minimal dose required for an 
effect. This means that the high dose that I used in this experiment (two injections of 25 
µg per mouse) might saturate the system. Saturation of the IFN-lambda receptors may 
have caused the lack of difference between young and old mice that was observed. 
These data strongly suggested that the reduction observed in IFNl-responsiveness of old 
mice is not an inherent cell defect that is persistent and cannot be reversed. I propose that 
it is rather an accumulation of adverse effects, most likely linked to the age-associated 
gut mucosal inflamm-aging environment and/or the age-related microbiota changes, that 
render the old mice hypo-responsive to endogenous IFNl and, thus, more susceptible to 
severe enteric viral infections. The data also suggested that the defect might be broader 
than just IEC-hyporesponsiveness to IFNl. There may also be a combined, yet 
unidentified, reduction in the production of protective IFNs (IFNl) by other immune 
cells and/or IECs themselves, that contributes to the development of the characteristic 
phenotype in the old mice. 
 
4.3.6 The Organoid/ IFNl Experimental Model is Viable in Human Samples 
 
In collaboration with Dr Matthias Zilbauer’s lab at Department of Paediatrics, University 
of Cambridge, we evaluated human organoids to test the feasibility of comparing our 
results in mice with human samples. Small intestinal organoids were generated from 
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endoscopic samples taken from two young-adults (age 23-26 years old) healthy 
volunteers in Addenbrooke’s Hospital. The human organoids were subsequently treated 
with recombinant human IFNl for 6 hrs and the expression levels of the ISGs: MX1 and 
ISG15 mRNA were measured by RT-qPCR (Figure 4.6). Compared to the untreated 
controls, IFNl treatment resulted in a strong induction, almost 3-fold, of both ISGs, 
confirming the sensitivity of the young-adult human IECs to IFNl. We are planning to 
extend this experimental protocol, in collaboration with Prof Tim Spector group, King’s 
College, London, in order to analyse and compare the responses of small intestinal 
organoids generated from elderly (>65 years old) volunteers.  
 
 
4.4 Discussion 
The aging process significantly impacts the gut mucosal homeostasis and alters the 
outcome of enteric (noro)virus infections. The data presented in this chapter demonstrate 
a clearly increased viral burden phenotype in aged wild-type mice infected with MNV-
O7. We analysed the immunological basis of the phenotype, identified a specific age-
dependent defect that could be reversed by exogenous IFNl treatment, and proposed an 
in vitro experimental model to compare and translate the results to humans.  
There remain questions to be answered. The exact cause(s) of the phenotype observed in 
old mice and the specific molecular mechanism(s) of IEC IFNl-hyporesponsiveness 
remain to be elucidated. The transcriptional defect of the IL-28Ra subunit of IFNl-
receptor is of interest, but needs to be confirmed at the protein level. Earlier reports 
linked the age-associated reduced IFN responses of innate immune cells to impaired 
STAT1 signalling. Yoon et al. (2004) observed impaired JAK/STAT signalling in aged 
macrophages from old BALB/c wild-type mice; these macrophages were found to be 
hyporesponsive to IFNg364. Quian and colleagues (2011) reported a reduced level of 
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STAT1 protein and phosphorylation in DCs isolated from aged (73.6 ± 6.0 years old) 
human donors and infected in vitro with West Nile virus365. Interestingly, in this study the 
authors observed no significant age-related changes in expression or nuclear 
translocation of signalling molecules in initial anti-viral responses, however, DCs 
isolated from older volunteers had diminished induction of late-phase responses (e.g., 
STAT1, IRF7, and IRF1), suggesting a defective regulation of type-I IFN365.                    
To our knowledge, the data presented in this chapter are the first to report age (beyond 
the adult-life)-related changes of the IECs responses to IFNs. Moreover, the fact that 
IFNg uses certain signalling mediators, such as STAT-1, that are shared with the 
IFNl transduction-pathway will allow their exclusion as sites of the defect, as IECs 
sourced from old mice are functionally responsive to the former but not the later.  
The regional variation in the IFN-responses of IECs along the full length of the intestinal 
tract further highlights the naivety of the assumption that the gut is a single            
uniform organ and adds to a growing body of evidence for intestinal immune 
compartmentalization (Section 1.1). The difference between duodenal and ileal IEC 
expression of ISGs roughly correlates with the regional difference in viral loads. 
Generally, colonic IECs had much reduced levels of ISG expression in response to IFNl 
treatment, almost half that of IECs isolated from small intestine (Supplementary Figure 
4.2). This might be a contributory factor for the preferred colonic tropism (higher viral 
titres) observed in MNV infection and the colonic persistence of many viruses including 
MNV283,284.  
The differential effects of the aging process, with age-associated IFNl-
hyporesponsiveness being apparent in the small intestine and absent in the colon, 
suggests that the defect might be more linked to the inflamm-aging environment in the 
gut mucosa rather than to the age-related changes in the microbiota. Further experiments 
with germ-free mice, antibiotic treatment and/or faecal transplantation will be necessary 
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to address and substantiate/support this hypothesis. Furthermore, employing the 
adoptive-transfer experimental model used in the previous chapter (Chapter 3) with 
transfer of young/old lymphocytes and/or mononuclear phagocytes into young/old    
Rag2-/- or Ccr2-/- mice will be important in interrogating these different immune cells and 
identifying their role in the development of this age-specific immune defect. 
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Chapter 5 MANIPULATION OF THE ARYL HYDROCARBON 
RECEPTOR (AhR) INFLUENCES EARLY GUT 
IMMUNITY AGAINST MURINE NOROVIRUS (MNV) 
  
5.1 Background 
AhR is a highly conserved, ligand-activated transcription factor that is abundantly 
expressed at barrier sites, including the gut. For details about AhR signalling, ligands, 
expression, regulation, interactions and immunological relevance please refer to Section 
1.2.5. Highly expressed by specific barrier-associated immune cells, the role of AhR 
signalling in immunity against infectious diseases continues to draw increasing attention. 
The ability of AhR to recognise distinct bacterial (M. tuberculosis and P. aeruginosa) 
virulence factors, and to subsequently induce protective anti-bacterial responses, has led 
to the suggestion that AhR can be regarded as an intracellular PRR216. The influence of 
AhR on immunity against viral infection, however, has so far only been investigated in 
the context of ‘stimulation’ by exogenous AhR-ligands, such as dioxin. Firstly, dioxin 
(also known as TCDD) administration enhances the replication of human 
cytomegalovirus in a fibroblast cell line through an AhR-dependent mechanism366. 
Secondly, 3-Methylcholanthrene (3-MC), a chemical homologue of dioxin, induces the 
replication of HIV-1 replication in a latently-infected promyelocytic cell line367. Thirdly, 
dioxin-induced AhR activation reduces the survival rate of mice infected with influenza-
A virus (IAV)368,369, and indirectly diminishes the induction of IAV-specific CD8 T cell 
responses through its immunoregulatory effects on DCs370 (discussed in more detail 
below). Lastly and interestingly, by using a mouse-model of IAV infection and directly 
(side-by-side) comparing the immunomodulatory properties of the two most commonly 
used high-affinity AhR-ligands, i.e. dioxin and FICZ, Wheeler et al. (2014) were able to 
demonstrate clear differential consequences of stimulation by the two distinct AhR-
ligands on innate and adaptive anti-viral responses371. Both dioxin and FICZ suppressed 
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the virus-specific CD8 T cell response, whereas dioxin, but not FICZ, enhanced 
neutrophil recruitment and pulmonary inducible nitric oxide synthase (iNOS) production 
in response to IAV infection371. Moreover, stimulation by a different AhR ligand (DIM) 
results in a completely different clinical outcome of viral infection372. One report 
suggested a protective anti-viral effect of the AhR ligand (DIM) by demonstrating a 
significant suppression of reovirus infection and faecal shedding in mice orally gavaged 
with DIM compared to controls372. However, caution should be taken in the 
interpretation of this finding as DIM has a number of AhR-independent signalling 
effects373, a fact that had not been accounted for in the above report by, for example, 
including Ahr-/- mice as an additional control372. 
In my opinion, additional emphasis and efforts should be applied to investigating the 
physiological significance of constitutive AhR-signalling, and the effects of induction by 
endogenous and natural AhR ligands, in the context of protection against viral infections. 
A landmark in the field is the demonstration of a direct link between the gut-associated 
AhR system and the biology of IELs203. Manipulation of the AhR system, either 
genetically (Ahr-/-) or through diet modification, was sufficient to alter the number and 
functions of IELs203. A primary aim of this chapter was to extend this previous research 
by applying an in vivo experimental model and analysing the consequences of such AhR-
manipulations on the outcome of enteric (Noro)virus infections. However, AhR has some 
indispensable roles in reproduction192,374, and Ahr-/- females show reduced fertility and 
reduced litter size. Therefore, in order to maintain a colony for the in vivo experiments 
we relied on breeding Ahr-/- males with AhR heterozygous females. This resulted in 
significant delays and a difficulty in generating consistent age- and sex-matched 
experimental groups. Moreover, most likely due to microbiota- and age-differences, there 
was a significant variation in the number of IELs in Ahr-/- offspring obtained by this 
breeding strategy (Dr Marc Veldhoen, personal communication). For these reasons (and 
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others), it proved to be quite difficult to meet the aim above within the time frame of my 
PhD.  
Another interesting finding, which is directly relevant to anti-viral immune responses, is 
the possible interactions and cross-talk between the AhR- and IFN-STAT1-signalling 
pathways. The consequences of the physical association between activated AhR and 
STAT-1 molecules198,199, have been discussed previously (Section 1.2.5). A recent report 
identified AhR-interacting protein (AIP), one of the cytoplasmic chaperones of inactive 
AhR, as a novel inhibitor of interferon-regulatory factor-7 (Irf-7)375. Irf-7 
phosphorylation and nuclear translocation are crucial steps in IFN-signalling and the 
induction of a subsequent anti-viral state (further details in Section 1.2.2). Upon viral 
infection of murine embryonic fibroblasts, AIP potently antagonises the nuclear 
localisation of Irf-7 and significantly reduces subsequent type-I IFN production and 
signalling375. Thus, the release of AIP from the cytoplasmic-AhR complex upon ligand 
activation might represent another mechanism through which the AhR activity modulates 
innate antiviral immune responses. I aimed to further address these findings by 
developing and characterising an in vitro bone marrow-derived mononuclear cell 
(BMMC) experimental model, with the specific objective of analysing the influences of 
such interactions and cross-talk on the viral replication of MNV-O7. 
The AhR is constitutively expressed by mononuclear phagocytes: macrophages and 
DCs212. This expression is further augmented by exposure to LPS and CpG198,376. 
Functional AhR signalling in DCs is required for normal induction of indoleamine 2,3-
dioxygenase (IDO) expression376,377. IDO is an immunosuppressive enzyme that 
catabolises tryptophan into Kynurenine (Kyn) and other metabolites in DCs378. Kyn was 
reported to promote Foxp3-expression and regulatory T cell differentiation376, and is 
(itself) considered to be a putative AhR agonist215, providing a possible positive feedback 
loop for AhR-induced immune tolerance. FICZ-mediated activation of AhR in bone 
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marrow-derived DCs (BMDCs) of wild-type mice decreased the expression of CD11c 
and increased that of MHC-class II (MHC-II), CD86 and CD25379. Comparing BMDCs 
from bone marrow of wild-type and Ahr-/- mice differentiated in the presence of 
granulocyte-monocyte colony-stimulating factor (GM-CSF), Vogel and colleagues 
(2013) demonstrated characteristic phenotypic differences of the Ahr-/- BMDCs with a 
significant increase in the proportion of immature cells380. In this report, the authors used 
CD11c expression to identify DC populations and MHC-II expression to determine the 
DC-maturation status380.  
 
Using MNV-O7 as a model of enteric viral infections, the objective of this chapter was to 
investigate the role of AhR in enteric virus infection. Specifically, to: 
1) Compare MNV-O7 viral titres in wild-type and Ahr-/- mice in the context of acute and 
chronic (persistent) infection. 
2) Explore different BMMCs differentiation protocols and select the most appropriate 
protocol for further studies. 
3) Characterise the phenotypic features (surface marker expression) of BMMCs derived 
from wild-type and specific (AhR-related) knock-out mouse lines; Ahr-/-, Ahrr-/- (Ahr 
repressor-/-) and Cyp-/- (cytochrome p450-/-). 
4) Assess MNV-O7 replication in these different BMMCs. 
5) Analyse the early IFN-mediated anti-viral immune responses induced in different 
BMMCs in response to poly(I:C) stimulation by gene expression analysis and ELISA. 
6) Evaluate the influences of ligand-mediated manipulation of AhR signalling on wild-
type BMMC differentiation/maturation and MNV-O7 viral replication kinetics.         
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5.2 Materials and Methods 
For cell lines, viruses, in vivo infection, sample collection, RNA extraction, viral 
quantification, reverse transcription, gene expression assays and statistical analysis, 
please refer to Chapter 2. For flow cytometric analysis of the BMMC surface marker 
expression please refer to Section 3.2.4.  
 
5.2.1 Mice: 
 
C57BL/6 wild-type, Ahr-/-, Ahrr-/- and Cyp-/- mice were bred at the Babraham Institute 
under Specific Pathogen Free (SPF) conditions. The mice, or their long bones for BMMC 
extraction, were supplied by our collaborator Dr Marc Veldhoen (The Babraham 
Institute, Cambridge). For mouse transport, maintenance and setting up of the 
experimental mouse groups please refer to Section 2.4.1.  
 
5.2.2 Generation of Bone Marrow-Derived Mononuclear Cells (BMMCs) and Their 
Treatment with AhR-Agonist (FICZ) or AhR-Antagonist (CH223191) 
 
Bone marrow was extracted from the long bones (femurs and tibias) of mice by flushing 
with Iscove's modified Dulbecco's medium (IMDM) supplemented with 10 % foetal calf 
serum (FCS), 100 U penicillin/ml and 0.1 mg streptomycin/ml (10% IMDM), using 5 ml 
syringes and 25G needles. The bone marrow was filtered through a 70 µm cell strainer 
and centrifuged (5 min, 1280 xg) at 4 º C. Cells were subsequently resuspended at a 
density of 1 x 106 cells per ml in 10% IMDM supplemented with either GM-CSF (20 
ng/ml) alone or GM-CSF (20 ng/ml) with IL-4 (10 ng/ml). For certain experiments, BM 
cells extracted from wild-type mice were differentiated in 10% IMDM supplemented 
with GM-CSF (20 ng/ml) and either 500 nM FICZ (Tocris, 5304) or 3 µM CH223191 
(Tocris, 3858). 
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The cells were immediately transferred into six-well tissue culture plates, at 2 ml per 
well, and incubated for 8 days at 37 º C, 5 % CO2. For specific experiments 
(Supplementary Figure 5.2), microscopic images were taken of the differentiating cells 
on Day 0, 3, 6 and 8. During this 8 day incubation period, the specific medium of each 
differentiation protocol was renewed once (usually in day 5 of the incubation) by 
aspiration of the old medium in the wells, with the removal of floating cells in the 
process, and replacing it with a fresh medium (consisting of exact same components) for 
the final 3 days of differentiation. 
To harvest the cells in day 8 of differentiation, the 6-well plates containing the cells were 
placed on ice for at least 30 min. The cells were then mechanically scraped from the 
wells and centrifuged (5 min, 400 xg) in 50 ml tubes. Cells were washed once in ice-cold 
10% IMDM, centrifuged again (5 min, 400 xg) and finally re-suspended into 10% 
IMDM at the required cell density for subsequent assays. 
         
5.2.3 MNV-O7 Infection of BMMCs 
 
BMMCs generated by the protocols described above were seeded into individual wells of 
96-well tissue culture plates (flat-bottomed), at a density of 2 x 105 cells per well. Cells 
were allowed to adhere to the plates for at least 16 hrs at 37 º C, 5 % CO2. After this 
incubation period, the medium was removed from the wells and replaced with the MNV-
O7 virus inoculum diluted to the stated multiplicity of infection (MOI) in warm 10% 
IMDM, or replaced with 10% IMDM alone (mock infection). Cells were incubated with 
the virus for 1 hrs, 37 º C, 5 % CO2 with gentle agitation every 15 min. After this 1 hrs 
infection period, the viral inoculum was removed and cells overlaid with warm PBS as a 
part of a washing step. Plates were centrifuged (5 min, 400 xg) after which the PBS was 
removed and replaced with warm 10% IMDM. Cells corresponding to the 1 hrs post 
infection (P.I.) time-point were processed at this stage, by removal of the supernatant, 
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lysis of the cells for RNA extraction (Section 2.6.3) and quantification of the viral RNA 
titres by RT-qPCR (Section 2.7). Otherwise, cells were returned to the incubator (37 º C, 
5 % CO2) until the required time points (9, 12, 24 and 48 hrs P.I.) for similar processing.  
 
5.2.4 Treatment of BMMCs with Poly(I:C) and Gene Expression Analysis 
 
BMMCs generated by the method detailed in Section 5.2.2 were seeded into individual 
wells of 96-well tissue culture plates (flat-bottomed), at a density of 2 x 105 cells per 
well. Cells were allowed to adhere to the plates for at least 16 hrs at 37 º C, 5% CO2. 
After this incubation period, the medium was removed from the wells and replaced with 
10% IMDM supplemented with 100 µg Poly(I:C)/ml (Sigma-Aldrich, P1530). Cells 
corresponding to the baseline time point were processed at this stage, by removal of the 
supernatant for ELISA analysis (Section 5.2.5), and lysis of the cells for RNA extraction 
(Section 2.6.3), reverse transcription and gene expression analysis (Section 2.8). 
Otherwise, cells were returned to the incubator (37 º C, 5 % CO2) until the required time 
points (1, 3, 6, 9, 12 and 24 hrs P.I.) for similar processing.  
 
5.2.5 IFN-b Enzyme-Linked Immunosorbent Assay (ELISA) 
 
The concentration of IFN-b in supernatants collected from individual wells of the 
poly(I:C)-treated cell cultures (Section 5.2.4) was quantified by ELISA. The mouse IFN-
β ELISA Kit (Biolegend, 439407) was used according to the manufacturer’s protocol. 
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5.3 Results 
5.3.1 Comparison of MNV-O7 Viral Load in Wild-type and AhR-Deficient Mice 
 
In order to assess the role of constitutive AhR signalling in immunity against enteric viral 
infection, we compared the viral load in tissues following infection with a standardised 
dose of MNV-O7. An infectious viral dose of 5 x 106 TCID50 was administered orally to 
C57BL6 wild-type and Ahr-/- mice. To assess the effects of AhR signalling during acute 
infection, a group of mice was sacrificed 40 hrs after viral challenge to determine the 
viral burden at different sites of the small intestine and draining lymph nodes (MLN)    
(Figure 5.1A). The remaining infected mice were maintained to establish chronic 
(persistent) infection and were followed by RT-qPCR measurement of viral shedding in 
faeces. On day 21 P.I. all mice were sacrificed and viral titres were measured at various 
sites of the small intestine (Figure 5.1B). 
As shown in Figure 5.1A, MNV-O7 virus replicated in the wild-type mice and 
established homogeneous levels of infection throughout the length of the small intestine 
(duodenum, jejunum and ileum) and in the MLN. In contrast, virus replication in Ahr-/- 
mice was more variable. The mouse to mouse variation and the range of the viral titres 
detected in the Ahr-/- mice were much greater than that seen in the wild-type counterparts. 
Initially, I thought this variation could be explained, at least in part, by the fact that Ahr-/- 
mice have a variable deficiency of the CD8αα+ (natural) IELs203 (and Dr M Veldhoen, 
personal communication). However, the data presented in Chapter 3, especially the 
comparable levels of MNV-O7 infection in the Il15ra-/- and wild-type mice, suggested 
that these natural IELs are not essential and, if anything, play a minor role in resisting the 
establishment of MNV-O7 infection. Another possible explanation for this variation 
observed is the wider range of age (between 8 – 16 weeks) of Ahr-/- mice used to set up 
the experimental groups. This, as explained earlier, was unavoidable due to the difficulty 
in breeding Ahr-/- mice colony. It is important to note, however, that I could not detect a 
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specific correlation between the MNV-O7 viral titres and the increase/decrease of mouse 
age at the time of infection (data not shown). 
Another important observation that can be drawn from the acute infection setting was the 
‘partial’ resistance to MNV-O7 infection displayed by the Ahr-/- mice (Figure 5.1A). 
The median viral titres of the Ahr-/- mice were significantly lower than those of the wild-
type controls in all tissues examined. The difference was more apparent in the proximal 
parts of the gut (duodenum, jejunum) and in the MLNs. This resistance of Ahr-/- mice to 
MNV-O7 replication was also evident at chronic infection time points (Figure 5.1B). 
Though fluctuating, the overall faecal shedding of MNV-O7 was significantly lower in 
the AhR-deficient mice compared to that of wild-type controls. The tissue viral load on 
day 21 P.I. was also clearly reduced in all segments of Ahr-/- gut examined (Figure 5.1B). 
It is worth noting that, in another small preliminary study, I was able to detect a similar 
sort of resistance in the same gut tissues of Ahr-/- mice using the acute strain MNV-
1.CW3 (data not shown). These findings suggest that the resistance to viral infection 
exhibited by the Ahr-/- mice is not specific to the MNV-O7 strain and might not even be 
specific for the MNV virus. 
Thus, compared to the wild-type controls, Ahr-/- mice established variable levels of 
MNV-O7 infection with a partial resistance to viral replication that was more apparent in 
the proximal gut and MLNs. This resistance did not prevent the progression to chronic 
persistent infection, however, it was associated with a significant reduction of viral 
shedding in faeces, and of gut tissue viral titres.  
 
5.3.2 MNV-O7 vRNA Titres vs Infectious Virus Titres    
         
To confirm the correlation between the vRNA (RT-qPCR) titres and the infectious virus 
titres of MNV-O7, I used a TCID50 virus titration assay optimised for MNV-O7 infection 
by Dr James Chettle (Section 2.5). Indeed, measurement of MNV-O7 infectious virus 
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titres by this assay, on samples obtained from the same mice used in the experiment 
above (Figure 5.1A), showed the exact same differences between wild-type and Ahr-/- 
mice with maintenance of the same layout of the figures (Supplementary Figure 5.1A). 
Furthermore, a strong correlation between viral genome copy number and TCID50 
infectious titre was detected with an R-squared value of 0.844 (Supplementary Figure 
5.1B). However, the TCID50 assay was consistently less sensitive, with about three orders 
of magnitude lower viral titres compared to those obtained by RT-qPCR. This 
discrepancy between vRNA copies and infectious titres has been detected in previous 
reports266,314, and has been attributed to an inherent problem of the TCID50 assay in 
which the induction of primary anti-viral responses by the BV-2 cells used in the assay 
prevents the spread of the cytopathic changes across the entire well and thus leads to its 
scoring as negative, as well as to the presence of non-pathogenic virus, non-packaged 
viral RNA and defective-interfering particles (Dr James Chettle’s, unpublished data). 
 
5.3.3 Selection of a Differentiation Protocol to Generate Bone Marrow-derived 
Mononuclear Cells (BMMCs) 
 
I aimed to address and further analyse the resistance to MNV-O7 infection observed in 
the Ahr-/- mice by developing and characterising an in vitro BMMC-based experimental 
model. The successful replication of MNV in phagocytic cells (macrophages and DCs) 
has been described in several reports271,285–287,381,382. However, the exact protocol used to 
generate these phagocytes from the bone marrow and, consequently, their expression of 
surface markers varies significantly from one study to another. In an unpublished work, 
Dr James Chettle (PhD thesis, University of Cambridge, 2015) observed higher levels of 
both initial binding and replication of MNV-O7 in mononuclear phagocytes 
differentiated by a protocol that include the use of a combination of GM-CSF and IL-4 
compared to those of cells generated by other differentiation protocols. In the field of 
AhR research, the most commonly used differentiation protocol for the generation of 
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bone marrow cells is the one using GM-CSF alone376,377,379,380. Another problem is the 
confusion in the terminology used to describe the derived cells. It seems that the terms 
bone marrow-derived DCs and macrophages are used interchangeably between different 
reports using various differentiation protocols271,383,384. Helft and colleagues (2015) 
clearly demonstrated the heterogeneity of cells generated in GM-CSF bone marrow 
cultures385. The bone marrow cells generated by different differentiation protocols are 
termed bone marrow-derived mononuclear cells (BMMCs) in this chapter to avoid this 
confusion. 
To select a single differentiation protocol that may allow a meaningful comparison of the 
replication patterns of MNV-O7 and the early cellular responses to poly(I:C) stimulation, 
I cultivated and differentiated bone marrow precursors derived from wild-type and Ahr-/- 
mice according to one of two different protocols: either in the presence of GM-CSF alone 
or in the presence of a combination of GM-CSF and IL-4. At different time points during 
the 8 day maturation period, I compared the microscopic features of the growing cells 
(Supplementary Figure 5.2A) and at the end of that incubation period, I stained the 
cells with fluorescent antibodies to common macrophage/DC surface-markers for flow 
cytometric analysis (Supplementary Figure 5.2B).  
On early days of maturation, cells from wild-type and Ahr-/- mice looked similar by phase 
contrast microscopy using both types of differentiation protocols. However, with time the 
Ahr-/- cells started to become bigger and had more vacuoles than their wild-type 
counterparts in the presence of IL-4, while the GM-CSF-only protocol resulted in more 
fibroblast (DC)-like cells, with dendrites in both wild-type and Ahr-/--derived cells 
(Supplementary Figure 5.2A).           
Distinct patterns of surface-markers expression were also observed by flow cytometry. 
The differences between wild-type and Ahr-/- BMMCs are addressed in more detail in 
subsequent sections. The main objective of this experiment was to compare the two 
                                                   			
- 115 - 
commonly used protocols for differentiation, and the most distinguishable difference was 
the expression of CD8a by wild-type but not Ahr-/- BMMCs in the presence of IL-4 
(Supplementary Figure 5.2B). CD8a+ DCs are responsible for cross-priming cytotoxic 
T cells in vivo386, and the induction of CD8a expression on wild-type BMMC in the 
presence of IL-4 has been reported before387–389. However, the absence of such induction 
in the AhR-deficient cells has not previously been reported. There was also a difference 
in CD86 expression between wild-type and Ahr-/- BMMCs in both differentiation 
protocols. 
All in all, given the differences observed when using the GM-CSF + IL-4 protocol and to 
be able to compare baseline cells as similar as possible, I chose the GM-CSF-only 
differentiation protocol to generate BMMCs from different mouse lines for subsequent 
experiments.   
 
5.3.4 Phenotypic Analysis of BMMCs by Flow Cytometry 
 
BMMCs from C57BL6 wild-type, Ahr-/-, AhR repressor-deficient (Ahrr-/-) and Cyp1 
triple-knockout (Cyp-/-) mice were differentiated with GM-CSF for 8 days. Elimination 
of the AhR autoregulatory mechanisms, by knocking out the AhRR or Cyp1-enzymes, 
results in augmentation and prolongation of the endogenous ligand-mediated constitutive 
AhR signalling390,391. 
Confirming previous reports380,392, Ahr-/- BMMCs were less mature than the wild-type 
controls with a clear reduction in MHC class II and CD86 expression (Figure 5.2A). No 
clear differences were observed between the two sets of cells in the expression of CD11c 
and CD80. Augmentation of endogenous AhR signalling in Ahrr-/- and Cyp-/- resulted in 
more subtle changes with a minor increase in MHC class II expression and a reduction in 
CD11c expression (Figure 5.2A). Dividing the CD11c+ BMMCs according to their MHC 
class II expression (as in 380) into immature (MHC-IIlo), and moderately (MHC-IIint) and 
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highly (MHC-IIhi) mature cells revealed a characteristic reduction of the highly and 
moderately mature cells in BMMCs extracted from Ahr-/- mice compared to those 
derived from wild-type controls, with the frequencies dropping from 7.5 % and 41.7 % to 
2.0 % and 15.2 %, respectively (Figure 5.2B). Contrarily, the proportions of these 
mature cells increased markedly in the Ahrr-/- and Cyp-/- BMMCs compared to the wild-
type counterparts, with a clear shift of cells towards higher MHC class II expression 
(Figure 5.2B). This increase in the percentages was actually an under representation, as 
the associated reduction in CD11c expression (in the Ahrr-/- and Cyp-/- BMMCs) affected 
my ability to gate the cells using a clear cut off with CD11c expression.  
 
5.3.5 Replication Profiles of MNV-O in Wild-type and AhR-Manipulated BMMCs 
 
To determine the effects of genetic manipulation of constitutive AhR signalling on the 
ability of different BMMCs to support MNV-O7 replication, BMMCs generated as in 
Section 5.3.4 were infected with MNV-O7 at an MOI of 0.03 or 0.05. Infection of 
BMMCs extracted from the 4 different mouse lines (wild-type, Ahr-/-, Ahrr-/- and Cyp-/-) 
showed similar viral growth kinetics within the first 12 hrs P.I., as MNV-O7 displayed 
only low levels of vRNA replication (Figure 5.3A & B). Beyond this point, however, 
viral replication in the wild-type BMMCs was substantially greater than that observed in 
the Ahr-/- BMMCs, with the peak at 48 hrs P.I. being almost 3-fold higher in the wild-
type cells. MNV-O7 replication showed a slight, albeit statistically significant, rise in the 
Ahrr-/- BMMCs (Figure 5.3A), while the replication in the Cyp-/- cells was similar to that 
detected in wild-type controls (Figure 5.3B). The appearance of the differential 
replication patterns at later time points post-infection suggests that the differences are not 
related to the initial binding and internalisation of the virus, but rather most likely 
attributed to variation in later viral replication processes.  
Taken together, these data indicate the major impact of genetically modifying the 
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endogenous ligand-mediated constitutive signalling of the AhR pathway on the 
phenotypic characteristics and maturation of BMMCs with the associated influences on 
the ability of these cells to support MNV-O7 replication. The resistance to MNV-O7 
replication in Ahr-/- BMMCs mirrored that observed in Ahr-/- mice when infected in vivo 
(Figure 5.1). Moreover, when we orally infected Cyp-/-  mice with MNV-O7, the viral 
titres in different gut sections and MLNs were comparable to those of MNV-O7-infected 
wild-type mice (Supplementary Figure 5.3), simulating the identical viral growth 
curves in BMMCs extracted from these mice. These findings strengthen the validity of 
the in vitro BMMC model and its relevance to study the influences of AhR signalling on 
immunity against MNV.   
 
5.3.6 Gene Expression Patterns of Poly(I:C) Stimulated BMMCs   
                
In an attempt to correlate the different MNV-O7 viral replication profiles observed in the 
BMMC populations with possible variations in the early IFN-mediated anti-viral 
responses, I treated BMMCs, generated as in Section 5.3.4, with a standardised dose of 
poly(I:C) and analysed the anti-viral genes expression patterns induced at different time 
points within the first 24 hrs of stimulation (Figure 5.4). Poly(I:C) is an agonist of   
TLR-3 that induces a potent type I IFN response393,394. Indeed, poly(I:C)-treated       
wild-type BMMCs displayed a robust induction of Ifnb1 expression that peaked within 
the first hour of stimulation (Figure 5.4). The expression fluctuated and reduced 
subsequently, however, remained higher than that of the unstimulated cells even at 24 hrs 
post-stimulation. This IFN-b induction was followed by increased expression of the 
intermediate regulators, Irf3 and Irf7, and the ISGs, Mx1 and Isg15 (Figure 5.4). With 
some variation, the induction of these genes in general started after 3 hrs, and peaked 
within 6-9 hrs, of poly(I:C) stimulation. Of note, unlike other mRNA, there was a 
detectable baseline expression of the Irf3 before stimulation with poly(I:C) (Figure 5.4). 
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This finding was consistent with the previously documented constitutive expression of 
this regulatory mediator (Irf3) in most cells395.  
Compared to wild-type controls, Ahr-/- BMMCs showed a significantly enhanced 
poly(I:C)-stimulated anti-viral response (Figure 5.4). Except for similar Irf3 expression, 
the induction of all other genes was both stronger and more prolonged in the Ahr-/- 
BMMCs. At 6 hrs post-poly(I:C) stimulation, the expression levels of Irf7, Mx1 and 
Isg15 in the Ahr-/- BMMCs were almost double that observed in the wild-type cells. This 
enhanced expression was maintained until 12 hrs post-stimulation for Mx1 and Isg15 and 
for the full 24 hrs for Irf7. The expression patterns of the Ahrr-/- and Cyp-/- BMMCs, on 
the other hand, were more complicated (Figure 5.4). Although associated with 
considerable variation in the maximum (peak) expression time point, the magnitudes of 
poly(I:C)-mediated induction of Irf3, Irf7 and Mx1 genes were comparable in both types 
of BMMCs and the wild-type controls. The expression of Ifnb1, however, was clearly 
reduced with mRNA levels measured at different time points lower than those of wild-
type counterparts. The Isg15 gene expression was unusual, as while that of Ahrr-/- 
BMMCs was nearly equivalent to the wild-type’ expression, the Cyp-/- BMMCs 
displayed an augmented induction of Isg15 expression especially between 6-12 hrs of 
poly(I:C) stimulation (Figure 5.4).  
Collectively, the data presented in this section demonstrate differential poly(I:C)-
stimulated, IFN-mediated anti-viral gene expression patterns of BMMCs generated from 
wild-type and AhR-(genetically) modified mouse lines. The augmented response 
observed in the Ahr-/- BMMCs with stronger and extended type I IFN and ISG 
expression, is consistent with the resistance displayed by these cells to MNV-O7 
replication and logically correlates with the ability of Ahr-/- mice to suppress in vivo viral 
infection.    
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5.3.7 Production of IFN-b by different BMMCs  
 
To exclude the possibility of a discrepancy between the mRNA and protein levels, due to 
a post-translational modification, I performed an ELISA assay to measure the levels of 
IFN-b in the supernatant of poly(I:C)-stimulated BMMCs at baseline and 24 hrs post-
stimulation. The amount of INF-b produced by Ahr-/- BMMCs was significantly higher 
than that of the wild-type control cells (Figure 5.5). A finding which reflected the same 
gene expression differences discussed in the previous section. The same was true for the 
Ahrr-/- and Cyp-/- BMMCs, which showed reduced (barely detectable) levels of INF-b 
production 24 hrs post-poly(I:C) stimulation compared to wild-type counterparts  
(Figure 5.5).      
 
5.3.8 Ligand-Mediated Modulation of AhR Signalling 
 
To provide additional evidence for the involvement of AhR signalling in the early 
induction and regulation of anti-viral immune responses, I treated BMMCs generated 
from C57BL/6 wild-type mice with either the AhR-endogenous ligand, FICZ, or the 
AhR-specific antagonist, CH223191, while having cells derived from Ahr-/- mice as a 
control. FICZ is a tryptophan-derivative with a strong affinity for the AhR comparable to 
that of dioxin (Section 1.2.5 for more details). CH223191 is a potent AhR antagonist 
(IC50: 30 nM), which has been reported in several studies to significantly inhibit 
endogenous AhR signalling396–398.  
Treatment of Ahr-/- BMMCs with either FICZ or CH223191 had no effects on their 
phenotypic differentiation and surface marker expression (Figure 5.6), indicating that the 
changes observed in the wild-type cells are AhR-dependent. Consistent with previous 
reports379,392, administration of CH223191 decreased the expression of MHC class II, 
CD11c, CD80, CD86 (Figure 5.6A) and reduced the proportion of moderately (MHC-
IIint) and highly (MHC-IIhi) mature wild-type BMMCs (Figure 5.6B). Although less 
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apparent, treatment with FICZ had the opposite effect on the wild-type cells. 
Infection of these CH223191 and FICZ-treated wild-type BMMCs with MNV-O7 
revealed characteristic viral replication patterns quite similar to those observed in the 
AhR-deficient (Ahr-/-) and AhR-hyperactive (Ahrr-/- and Cyp-/-) BMMCs, respectively. 
Thus, MNV-O7 replication in wild-type BMMCs treated with CH223191, albeit not 
reaching that of Ahr-/- cells, was clearly reduced compared to the untreated controls 
(Figure 5.7). Treatment of wild-type BMMCs with the AhR-agonist FICZ only slightly 
increased viral replication compared to the untreated cells (this was not significant). 
Again, the different patterns of replication became apparent beyond the 12 hrs P.I. time 
point, suggesting a modulation in the viral replication cycle rather than in initial cellular 
binding and internalisation. 
Although not confirmed experimentally, the different patterns of MNV-O7 replication in 
these AhR agonist/antagonist-treated BMMCs are most likely consequences of alteration 
in the early IFN-mediated anti-viral responses similar to those observed in the knockout 
BMMCs (Figure 5.4). Generally, the findings observed in these two last figures indicate 
that ligand-mediated modulation of the AhR signalling affects the phenotypic maturation 
of wild-type BMMCs and their ability to support MNV-O7 replication. They further 
support the relevance of the AhR pathway in the innate anti-viral immune response and 
the viability of modulating AhR signalling to influence the outcome of a viral infection.   
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5.4 Discussion: 
AhR is a highly conserved, ubiquitously expressed cytosolic transcription factor, which 
has been the centre of extensive immunological research owing to its demonstrated roles 
in maintenance and functions of specific immune cells at barrier sites, its potential 
contribution to the development and progression of inflammatory disorders at these sites 
(including the gut and lung) and its proposed ability to link environmental 
(dietary/inhaled) cues to intracellular immunological signalling and responses.                
A pressing challenge, however, is the need for a major paradigm shift from, or at least a 
reconciliation of, a detoxifying system that responds to man-made exogenous toxins and 
a physiologically relevant biological system that is influenced by endogenous and 
naturally occurring ligands.  
In this chapter, my main findings were that in the absence of constitutive AhR signalling 
(as in an Ahr-/- background) there was an associated increased resistance to MNV-O7 
infection and replication both in vivo and in an in vitro BMMC experimental model. The 
same resistance to viral replication was observed when the AhR-endogenous signalling 
was inhibited in wild-type BMMCs by adding the AhR-specific antagonist CH223191. 
Augmentation of constitutive AhR signalling either resulted in higher replication of 
MNV-O7 virus, as in Ahrr-/- and FICZ-treated BMMCs, or did not affect the rate of viral 
growth, as in Cyp-/- mice and BMMCs. The lack of change in viral titre in Cyp-/- BMMCs 
(where the absence of the feedback endogenous ligands metabolism augments the whole 
signalling pathway, Figure 1.3) compared to the observed increase in virus replication in 
the Ahrr-/- BMMCs (where the augmentation is restricted mainly to the nuclear part of 
the pathway) suggested more intricate and complex interactions between the AhR and 
IFN-STAT1 signalling pathways than anticipated and warrant further investigation.  
These different abilities to support MNV-O7 infection were associated with distinct 
phenotypic characteristics and maturation status of the specific BMMCs and are reflected 
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in different (both in terms of magnitude and duration) IFN-mediated anti-viral responses 
following poly(I:C) stimulation. Although displaying the phenotypic features of 
immaturity at baseline, Ahr-/- BMMCs demonstrated a stronger and more prolonged 
poly(I:C)-stimulated anti-viral response that was associated with a significant ability to 
inhibit MNV-O7 replication. It is important to note, however, that as we examined bone 
marrow derived cells, this might not be a full reflection to the characteristics of 
mononuclear phagocytes at the site of infection, i.e. the gut, where macrophages and DCs 
are known to have higher thresholds for activation68,69 and different functional 
capabilities71,76.  
Nonetheless, the findings presented in this chapter are in concordance with other 
published data. The characteristic enhanced anti-viral response of Ahr-/- BMMCs 
following poly(I:C) stimulation, with higher expression of type I IFN and anti-viral ISGs, 
supports the hypothesis of possible cross-talk between the functional AhR system and the 
IFN-STAT1 anti-viral pathway through interaction at the level of active AhR binding to 
the STAT1 molecule198,199 and/or at the level of AIP chaperone protein modulating the 
activation of the signalling intermediate Irf7375. The latter was further supported by the 
persistently augmented expression of Irf7 in the poly(I:C)-stimulated Ahr-/- BMMCs (at 
least for the first 24 hrs following stimulation) (Figure 5.4). Moreover, a recently 
published report confirmed the negative regulatory effect of constitutive AhR signalling 
on type I IFN responses during infection with various (both DNA and RNA) viruses399. 
In this comprehensive report, Yamada et al. (2016) elegantly demonstrated that AhR 
endogenous signalling up-regulates the expression of ADP-ribosylase TIPARP, one of the 
target genes of AhR-signalling (Figure 1.3), which in turn interacts with the kinase  
TBK-1, suppresses its activity by ADP-ribosylation and hence regulates type I IFN 
production399. 
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Taken together, either through AhR-STAT1, AIP-Irf7, TIPARP-TBK1, another not yet 
identified interaction or a combination and contribution of all, these data indicate a direct 
link between constitutive AhR signalling and innate interferon-mediated anti-viral 
responses that can be exploited as a potential preventive/therapeutic target for enhancing 
anti-viral responses. Ligand-dependent activity of AhR was shown to reduce 
inflammation in skin samples of psoriasis patients214, and protected mice from severe 
intestinal inflammation400. Being natural and mostly dietary-derived, AhR ligands are 
proposed as highly attractive options for site-directed therapeutics for many 
inflammatory conditions, including IBDs. However, the data presented in this chapter, 
together with the recent insights discussed above, indicate that the ramifications of AhR 
activation are wide and, as the case in steroid treatment, might be associated with 
increased risk of (viral) infections. Further illumination of the exact and specific 
contribution of different mechanisms by which the cross-talk occurs between AhR and 
various other signalling pathways, including the IFN-STAT1 pathway, would have 
several potential applications to better understand the nature and the impact of AhR 
modulation and might facilitate the development of novel, more precisely-targeted modes 
of intervention applicable to both inflammation and infection.   
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Chapter 6 GENERAL DISCUSSION & CONCLUDING REMARKS 
  
6.1 Limitations and Areas of Improvements 
The data presented in my thesis has covered a range of topics that may, at first sight, 
appear unconnected. Nonetheless, I kept MNV as my sole pathogen, and the gut mucosal 
immune system as the main theme of all my work. The diversity of the topics covered 
was unintentional. It was a direct consequence of the unfortunate combination of some 
unavoidable obstacles (such as a difficulty in breeding some mouse lines, the inability to 
set-up and maintain homogeneous experimental groups in term of age and sex, the 
variability in the responses obtained in some experiments and the necessary prolonged 
mouse incubation period for the aging and adoptive transfer experiments) and some 
unexpected results (such as the finding that natural IEL might not be essential for MNV 
protection and reduced viral titres in the AhR-/- mice) in addition to other causes. 
Although these factors may be regarded as drawbacks, the tackling of different aspects 
and the attempts to answer different questions has allowed me to explore many different 
experimental techniques and to improve my understanding of the gut mucosal immunity.  
A major caveat to our experimental model of investigating the anti-viral role of IEL is the 
broad activity of the agonistic anti-CD3 antibody, which when injected intraperitoneally 
results in bystander T cell activation systemically. The resulting biological readouts that I 
detect in wild-type mice cannot be attributed only to the activity of the gut associated 
immune system. My attempts to activate the IELs by oral administration of anti-CD3 
were unsuccessful, likely due to the thick mucus layer that protects the epithelial 
surfaces. I, therefore, employed more complex knockout and adoptive transfer 
experimental models to assess the potential contribution of IELs in the protection 
induced by anti-CD3 antibodies. The results obtained from these experiments may not 
necessarily reflect the physiological responses occurring in homeostatic gut conditions, 
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especially with the possibility of a heightened basal inflammatory state and development 
of several compensatory feedback mechanisms in the immunodeficient (Il15ra-/-, Tcra-/- 
and Rag2-/-) mice. One possible way to overcome this, in my opinion, is the use of         
in vitro intestinal organoid-IEL co-culture system. In the light of our findings that the 
persistent strains of MNV (MNV-O7 and -3) can infect intestinal organoids, this model 
may be relevant to investigate the role of IEL in the context of MNV infection. However, 
it may not reflect all aspects of the gut mucosal immune response as certain factors (such 
as the microbiota) are not represented. 
 
6.1 Summary, Interpretation and Future Work 
The gut is the largest surface area in the body directly exposed to the external 
environment, the food we eat and the microbes that help us digest it. The gut mucosa has 
developed a complex and unique immune system that allows for an intense scrutiny of 
the epithelial surfaces to prevent the establishment and invasion of harmful 
microorganisms, while at the same time operating robust mechanisms to differentiate 
between ‘friend’ and ‘foe’ and allow commensal microorganism survival. Using a 
mouse-model of MNV infection, the main aim of this PhD thesis was to investigate the 
role of three major modulators; namely the IEL, the AhR signalling and the effect of 
aging on the specialised gut mucosal immunity. The data obtained during this study lays 
the groundwork for better understanding not only of Norovirus pathogenesis and 
immunobiology, but also in the broader sense the mucosal immune response against 
enteric viral infections, with possible translational applications for development of better 
immuno-protective (vaccine) and immuno-therapeutic (anti-viral) strategies.  
Building on previous work in our lab by Dr. James Chettle to define the anti-viral role of 
IELs, and to identify features of viral pathogenesis and immune response associated with 
both persistence and virulence of different MNV strains, in this thesis I used the 
                                                   			
- 127 - 
experimental anti-CD3-MNV model to investigate the role of IELs and to employ the 
model in the context of different knockout and adoptive transfer experiments. I 
concluded that, at least in our experimental conditions and in a viral strain-specific 
manner, the activated (gd TCR+) IELs are not essential and may play a minor role in the 
protective response against MNV-O7 infection. Their role might be more prominent in 
the context of acute (MNV-CW3) infection. These data do not exclude a role of the more 
conventional ‘induced’ subtypes of IELs, i.e. αβ TCR+ CD8αβ+ and CD4+ IELs. Future 
work concerning this aspect may include the application of the newly developed 
intestinal organoid-IEL co-culture system as a reductionist approach to assess/study the 
fine IEC-IEL interactions in the context of MNV infection. 
In this section of the thesis we were able to demonstrate the differential abilities of 
different MNV strains to activate IELs in a microbiota-dependent manner, and for the 
first time (to our knowledge) to identify the distinctive abilities of these various viral 
strains to infect IECs. Considering the close genetic similarity between different MNV 
strains278, it was quite remarkable to observe such striking differences in cellular tropism 
and immunological sequelae. It is important to recognise that HuNoV strains display 
much more substantial genetic diversity, and I would predict that they may display an 
even broader range of interactions with the host immune system. Further analysis of the 
expected barrier dysfunction associated with the acute strain (MNV-1.CW3) infection 
and the specific microbiota component(s) that are involved in IEL activation may prove 
advantageous for developing better clinical management protocol and vaccine strategies. 
Moreover, investigating this phenomenon in the context of reovirus (replicating in both 
epithelial and non-epithelial cells of the gut358) and rotavirus (with their specific tropism 
for mature enterocytes357) infections may reveal a common feature for all enteric viral 
infections.  
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Recognising a different response in old (2-year) mice, we followed that lead and were 
able to identify a specific defect in the IFN-l response of aged IECs. The demonstration 
of the reversibility of the defect (by administration of a high dose of exogenous IFN-l) 
and the setting up of a viable experimental model to compare and translate our findings 
to human samples will pave the way for development of better therapeutic modalities for 
the severely affected elderly population. Furthermore, the in vivo experimental MNV-
mouse model and/or the intestinal organoids will facilitate the identification of the exact 
cause(s) of the phenotype observed in old mice and the specific molecular defect(s) of 
the IEC’s IFN-l-hypo-responsiveness. It is my intention to age a colony of Rag2-/- and 
Ccr2-/- mice, compare their response to MNV infection to that of old wild-type controls 
and to employ the adoptive-transfer experimental model with transfer of young-vs-old 
lymphocytes and/or mononuclear phagocytes into young-vs-old Rag2-/- or Ccr2-/- mice in 
order to identify the role of the aged phenotype of different immune cells in the 
development of the age-specific immune defects. 
 
Extending our model of MNV infection to investigate the role of AhR signalling, the data 
I generated suggested a direct link between constitutive AhR signalling and innate 
interferon-mediated anti-viral responses that can be exploited as a potential 
preventive/therapeutic target for enhancing anti-viral responses. My results were in 
agreement with recently published reports identifying AhR-STAT1, AIP-Irf7 and/or 
TIPARP-TBK1 interactions as potential crosstalk points between the two signalling 
pathways. Further analysis of the precise contribution of these (and possibly other) 
different mechanisms will help in better understanding of the role of AhR signalling and 
in the development of targeted modes of intervention applicable to both inflammation 
and infection. 
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Figure 1.1 Regional specialisation of the intestinal tract and gut mucosa in terms of differences 
in macroscopic (A) and histological (B) features, antigenic stimuli (C) and cellular 
constituents/distribution of the lymphoid tissues and immune apparatus (D). Data mostly drawn from 
studying the gut mucosa in mice. Although less clear, due to lack of specific segmented studies, 
similar specialisation and immune cell distribution are expected in human intestines1. The figure was 
adopted from Mowat et al (2014)11. GALT: Gut Associated Lymphoid Tissues. SILTs: Solitary 
Isolated Lymphoid Tissues. IEL: Intra-Epithelial Lymphocytes. DCs: Dendritic Cells. TH: T Helper. 
FOXP3: Forkhead Box P3. TReg: regulatory T cells. 
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Figure 1.2 Intraepithelial Lymphocytes (IEL). Thymic development and differentiation into 
Natural IELs (blue coloured) by alternative positive selection, and Induced IELs (green coloured) 
by conventional positive selection (A). The Natural IELs migrate directly to the gut, while the 
Induced IELs undergo priming at the secondary lymphoid organs (MLNs and Peyer’s Patches) before 
travelling to the gut. The figure also shows the unique location of IEL within the epithelial 
compartment (A) and (B) red circle. The figure was modified from Cheroutre et al. (2011)129 and 
Abreu (2010)130.    
 
 
 
 
 
A B 
	-	132	-	
 
 
 
 
Figure 1.3 Aryl Hydrocarbon Receptor (AhR) Signalling. Inactive AhR in the cytoplasm forms a 
complex with HSP90, p23 and AhR-interacting protein (AIP). Upon ligand binding, AhR translocates 
into the nucleus, where it dissociates from the chaperones and forms a complex with AhR-nuclear 
transporter (ARNT). This complex binds to dioxin-response elements (DRE) and induces the 
expression of many genes including cytochrome P (CYP1) enzymes, TCDD-inducible poly(ADP-
ribose) polymerase (TIPARP) and AhR repressor (AhRR). Possible crosstalk with the STAT1 
pathway includes: AhR-STAT198 and AIP-Interferon regulatory factor 7 (Irf7)375 interactions. The 
figure was adopted from Stockinger et al. (2014)188.    
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Figure 3.1 continued overleaf 
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Figure 3.1 The effects of intraperitoneal (I.P.) vs (Oral) administration of anti-CD3 antibodies in wild-type mice.  
C57BL/6 wild-type mice administered anti-CD3 antibodies either orally (with one of three different doses; 5 µg, 25 µg, 50 µg) or I.P. (dose of 25 µg). 
The controls (black bars) received 50 µg of isotype control (ITC) antibodies. Three hours later, mice were sacrificed and gut sections, MLNs and spleens 
were collected. Intraepithelial lymphocytes (IEL) were extracted from gut sections as outlined in Section 3.2.3. RNA was extracted from IELs (A), MLN 
(B) and gut sections (Duodenum and Ileum) (D), reverse transcribed and analysed for the gene expression of the cytokines; TNFa, IFNg, IFNl3 and 
IFNb1 (A and B), TNFa and the ISGs; Mx1 and Isg15 (D). The spleen samples (C) were analysed by flow cytometry as detailed in Section 3.2.5, with 
analysis of an additional time-point at 8 hrs post-stimulation with I.P. anti-CD3 (solid red bar) and plotting the percentages of IFNg-expressing CD8+ T-
cells.  
(E and F) C57BL/6 wild-type mice were infected orally with 5 x 106 TCID50 (MNV-O7) 8 hrs after (E) or before (F) being injected I.P. with 25 µg of 
either anti-CD3 (+) or ITC (-) antibodies. 40 hrs after the infection, mice were sacrificed and gut sections (Duodenum, Jejunum, and Ileum) and MLNs 
were collected. RNA was extracted from the tissues and viral titres (RNA copy numbers) determined by RT-qPCR. Titres were normalised to the weight 
of the tissue sections. The dotted line indicates the limit of detection (30 viral genome copies per mg tissues). Each point represents an individual mouse. 
The line in each dataset represents the median viral titre. Statistical significance was determined by Mann-Whitney test (*; P<0.05, **; P<0.01). 
E F After Before 
Duodenum 
- +
101
102
103
104
105
106
107
AntiCD3
**
V
ir
al
 g
en
o
m
e 
co
p
ie
s/
m
g
 t
is
su
e
Jejunum 
- +
101
102
103
104
105
106
107
AntiCD3
**
V
ir
al
 g
en
o
m
e 
co
p
ie
s/
m
g
 t
is
su
e
Ileum 
- +
101
102
103
104
105
106
107
AntiCD3
**
V
ir
al
 g
en
o
m
e 
co
p
ie
s/
m
g
 t
is
su
e
MLN 
- +
101
102
103
104
105
106
107
V
ira
l g
en
o
m
e 
co
p
ie
s/
m
g
 ti
ss
u
e
AntiCD3
*
Duodenum 
- +
101
102
103
104
105
106
107
AntiCD3
**
V
ir
al
 g
en
o
m
e 
co
p
ie
s/
m
g
 t
is
su
e
Jejunum 
- +
101
102
103
104
105
106
107
AntiCD3
**
V
ir
al
 g
en
o
m
e 
co
p
ie
s/
m
g
 t
is
su
e
Ileum 
- +
101
102
103
104
105
106
107
AntiCD3
**
V
ir
al
 g
en
o
m
e 
co
p
ie
s/
m
g
 t
is
su
e
MLN 
- +
101
102
103
104
105
106
107
AntiCD3
**
V
ir
al
 g
en
o
m
e 
co
p
ie
s/
m
g
 t
is
su
e
	 -	135	-	
 
Figure 3.2 STAT-1 is absolutely essential for the protection against MNV-O7 in the gut.  
(A) 129 wild-type and Stat1-/-	mice infected orally with MNV-O7 (5 x 106 TCID50) 8 hrs after 
intraperitoneal injection with 25 µg of either anti-CD3 (+) or isotype control (-) antibodies. 40 hrs 
after the infection, mice were sacrificed and gut sections (Duodenum, Jejunum, and Ileum) were 
collected. RNA was extracted from the tissues and viral titres (RNA copy numbers) measured by RT-
qPCR. The titres were normalised to the weight of the tissue sections. Dotted line indicates the limit 
of detection (30 copies/mg). Statistical significance was calculated by Mann-Whitney test                     
(n.s.; not significant, **; P<0.01). (B, C & D) Anti-CD3 treated (+) and untreated (-) 129 wild-type 
and Stat1-/- mice were sacrificed 3 hrs after treatment with anti-CD3. Gut sections (Duodenum, Ileum) 
and MLNs were collected, RNA was extracted, reverse transcribed and analysed for the gene 
expression of the ISG: Mx1 (B) and the cytokines IFNl3 and IFNg (C), IFNg and TNFa (D).    
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Figure 3.3 Effect of Antibiotic treatment in the Anti-CD3/MNV-O7 experimental model. 
C57BL/6 wild-type mice were treated orally with antibiotic cocktail (Abx) for 2 weeks and compared 
to untreated age-matched wild-type mice. C57BL/6 mice without antibiotic (black dots) and with 
antibiotic (red dots) were infected orally with MNV-O7 (5 x 106 TCID50) 8 hrs after being injected 
(I.P.) with either anti-CD3 (+) or isotype control (-) antibodies. 40 hrs after infection, mice were 
sacrificed and gut sections (Duodenum, Jejunum, Ileum) and MLN collected and analysed for viral 
RNA titres determined by RT-qPCR. The titres were normalised to the weight of the tissue sections.  
Each point represents an individual mouse. The line in each dataset represents the median viral titre. 
Statistical significance was determined by Mann-Whitney test (n.s.; not significant, *; P<0.05,          
**; P<0.01). 
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Figure 3.4 Gamma/Delta TCR+ IELs are not essential for, and play a minor role in, the 
inhibition of MNV-O7 viral titres mediated by anti-CD3 injection.  
C57BL/6 wild-type, Il15ra-/- (A) and Tcra-/- (B) mice infected orally with MNV-O7 (5 x 106 TCID50) 
8 hrs after being injected intraperitoneally with 25 µg of either anti-CD3 (+) or isotype control (-) 
antibodies. 40 hrs after infection, mice were sacrificed and gut sections (Duodenum, Jejunum, and 
Ileum) and Mesenteric lymph nodes (MLNs) were collected. RNA was extracted from the tissues and 
viral titres (RNA copy numbers) were determined by RT-qPCR based on a standard curve. The titres 
were normalised to the weight of the tissue sections. The dotted line indicates the limit of detection 
(30 copies per mg tissue). Each point represents an individual mouse. The line in each dataset 
represents the median viral titre. Statistical significance was determined by Mann-Whitney test     
(n.s.; not significant, *; P<0.05, **; P<0.01). 
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Figure 3.5 Flow cytometric analysis of Spleens and IEL-compartments post-adoptive transfer of Gfp+ IEL.  
Rag2-/- (Rag-/-) mice injected intravenously with Gfp+ IELs (at ~ 2 x 105 cells/mouse) extracted from Gfp-reporter (donor) wild-type mice. Four weeks 
post-adoptive transfer mice were sacrificed and spleens and gut sections were collected. IEL were extracted from gut sections as outlined in                
Section 3.2.3. The splenocytes (A) and IELs (B) were analysed by flow cytometry as detailed in Section 3.2.4, with detection of the surface markers 
CD19, CD8 and CD4 on y-axes and Gfp expression in x-axes. The percentages of Gfp+ IELs were plotted in (C). Tissues extracted from Gfp-reporter 
(donor), non-injected Rag2-/- and C57BL6 wild-type mice were included for comparison.   
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Figure 3.6 MNV-O7 infection of Wild-type, Rag2-/- injected with Gfp+ IELs and Rag2-/- mice.   
(A) Rag2-/- mice injected intravenously with Gfp+ IELs (at ~ 2 x 105 cells/mouse) purified from Gfp-
reporter (donor) wild-type mice. 4 weeks post-adoptive transfer the (Rag2-/- + IEL) mice were 
compared to wild-type C57BL/6 and non-injected Rag2-/- controls by oral infection of MNV-O7         
(5 x 106 TCID50) 8 hrs before being injected I.P. with 25µg of either anti-CD3 (+) or isotype control 
(-) antibodies. 40 hrs after the infection, mice were sacrificed, gut sections (Duodenum, Jejunum, and 
Ileum) and MLNs were collected and analysed for the level of viral RNA titres measured by RT-
qPCR. The titres were normalised to the weight of the tissue sections. The dotted line indicates the 
limit of detection (30 copies/mg). (B) The same MNV-O7-infected mice (as in A) were not treated 
with anti-CD3 antibodies and were maintained for 7 days with faecal samples collection at the 
indicated days post-infection. RNA was extracted from faecal samples and viral titres (RNA copy 
numbers) were determined by RT-qPCR. Shown are the numbers of genome copies of MNV per mg 
of faeces. Statistical significance was determined by Mann-Whitney test (A) and 2way ANOVA (B).  
(n.s.; not significant, *; P<0.05, **; P<0.01, ***; P<0.0001).   
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Figure 3.7 MNV-CW3 infection of Wild-type, Rag2-/- injected with Gfp+ IELs and Rag2-/- mice.   
Rag2-/- mice injected intravenously with Gfp+ IELs (at ~ 2 x 105 cells/mouse) purified from Gfp-
reporter (donor) wild-type mice. 3 weeks post-adoptive transfer the (Rag2-/- + IEL) mice were 
compared to wild-type C57BL/6 and non-injected Rag2-/- controls by oral infection of MNV-CW3  
(5 x 106 TCID50) 8 hrs before being injected intraperitoneally with 25 µg of either anti-CD3 (+) or 
isotype control (-) antibodies. 40 hrs after infection, mice were sacrificed, gut sections (Duodenum, 
Jejunum, and Ileum) and MLNs were collected and analysed for the level of viral RNA titres 
measured by RT-qPCR. The titres were normalised to the weight of the tissue sections. The dotted 
line indicates the limit of detection (30 copies/mg). Each point represents an individual mouse. 
The line in each dataset represents the median viral titre.  
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Figure 3.8 Comparison of MNV-O7 vs MNV-CW3 infection of wild-type and Rag2-/- mice.   
Wild type (C57Bl/6) and Rag2-/- mice infected orally with 5 x 106 TCID50 MNV-O7 (A) or MNV-
CW3 (B). 40 hrs after infection, mice were sacrificed and gut sections (Duodenum, Jejunum, Ileum) 
and MLN were collected. RNA was extracted from the tissues and viral titres (viral RNA copy 
numbers) were determined by RT-qPCR. The titres were normalised to the weight of the tissue 
sections. Dotted line indicates the limit of detection (30 viral genome copies per mg tissues). Each 
point represents an individual mouse. The line in each dataset represents the median viral titre. 
Statistical significance was determined by Mann-Whitney test. (n.s.; non-significant, **; P<0.01).
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Figure 3.9 Flow cytometric analysis of Spleens, L.P. and IEL-compartments post-adoptive transfer of T and B Splenocytes.  
Rag2-/- (Rag-/-) mice injected intravenously with either CD3+ T lymphocytes (at ~ 1x106 cells/mouse), CD19+ B lymphocytes (at ~ 1x106 cells/mouse), 
or both, purified from spleens of wild-type mice. 3 weeks post-adoptive transfer mice were sacrificed and spleens and gut sections were collected. L.P. 
lymphocytes and IEL were extracted from gut sections as outlined in Section 3.2.3. The splenocytes (A), L.P. Lymphocytes (B) and IEL (C) were 
analysed by flow cytometry as detailed in Section 3.2.4, with detection of the surface markers; CD19, CD8 and CD4 in y-axes and CD3 expression in 
x-axes. The percentages of CD3+ and CD19+ lymphocytes in each compartment were plotted in (C). Tissues extracted from non-injected Rag2-/- and 
C57BL6 wild-type mice were included for comparison.  
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Figure 3.10 MNV-O7 infection of Wild-type, Rag2-/- injected with T- and B-Splenocytes and 
Rag2-/- mice.   
Rag2-/- mice injected intravenously with either T lymphocytes (at ~ 1x106 cells/mouse), B 
lymphocytes (at ~ 1x106 cells/mouse), or both, purified from spleens of wild-type mice. 3 weeks post-
adoptive transfer the (Rag2-/- + B), (Rag2-/- + T) and (Rag2-/- + B & T cells) mice were compared to 
wild-type C57BL/6 and non-injected Rag2-/- controls by oral infection of MNV-O7 (5 x 106 TCID50). 
40 hrs after the infection, the mice were sacrificed, gut sections (Duodenum, Jejunum, and Ileum) 
were collected and analysed for the level of viral RNA titres measured by RT-qPCR. The titres were 
normalised to the weight of the tissue sections. The dotted line indicates the limit of detection (30 
copies/mg). Each point represents an individual mouse. The line in each dataset represents the median 
viral titre. Statistical significance was determined by Mann-Whitney test (**; P<0.01,                          
***; P<0.0001). 
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Figure 3.11 MNV-O7 does not infect B- and T-splenocytes in vitro.  
B and T lymphocytes were sorted from the spleens of C57BL/6 wild-type mice (total number of 3 mice) and the long bones of the same wild-type mice 
were used to extract bone marrow-derived mononuclear cells (BMMC) that were differentiated with 20 ng GM-CSF/ml for 8 days. The cells were 
subsequently infected with MNV-O7 virus at MOI of 0.05. After 1 hrs incubation with the virus, the cells were washed with PBS and incubated at 37	°	
C. (A) At specific post-infection times (1, 24 and 48 hrs), RNA was extracted from the cultured cells and viral titres (vRNA) were measured by RT-
qPCR. vRNA was expressed as the number of molecules per µg of total RNA in the sample well. Data points represent the mean vRNA level from 
triplicate wells, with error bars showing the range for each triplicate.  
(B) 12 hrs MNV-O7 infected cells (splenic B & T cells and BMMCs) were fixed, permeabilised, stained with the J2 mouse anti-double stranded RNA 
(dsRNA) monoclonal and anti-mouse PE-conjugated secondary antibodies and analysed by flow cytometry as detailed in Section 3.2.4. The B cells were 
shifted to the right because they were pre-stained with anti-CD19 (PE) antibodies for the sorting from the splenocyte pool.   
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Figure 3.12 MNV-CW3 (but not -O7) infection of wild-type mice results in significant changes in the IEL compartment.  
C57BL/6 wild-type mice were either uninfected or orally infected with 5 x 106 TCID50 of MNV-O7 or MNV-CW3. 40 hrs after infection, the mice were 
sacrificed and gut sections were collected. IEL were extracted from gut sections as outlined in Section 3.2.4 and analysed by flow cytometry (A) as 
detailed in Section 3.2.5 with detection of the surface markers CD19, CD8 and CD4 on the y-axes. The percentages of each lymphocyte subset are 
plotted in (B). Statistical significance was determined by Mann-Whitney test (n.s.; not significant, *; P<0.05). 
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Figure 3.13 MNV-CW3 (but not O7) infection of wild-type mice results in significant changes 
in the IEL compartment that are Microbiota-dependent.  
C57BL/6 wild-type (WT) mice were either uninfected or orally infected with 5 x 106 TCID50 of  
MNV-O7 or MNV-CW3. Half of the MNV(CW3)-infected mice were treated orally with antibiotic 
cocktail (Abx) for 2 weeks prior to infection and compared to untreated age-matched MNV(CW3)-
infected wild-type mice. At the indicated times post-infection, mice were sacrificed and intestinal 
tissues collected. Small segments of the ileum were analysed for the level of viral RNA titres 
measured by RT-qPCR (A). The titres were normalised to the weight of the ileum section. The dotted 
line indicates the limit of detection (30 copies/mg). Each point represents an individual mouse.  
The remaining of the small intestinal tissues were used to extract IEL as outlined in Section 3.2.3, 
and the IEL were permeabilised and stained by MitoTracker Green for flow cytometry analysis (B) 
as detailed in Section 3.2.4. Plotted are the Median Fluorescent Intensity (MFI) of splenic 
CD8+CD44lo (naïve), CD8+CD44hi (memory) T-cells and small intestinal CD8+ IELs harvested at 
indicated time points post infection. Statistical significance was determined by Mann-Whitney test 
(**; P<0.01, ****; P<0.00001).  The IEL MitoTracker Green staining was performed, and data kindly 
provided, by Ulrika Frising (The Babraham Institute, Cambridge).   
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Figure 3.14 Persistent strains of MNV	(MNV-O7 and MNV-3), but not acute strain (MNV-CW3), infect Intestinal Epithelial Cells.	  
Wild type C57BL/6 mice, 8-12 weeks of age, were sacrificed and small intestinal organoids were established as per the protocol outlined in Section 
(4.2.3.2). Intestinal organoids were infected with either MNV-O7, MNV-CW3 or MNV-3 at an MOI of 5. After 1 hrs incubation with the virus, the cells 
were washed with PBS and incubated at 37	 °	 C. Data from organoids infected with a UV inactivated cocktail of O7 and CW3 are also included.                     
(A) At indicated time-points (1, 12, 18, 24 and 45 hrs) post-infection RNA was extracted from the cultured cells and viral titres (vRNA copy numbers) 
were measured by RT-qPCR. vRNA copy number was expressed as the number of molecules per µg of total RNA in the sample well. Data points 
represent the mean vRNA level from triplicate wells, with error bars showing the range for each triplicate. The bottom graph display the viral titres in 
the absence of the intestinal organoids. (B) Non-infected and 24 hrs MNV-O7-infected organoids were fixed in 4 % formaldehyde, permeabilised, 
blocked and stained for proliferation markers at 4 ° C overnight using anti-Edu, anti-Ki67 and anti-EpCam primary antibodies. The following day, the 
samples were stained with AF555, AF488, APC-coupled secondary antibodies, respectively. DAPI served as counterstain for nuclei. Images were 
acquired on a Zeiss 780 confocal microscope in two independent experiments. Shown are representative pictures. Scale bar = 50µm. The organoids were 
generated, stained, and picture kindly provided, by Ulrika Frising (The Babraham Institute, Cambridge). 
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Supplementary Figure 3.1 Strategy for flow cytometric analysis of spleens.   
Splenocyte activation following administration of anti-CD3 or isotype control (ITC) antibodies to 
C57BL/6 wild-type mice was analysed according to the gating strategy above. Samples were stained 
with various cocktails of fluorophore conjugated antibodies targeting surface markers or cytokines 
(following fixation and permeabilisation) are shown (refer to Section 3.2.4 for details).                      
(A) Prior to plotting the data, all samples were gated to exclude dead cells, based on forward scatter 
(FSC-A) versus side scatter (SSC-A) and to remove doublets (FSC-A versus pulse width). No 
background staining was observed on cells stained with matched isotype control antibodies and these 
cells were used to help set the quadrant gates. The cells were then gated into CD8+ (R3) and CD4+ 
(R4) and subsequently analysed for the expression of IFNg and IL-10. For oral ITC-administered 
mice (B) oral anti-CD3-adminstered mice (C) and I.P anti-CD3-injected mice (D). The data are 
representative of 3 replicates of each condition.   
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Supplementary Figure 3.2 Representative gut histopathology of Wild-type and Tcra-/- mice.   
Small ileal samples were taken from non-infected wild-type (A) and Tcra-/- (B) mice during necropsy, 
flushed with PBS and placed in 10 % buffered formalin saline. After 24 hrs fixation period, samples 
were embedded in paraffin, cut into 3 mm sections on glass slides and stained with haematoxylin and 
eosin. Preparation of slides and staining was performed in the Diagnostic Histopathology Section, 
Department of Veterinary Medicine, University of Cambridge. The slides were viewed using a Nano-
zoomer Digital Slide Scanner (Hamamatsu). Images were processed from the scans using the 
NDP.view2 software (Hamamatsu). Images shown were taken at 20x magnification.  
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Supplementary Figure 3.3 MNV-O7 infection of Wild-type and Il22-/- mice.   
5 Wild type (C57Bl/6) and Il22-/- mice were infected orally with MNV-O7 (5 x 106 TCID50). Forty 
hours (square-shaped dots) and 14 days (triange-shaped dots) after the infection, mice were sacrificed 
and gut sections (Duodenum, Jejunum, and Ileum) were collected. RNA was extracted from the 
tissues and viral titres (viral RNA copy numbers) were measured by RT-qPCR. The titres were 
normalised to the weight of the tissue sections. Dotted line indicates the limit of detection                     
(30 viral genome copies per mg tissues). Each point represents an individual mouse. The line in each 
dataset represents the median viral titre. Statistical significance was detremined by Mann-Whitney 
test. (n.s.; non-significant).  
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Figure 4.1 Old mice exhibit impaired control of a persistent MNV-O7 infection.   
Wild type (C57Bl/6) mice, 8-week (Young) or 24-month (Old) of age, were challenged orally with 
MNV-O7 (5 x 106 TCID50). Faecal samples were collected at the indicated days (1-7) post-infection 
(P.I.). The mice were sacrificed and intestinal tissues and mesenteric lymph nodes (MLN) collected 
in day-7 P.I.. RNA was extracted from the faeces/tissues and viral titres (RNA copy numbers) were 
measured by RT-qPCR. Shown are the numbers of genome copies of MNV per mg of faeces (A) 
and tissue (B). Statistical significance was calculated by 2-way ANOVA (A) and an unpaired t test 
(B). (*; P<0.05, **; P<0.01, ***; P<0.0001). 
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Figure 4.2 Old mice exhibit impaired control of small intestinal MNV viral infection after     
in vivo anti-CD3 stimulation.  
Wild type (C57Bl/6) mice, 8-week or 24-month (Old) of age, were infected orally with MNV-O7  
(5 x 106 TCID50) 8 hours after being injected intraperitoneally with 25µg of either anti-CD3 (+) or 
isotype control (-) antibodies. 40 hrs after the infection, the mice were sacrificed and gut sections 
(duodenum, jejunum, and ileum) and mesenteric lymph nodes (MLN) were collected. RNA was 
extracted from the tissues and viral titres (RNA copy numbers) measured by RT-qPCR. The titres 
were normalised to the weight of the tissue sections. Dotted line indicates the limit of detection (30 
viral genome copies per mg tissues). Each point represents an individual mouse. 
The line in each dataset represents the median viral titre. Statistical significance was calculated by 
Mann-Whitney test (n.s; non-significant, *; P<0.05, **; P<0.01). 
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Figure 4.3 In vivo anti-CD3 stimulation of old mice resulted in systemic and gut-associated 
inflamm-aging with impaired small intestinal antiviral response.   
C57Bl/6 mice, 8 weeks (Young) or 24 months (Old) of age, were injected intraperitoneally with 
25µg of anti-CD3 antibodies. Mice were sacrificed 3 hrs post-stimulation. Splenic CD8+ memory 
(CD44hi) T cells (A), intra-epithelial lymphocytes (B) and small intestinal (proximal and distal) 
epithelial cells (C) were sorted and isolated. RNA was extracted from each cell population, reverse 
transcribed and analysed for the gene expression of TNF and IFNs (A and B) and ISGs; Mx1, Adar, 
Rsad2 and Prkr (C). Expression levels are shown as 2^(-∆Ct), normalised to the mean of two 
housekeeping genes (Rpl38, Eef2) and multiplied by a factor of 1000. Error bars indicate the range 
of values obtained. 
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Figure 4.4 IFN response of old versus young small Intestinal Epithelial Cells. 
Wild type (C57Bl/6) mice, 8-week (Young) or 24-month (Old) of age, were sacrificed and small 
intestinal epithelial cells (IECs) were purified, seeded into Matrigel droplets and cultured into 
growth factor-rich medium alone (Ctrl) or medium plus either 30 ng IFNl/ml (+IFNl) or 2.5 ng 
IFNg/ml (+IFNg) for 6 hrs. The IECs were then harvested, lysed, RNA extracted and analysed for 
the gene expression by RT-qPCR. IFN-specific responses were analysed by the expression levels of 
the IFNl-responsive genes: Mx1 and Isg15, or the IFNg-responsive genes: Cxcl9 and Ido1. 
Expression levels are shown as 2^(-∆Ct), normalised to the expression of Hprt housekeeping gene 
and multiplied by a factor of 100. The data shown were pooled from two independent biological 
repeats (n=7), each dot represents a single data point with error bars indicating standard deviations. 
These ex vivo experiments and the figures displayed above were performed in collaboration with, 
and data kindly provided by, M. Stebegg (The Babraham Institute).  
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Figure 4.5 In vivo therapy with a high dose of IFN-λ reversed the anti-viral defect in old mice.   
Wild type (C57Bl/6) mice, 8-week (Young) or 24-month (Old) of age, were challenged orally with 
MNV-O7 (5 x 106 TCID50). Mice were injected with 25 µg of IFN-λ or phosphate-buffered saline 
(PBS) intraperitoneally 1- and 3-days post-infection (P.I.). Faecal samples were collected at the 
indicated days (1-7) P.I. The mice were sacrificed and intestinal tissues and mesenteric lymph 
nodes (MLN) collected on day-7 P.I. RNA was extracted from the faeces/tissues and viral titres 
(RNA copy numbers) were measured by RT-qPCR. Shown are the numbers of genome copies of 
MNV per mg of faeces (A) and tissue (B). Statistical significance was calculated by an unpaired t 
test (B).   (**; P<0.01, ***; P<0.0001).  
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Figure 4.6 Human Intestinal Organoids were responsive to IFN-lambda.   
Small intestinal organoids were generated from endoscopic samples taken from two young-adult (in 
their 20s), healthy human volunteers in Addenbrooke’s hospital. The organoids were treated with 
25 µg of recombinant human Interferon lambda (L) for 6 hrs and intestinal epithelial cells were then 
lysed, RNA extracted, reverse transcribed and analysed for the expression of the human ISGs: MX1 
and ISG15. Expression levels were depicted as mean 2^(-∆Ct), normalised to the mean of two house-
keeping genes (Rpl38, Eef2) and multiplied by a factor of 1000. Error bars indicate the range of 
results. The organoids were generated and treated with IFN-l (IFNL) by our collaborators (Dr. 
Matthias Zilbauer’s lab) at Department of Paediatrics, University of Cambridge. I performed the 
RNA extractions and RT-qPCR analysis. 
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Supplementary Figure 4.1 Small Intestinal Epithelial Cells (IECs) are more responsive ex vivo 
to type-III IFN compared to type-I IFN 
Wild type (C57Bl/6) mice, 8-week of age, were sacrificed and small intestinal organoids were 
established as per protocol outlined in Section 4.2.3.2. Intestinal organoids were treated with        
25 ng/ml of either IFNa-2b (black bars) or IFNl-2 (grey bars) for the indicated time points. 
Intestinal organoids were then harvested, IECs lysed, RNA extracted and analysed for the gene 
expression of IFNl2 and ISGs: Mx1 and Isg15 by RT-qPCR. Expression levels are shown as 2^(-
∆Ct), normalised to the expression of Hprt house-keeping gene and multiplied by a factor of 100 or 
1000. Error bars indicate standard deviations. These ex vivo experiments and the figures displayed 
above were performed, and data kindly provided, by M. Stebegg (The Babraham Institute).    
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Supplementary Figure 4.2 The defective IFNl response in old mice is confined to the small 
intestine and is more apparent at certain age groups. 
Intestinal epithelial cells (IECs) were isolated from the small intestine and colon of 8-week old 
(young) mice and either 24-month old mice (A) or 15-month old mice (B). Purified IECs were 
cultured as described in Section 4.2.3.2. and analysed for the expression of IFNl-responsive genes: 
Mx1 and Isg15, and the IFNl-receptor subunits: Il28ra and Il10rb. The data shown were pooled 
from at least two independent biological repeats, each dot representing a single data point and error 
bars indicates standard deviations. These experiments and the figures displayed above were 
performed in collaboration with, and data kindly provided by, M. Stebegg (The Babraham 
Institute).     
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Figure 5.1 MNV-O7 Infection of Wild-Type and AhR-/- Mice.   
Wild-type (C57BL/6) and Ahr-/- mice were infected orally with MNV-O7 (5 x 106 TCID50). (A) 40 
hrs after the infection, the mice were sacrificed and gut sections (duodenum, jejunum, and ileum) 
and mesenteric lymph nodes (MLN) were collected. The dotted line indicates the limit of detection 
(30 viral genome copies per mg tissue). Each point represents an individual mouse. 
The line in each dataset represents the median viral titre. (B) Faecal samples were collected at the 
indicated days P.I.. The mice were sacrificed and intestinal tissues collected in day 21 P.I.. RNA 
was extracted from the faeces/tissues and viral titres were measured by RT-qPCR and normalised 
by the weight of faeces/tissue. The data shown were pooled from two independent biological 
repeats. Statistical significance was calculated by Mann-Whitney test (A) and 2-way ANOVA (B) 
(*; P<0.05, **; P<0.01). 
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Figure 5.2 Flow Cytometry of Bone Marrow-Derived Mononuclear Cells (BMMC) derived from Wild-Type, Ahr-/-, Ahrr-/- and Cyp-/- mice. 
BMMC from wild-type, Ahr-/-, Ahrr-/- and Cyp-/- mice differentiated with GM-CSF were analysed by flow cytometry for the expression of the surface 
markers MHC class II, CD11c, CD80 and CD86 (A). The different BMMC were gated on CD11c and MHC class II expression for differentiation into 
immature (R6), moderate (R7) and high (R8) maturation states (B). The data are representative of two independent experiments. 
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Figure 5.3 MNV-O7 replication in Wild-Type, Ahr-/-, Ahrr-/- and Cyp-/- BMMCs.  
BMMC generated from wild-type, Ahr-/-, Ahrr-/- (A) and Cyp-/- (B) mice were differentiated as in        
Figure 5.2. The BMMC were infected with MNV-O7 virus at an MOI of 0.05 (A) and 0.03 (B). 
After 1 hrs incubation with the virus, the cells were washed then incubated at 37	 °	C. At specific 
times post-infection (1, 9, 12, 24 and 48 hrs), RNA was extracted from the cells and viral titres 
(vRNA copy numbers) were measured by RT-qPCR. vRNA copy number was expressed as the 
number of molecules per µg of total RNA in the sample well. Data points represent the mean vRNA 
level from triplicate wells, with error bars showing the range for each triplicate. Statistical 
significance was calculated by 2-way ANOVA (*; P<0.05, **; P<0.01). 
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Figure 5.4 RT-qPCR-based Gene Expression Analysis of BMMCs Following Poly(I:C) Stimulation.  
BMMC generated from wild-type, Ahr-/-, Ahrr-/- and Cyp-/- mice were differentiated as in Figure 5.2 and seeded into individual wells. The BMMC were 
subsequently treated with 100 µg Poly(I:C)/ml and at specific time points RNA was extracted from each well, reverse transcribed and analysed for the 
expression of genes Ifnb1, Irf3, Irf7, Mx1 and Isg15. Data points represent the expression levels, which are shown as 2^(-∆Ct), normalised to the mean of 
two housekeeping genes (Rpl38, Eef2) and multiplied by a factor of 1000. Error bars indicate ranges. The data shown were pooled from two 
independent repeats (except for Ifnb1). Statistical significance was calculated (at 6 hrs post-stimulation) by Mann-Whitney test (*; P<0.05). 
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Figure 5.5 Production of IFN-b by BMMC following Poly(I:C) Stimulation.  
BMMC generated from wild-type, Ahr-/-, Ahrr-/- and Cyp-/- mice were differentiated as in        
Figure 5.2 and stimulated with 100 µg poly(I:C)/ml as in Figure 5.4.. At 0 and 24 hrs post-
poly(I:C) stimulation, the supernatant from individual wells was collected for an ELISA assay to 
quantify the amount of IFN-b produced by the cells. The dotted line indicates the limit of detection 
(17.5 pg/ml). Bars represent the median of three technical replicates of a single sample, with error 
bars showing the range of these replicates. Statistical significance was calculated by an unpaired t 
test.  (*; P<0.05). 
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Figure 5.6 Flow Cytometry of Wild-Type and AhR-/- BMMC treated with an AhR agonist (FICZ) and AhR antagonist (CH223191).  
BMMC from wild-type and Ahr-/- mice were differentiated with GM-CSF (untreated) or in combination with either 500 nM FICZ or 3 µM CH223191 
(CH).  The BMMC were analysed by flow cytometry for the expression of the surface markers MHC class II, CD11c, CD80 and CD86 (A). M1 and 
M2 gates show the proportions of positive cells. The different BMMC were gated on CD11c and MHC class II expression for differentiation into cells 
of immature (R6), moderate (R7) and high (R8) maturation status (B). The data are representative of two independent experiments.
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Figure 5.7 MNV-O7 replication in BMMC Derived from Wild-Type and Ahr-/- mice and 
treated with an AhR-agonist (FICZ) and AhR-antagonist (CH223191).  
BMMC generated from wild-type and Ahr-/- mice were differentiated as in Figure 5.6. The BMMC 
were infected with MNV-O7 at a MOI of 0.05. After 1 hrs incubation with the virus, the cells were 
washed then incubated at 37	° C. At specific post-infection times (1, 9, 12, 24 and 48 hrs), RNA was 
extracted from the cultured cells and viral titres (vRNA copy numbers) were measured by RT-
qPCR. vRNA copy number was expressed as the number of molecules per µg of total RNA in the 
sample well. Data points represent the mean vRNA level from triplicate wells, with error bars 
showing the range for each triplicate. Statistical significance was calculated by 2-way ANOVA. 
 (**; P<0.01). 
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Supplementary Figure 5.1 MNV-O7 viral titres measured by TCID50 assay and correlation 
with those measured by RT-qPCR assay.  
Wild type (C57BL/6) and Ahr-/- mice were infected orally with MNV-O7 (5 x 106 TCID50).         
(A) 40 hrs P.I. the mice were sacrificed and gut sections (duodenum, jejunum, and ileum) were 
collected. Infectious viral titres were measured by a limiting dilution 50 % Tissue Culture Infectious 
Dose (TCID50) assay as detailed in Section 2.5. The titres were normalised to the weight of the 
tissue sections (in mg). Each point represents an individual mouse. The line in each dataset 
represents the median viral titre. The data shown were pooled from two independent biological 
repeats. (B) The correlation between MNV-O7 viral titres measured by TCID50 (plotted in the x-
axis) and RT-qPCR (plotted in the y-axis). Statistical significance was calculated by Mann-Whitney 
test (A) and regression analysis (B). (n.s.; non-significant, *; P<0.05, **; P<0.01). 
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Supplementary Figure 5.2 continued overleaf 
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Supplementary Figure 5.2 Microscopic and Flow Cytometric Comparison of BMMC differentiated by GM-CSF + IL-4 Vs GM-CSF alone.  
BM cells extracted from the long bones of wild-type and Ahr-/- mice were differentiated for 8 days in medium containing either a combination of GM-
CSF and IL-4 or GM-CSF alone.  The BMMC were examined by microscopy with images taken on day 0, day 3, day 6 and day 8 post-addition of the 
differentiation medium (A). The phase contrast images shown were taken at 20x magnification. The red arrows point to the vacuolization.                  
On day 8 of differentiation, the cells were also analysed by flow cytometry for the expression of the surface markers MHC class II, CD11c, CD103, 
CD8a, CD80 and CD86 (B).  
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Supplementary Figure 5.3 MNV-O7 infection of Wild-Type and Cyp-/- mice.   
Wild-type (C57BL/6) and Cyp-/- mice were infected orally with MNV-O7 (5 x 106 TCID50). 40 hrs 
after infection, the mice were sacrificed and gut sections (duodenum, jejunum, and ileum) were 
collected. RNA was extracted from the tissues and viral titres (viral RNA copy numbers) were 
measured by RT-qPCR. The titres were normalised to the weight of the tissue sections. The dotted 
line indicates the limit of detection (30 viral genome copies per mg tissues). Each point represents 
an individual mouse. The line in each dataset represents the median viral titre. Statistical 
significance was calculated by Mann-Whitney test. (n.s.; non-significant) 
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